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Neuromuscular diseases are degenerative and, thus far, incurable disorders that lead to large mus-
cle wasting. They result in constant deterioration of activities of daily living and in particular of ambulation. 
Some common types include Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, polymyositis and 
amyotrophic lateral sclerosis. While these diseases individually have a low rate of occurrence and are mostly 
unknown to most people, collectively they affect a significant part of the population. About 1 person in 2000 
suffer from neuromuscular diseases, which means an approximate total of 370’000 people over the European 
continent. Recent technology breakthroughs have made possible the realization of advanced powered or-
thotics, which are commonly called exoskeletons. The most advanced devices have successfully been able to 
support patients in walking despite a debilitating condition such as complete spinal cord injury. Such tech-
nology could be ideal for people with mid-stage neuromuscular diseases as it provides more mobility and 
independence. 
This work investigates the definitions and requirements that would need to be fulfilled for any proposed 
orthotic device to assist people living with neuromuscular diseases. To define the needs of patients with 
neuromuscular disease, a large literature review is conducted on gait compensation patterns. The research 
also includes the data collection of experimental gait measurements from fourteen people with heterogene-
ous neuromuscular diseases. Conclusions show that orthotics for people with neuromuscular diseases re-
quire tunable assistance at each joint and a collaborative control strategy in order to let the user control 
motion. Eventually, most people may not be able to use crutches. 
A full lower limb exoskeleton, AUTONOMYO, is designed, realized and evaluated. A particular attention is put 
on the optimization of the actuator and transmission units. In order to reduce the effects of inertia and weight 
of those units, a design is explored with actuation remotely located from the joints. The transmission is real-
ized by custom cable wire and pulley systems, combined with standard planetary gears. The dynamics of 
different coupling between the hip and the knee flexion/extension joints are explored, and their benefits and 
tradeoffs analyzed. 
A novel control strategy based on a finite-state active impedance model is designed and implemented on the 
AUTONOMYO device. The controller consists of three states of different active impedances mimicking a visco-
elastic behavior. The switching condition between states is uniquely based on the hip flexion velocity to de-
tect the user intent. The performance of the strategy regarding the detection of intention and the modulation 
of the assistance is evaluated on a test bench and in real conditions with healthy pilots and with a person 
with limb girdle muscular dystrophy. The preliminary results are promising since all pilots (including the one 
with muscular dystrophy) are able to initiate and terminate assisted walking on demand. They are all able 
both to walk with a good stride rate and to reach moderate velocities. Healthy pilots are able to ambulate 
alone with the exoskeleton, while the pilot with muscular dystrophy requires human assistance for the man-
agement of balance. 
 viii 
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Les maladies neuromusculaires sont dégénératives et, malheureusement, encore incurables à ce 
jour. Elles sont notamment marquées par une perte importante de la capacité musculaire, ce qui induit une 
détérioration des activités du quotidien dont la marche en particulier. Les principales formes de ces maladies 
sont, par exemple : la dystrophie musculaire de Duchenne, la maladie de Charcot-Marie-Tooth, les polymyo-
sites ou encore la sclérose latérale amyotrophique. La somme de ces maladies dites rares touche d’une ma-
nière générale une part significative de la population, malgré cela, elles restent encore largement méconnues 
du grand public. Environ une personne sur 2000 souffre d’une maladie neuromusculaire, ce qui correspond 
à environ 370'000 cas en Europe uniquement. Le début du siècle a été marqué par l’avènement de techno-
logies qui permettent la réalisation de systèmes orthopédiques motorisés, qui sont plus communément ap-
pelés exosquelettes. Les premiers développements de tels appareils ont réussi l’étonnant pari de permettre 
à des personnes paraplégiques de remarcher avec l’aide du dispositif. Une telle technologie pourrait égale-
ment s’avérer très utile pour des personnes souffrant d’une maladie musculaire en stade modérément 
avancé, afin de leur offrir une meilleure mobilité et plus d’indépendance. 
Le présent travail se concentre sur la définition des besoins nécessaires à l’assistance adaptée aux personnes 
souffrant d’une maladie neuromusculaire. La conception et l’implémentation d’un exosquelette complet 
pour les membres inférieurs, ainsi que d’une stratégie de contrôle, sont proposées et évaluées en termes de 
faisabilité et de performances. La compréhension et la définition des besoins relatifs aux maladies neuro-
musculaires sont explorées à travers une revue de la littérature des mouvements de compensation, ainsi qu’à 
travers des données expérimentales d’analyse de marche récoltées sur un groupe hétérogène de quatorze 
personnes souffrant de maladies neuromusculaires. La conception d’un exosquelette complet pour les 
membres inférieurs, AUTONOMYO, est réalisée. Une attention particulière est portée sur l’optimisation de 
la motorisation et des transmissions mécaniques. Afin de réduire les effets d’inertie et de masse de ces élé-
ments, une conception avec des moteurs déportés des centres de rotation articulaires est évaluée. La trans-
mission est réalisée par un système de câble et poulies combinés à un train d’engrenages planétaires en 
amont. La dynamique de différentes solutions couplant les articulations de flexion/extension de la hanche et 
du genou sont explorées. 
Une stratégie de contrôle basée sur un modèle d'états-finis avec impédance active est conçue et implémen-
tée sur le dispositif AUTONOMYO. Le contrôleur consiste en trois états avec une impédance active propre 
imitant un comportement visco-élastique. La condition de changement d’état est basée sur la vitesse de 
flexion de la hanche qui permet de détecter l’intention de l’utilisateur. Les performances de la stratégie, pour 
la détection d’intention et la modulation du niveau d’assistance, sont évaluées sur un banc d’essai et en 
 x 
conditions réelles avec des pilotes sains ainsi qu’un pilote atteint par une dystrophie musculaire des cein-
tures. Les résultats préliminaires sont encourageants alors que tous les pilotes (incluant le pilote souffrant 
de dystrophie musculaire) sont capables de marcher avec le dispositif. 
Keywords – Maladie neuromusculaire, dystrophie musculaire, myopathie, exosquelette, orthèse motorisée, 
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Ambulation is one of the fundamental freedoms that humans possess. Mobility plays a key role in the inde-
pendence of people [1] and largely supports a good quality of life [2], [3]. A study by the National Health 
Interview Survey from 2012 [4] reported that about 7% of the adult population in the United States, about 
17 million people, claimed not to be able to walk a quarter of a mile (about 400m), or to be able to do so with 
significant difficulty. The first representations of a “rolling chair” go back to the end of the 16th century, when 
such a device was built for the King Philipp II of Spain [5]. While medical assistive technology has made im-
portant breakthroughs since then, the most common solution today against severe ambulation disorders is 
still the wheelchair. The only recent radical innovation in wheelchairs is the embedding of motors that allow 
the user to move without assistance of another person, and without the necessity of using arms to self pro-
pel. Nevertheless, wheelchairs still suffer from various limitations in standard non-adapted areas such as 
stairs, sidewalk edges, hinged doors, and so on. They are furthermore difficult to carry and transfer in stand-
ard cars. 
Impairment of ambulation can arise from several medical causes, including but not limited to traumatic brain 
injury, spinal cord lesions, hip or knee replacements, arthritis, Parkinson’s disease, multiple sclerosis, cerebral 
palsy, and muscular dystrophy. This work focuses on neuromuscular disease that affect skeletal muscles; a 
definition which encompasses a large group of rare and hereditary diseases with which a genetic default or 
mutation leads to fiber deterioration and muscular atrophy. Approximately 1 person in 2’000 is affected by 
such diseases (see Chapter 2); this extends to about 370 thousand people over Europe. The targeted diseases 
include muscular dystrophies and atrophies, inflammatory myopathies and diseases of peripheral nerves. 
These disorders are reputed to be incurable and degenerative. They are also known for having a great varia-
tion in degenerating rate, primary muscles affected, age of onset and lifespan. People affected by such dis-
eases usually begin to experience minor discomfort or abnormalities during sport activities, a diagnosis fol-
lows after a few visits to a specialized neurologist. As the degenerative mechanism progresses, muscles begin 
to atrophy and difficulties in daily activities grow. Climbing stairs, rising from a sitting position and managing 
balance can become difficult or even impossible. At the same time, gait compensating patterns become very 
apparent, often causing patients to feel uncomfortable in public. Any uneven terrain begins to pose a signif-
icant risk of falling and the person usually adopts a quite sedentary life or begins to use a wheelchair for 
safety. Using a wheelchair and reducing exercise then rapidly worsens the muscular condition of the person, 
who has lost much of its former independence by this point. In cases of rapid degeneration, as often seen 
with Duchenne muscular dystrophy, the disease can lead to death in patients aged in their twenties. In other 
cases, with slow degeneration, the person will be able to keep her/his walking ability until an advanced age. 
1.1 Motivation 
2 
Medical research is still a few decades away from developing viable cures. This heightens the importance of 
finding alternatives that can improve quality of life for patients. For example, helping patients to stabilize 
their standing position and promoting motion and physical activity could help sustain a certain muscular 
strength and slow down atrophy, although, to prevent overloading muscles and potentially irreversible in-
jury, people with such diseases will require a varying level of intensity depending on their individual case [6]–
[8]. 
Since the beginning of the century, as technologies such as embedded electronics and computing have pro-
gressed, powered orthopedics has emerged as a developing field. The ability to couple human limbs with 
actuated robotics has been realized with success in patients with spinal cord injury (SCI), hemiplegia and 
multiple sclerosis among others [9], [10]. The first exoskeleton devices were stationary, i.e. the robotic legs 
are supported by a static frame over a treadmill, such as the Lokomat® (Hocoma AG, Switzerland) [11] or the 
LOPES from Twente University [12]. More recently, wearable exoskeletons emerged with the primary goal of 
providing mobility for people with SCI. These included products from companies such as ReWalk™ (ReWalk 
bionics, USA), Ekso™ (Ekso bionics, USA) or REX (Rex Bionics, New Zealand) among others. These devices have 
demonstrated  the  feasibility of autonomous and safe ambulation for people with complete SCI [13]. After a 
few years of availability on the market, the devices have also demonstrated major medical benefits for users 
with SCI, such as better bowel and bladder function and a reduction in the level of spasticity [13]. Despite 
these tremendous accomplishments, the accessibility of the exoskeleton as a personal device is still very low. 
This is certainly due not only to the high costs (about 80’000 $ to 140’000 $ per unit), but also to the limited 
performances; crutches in both hands are necessary in order to ensure balance control, walking velocities 
are about only 2 km/h and, for safety reasons, stair climbing is not yet fully supported. Currently, some of 
these devices, plus newly developed ones, are undergoing several clinical trials to evaluate the benefits as 
rehabilitative devices, not only for people with SCI, but also for stroke victims. It is the hope of researchers 
that growing the market availability will make the prices drop and make the devices more accessible to more 
people. 
Wearable exoskeletons have great potential to improve quality of life in people suffering from neuromuscular 
diseases (NMD). First, it could prevent early fatigue experienced by people with NMD, which leads to neces-
sary resting and greater risk of falling. It can also stabilize weaker joints for a greater range of activity. Even-
tually, it can also provide gait compensation to the user, or as a training device for physical therapy. With 
such a large list of benefits provided by the potential of wearable exoskeletons to those afflicted by NMD, 
one might wonder why it is not a more popular option for investment and advertisement.  
There are some complications in adapting exoskeletons to the needs of those suffering from NMD. The strat-
egies of “mobilization” employed for enabling persons with SCI to walk cannot be directly applied to mobi-
lizing those with NMD. Firstly, the use of crutches requires important strength in the upper limbs which is 
not compatible with symptoms of NMD. Secondly, the “mobilization” strategy implemented to assist persons 
with SCI is based on predefined trajectories performed by the exoskeleton independently from the contribu-
tion of the user. However, the complications of NMD require adaptive “assistive” strategies, where both the 
device and the user can contribute together to the motion. These adaptive strategies are important in allow-






The development and optimization of novel orthopedics integrating latest technologies to allow safe and 
efficient ambulation in people suffering from neuromuscular diseases is a tremendous project. The objectives 
and contributions to that work are partitioned in smaller tasks. 
1. Determine the specific needs for mobility assistance in people with NMD. 
2. Evaluate a specific orthopedic design to improve the quality of life in people with NMD. 
3. Develop adaptive control strategies for people with weak muscle condition but residual walking ca-
pacity. 
The first task is the understanding of the effect on mobility of neuromuscular diseases. It includes under-
standing symptoms and their implications in daily activities, particularly those involving ambulation. Data on 
these symptoms are gathered from multiple sources, such as interviews with physicians and physiotherapists 
specialized in neuromuscular diseases, interviews and experimental gait analyses of people with NMD, na-
tional statistics from Switzerland, interviews with orthopedists, and specialized scientific literature. A major 
contribution comes from gait analyses of 14 people with heterogeneous NMD. This information covers a wide 
range of the NMD problem space, from the diseases and their heterogeneity, through the difficulties encoun-
tered in daily activity, to the causes and consequences of compensating gait pattern. 
The second task consists in proposing solutions based on the specifications taken from the previous task. 
Particular attention will be focused on the architecture of the exoskeleton and determining which joints need 
to be assisted to provide the seven degrees of freedom within one human leg. The design will then focus on 
the design of actuators that are able to fulfill these specifications, while keeping the weight and bulk of the 
device to a minimum. Solutions of joint coupling between the hip and the knee flexion/extension are ex-
plored through design and implementation with a cable driven system. Further solutions to optimize the 
constraints on the actuation and transmission are then proposed. A full lower limb exoskeleton called AU-
TONOMYO is built for assessments with people with NMD. 
The last task considers the design of adaptable collaborative control strategies to assist people with NMD. A 
novel finite-state active impedance controller is implemented on the AUTONOMYO device. Preliminary tests 
on a test bench are conducted to evaluate the sensitivity of the gait initiation and termination. Tests with a 
few healthy pilots and a pilot with moderately severe limb girdle muscular dystrophy are conducted to tune 
the parameters of impedance of the assistance, and to evaluate the feasibility of the controller with regards 
to the condition of the pilot operator. 
??? ???????????????
The structure of the present document follows the order of the aims discussed in Section 1.2. Chapter 2 
introduces various types of neuromuscular diseases, key statistics and a literature review on the walking 
disorders and corresponding compensating patterns. Chapter 3 describes the methodology of collecting gait 
information from a small group of heterogeneous NMD patients, and discusses the specifications of the as-
sistance required by these people. Exoskeletons are introduced in 1.1, which focuses on the mechanical de-
sign of a lower limb device adapted for people with NMD. It addresses in particular the optimization of the 
actuation and transmission units to augment performances while keeping a compact and lightweight design. 
1.3 Thesis Outline 
4 
The general design of the AUTONOMYO exoskeleton is also described in this chapter, and the performances 
are evaluated on a test bench. Chapter 5 presents novel control strategies specifically adapted to people with 
NMD. The implementation and the first evaluations with healthy pilots and one pilot with limb girdle muscu-
lar dystrophy are also described. All the elements from the contribution of the thesis are summarized in the 
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 ?????????????? ????????
Neuromuscular diseases (NMD) are characterized by a disorder at the muscle level or at the periph-
eral nervous system responsible for the control of voluntary muscles. Such diseases are degenerative as the 
symptoms deteriorate with time. A large part of NMD are inherited such as muscular dystrophies but can 
also be inflammatory or caused by metabolic disorders. The NMD term groups together a large number of 
diseases that are individually categorized as rare; i.e. each affects less than 5 in 10’000 people following the 
definition of the European commission1. This chapter introduces different forms of neuromuscular diseases 
and presents the characteristics of the most common forms. It then discusses the implication of impairments 
in daily life and the statistical data available in Switzerland. 
??? ??????????????????? ????????????? ????????
More than one thousand varieties of NMD exist. These variants have been grouped in a limited number of 
diseases, such as Duchenne muscular dystrophy or amyotrophic lateral sclerosis. A variant is usually charac-
terized by a relative homogeneity in affected parts of the body, the rate of degeneration and the age of onset. 
Because of the numerous varieties of NMD and their low individual prevalence, NMD are often grouped un-
der a common name such as limb girdle muscular dystrophy or congenital muscular dystrophy. Thus, NMD 
can be quite heterogeneous and is usually unpredictable. For example, it is common that, within one family, 
two siblings can have large differences in the rate of degeneration of the disease. Those diseases can be very 
severe with rapid deterioration and poor longevity, or on the milder side, with a slow progression over a few 
decades and with muscle weakness limited to certain parts of the body. Table 2-1 summarizes the main 
groups of NMD with their principal characteristics. 
The following common types of NMD will be looked at in more detail: Duchenne and Becker muscular dys-
trophy, myotonic dystrophy, facioscapulohumeral muscular dystrophy, limb girdle muscular dystrophy, in-
clusion body myositis and Charcot-Marie-Tooth disease. 
  
1 https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en 
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Duchenne and Becker muscular dystrophies affect similar groups of muscles. The diseases both first affect 
the proximal muscles about the pelvic and shoulder girdles. Distal areas around the hands and feet, as shown 
in Figure 2-1, are affected less or at a later point.  
 
Figure 2-1 Muscles commonly affected in Duchenne and Becker muscular dystrophies (in red/dark)  
Duchenne muscular dystrophy (DMD) is notorious for often occurring in children and teenagers and fre-
quently decreasing life expectancy. Children affected by DMD are often bounded to wheelchairs by age 13; 
the disease leads to death by early adulthood due to vital organ dysfunction [22]. Moreover, DMD has the 
greatest rate of incidence among all muscular dystrophies. It is responsible for about fifty percent of the total 
incidence of all muscular dystrophies, combined. DMD primarily affects boys, as it is an X-linked disease; 
nevertheless, milder symptoms are also found in about 10% of female carriers [22]. Several studies report an 
incidence of 19-23.5 per 105 persons (~1/5’000) [23]–[25]. 
Becker Muscular Dystrophy (BMD) is a similar X-linked disease but takes a milder form than that of DMD. It 
progresses at a slower rate, with total loss of ambulation generally occurring in the thirties-forties. Persons 
with BMD have a near normal life expectancy and are, in most cases, diagnosed between the ages of 5 and 
45 [26]. The prevalence of BMD is about 1.53 per 105 males as reported by Mah et al. [27] based on ten 
studies completed between 1991 and 2009. 
????? ???????????????????
Myotonic Dystrophy (DM), also called Steinert’s disease, is the most frequent muscular dystrophy that sets 
in during adulthood. There exist two forms of DM, caused by two different mutated genes: DM type 1 (DM1) 
and DM type 2 (DM2). DM appears usually in patients’ twenties or thirties and reduces life expectancy due 
2.1 Types and forms of Neuromuscular Diseases 
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to cardiac conduction defects [28], [29]. Across Europe, between 3 and 15 cases per 105 are reported [14]. 
The muscles affected in DM1 are around the distal segments, such as hands, forearms, feet, calves, neck or 
face (see Figure 2-2). Muscles of the diaphragm are also often affected by DM1. DM1 also encompasses other 
disorders such as myotonia, which deteriorates the release of contracted muscles, cardiac conduction de-
fects, cataracts, potential intellectual deficits, gastrointestinal disorders and more. DM1 is a slowly progress-
ing muscular dystrophy where a loss of ambulation usually does not occur before the end of life [28]. People 
with DM1 suffer primarily from a lack of dexterity in the hands which prevents them from performing many 
simple activities of daily living (ADL) such as using a fork, a toothbrush and other tools. Foot drop is also 
common in people with DM1, and can be improved by the use of ankle foot orthosis (AFO). 
 
Figure 2-2 Muscles commonly affected in myotonic dystrophy type 1 (in red/dark) 
DM2 is a milder form of DM1  which is less likely to reduce life span [28], [29]. While both DM1 and DM2’s 
complications include myotonia and other disorders such as cataracts, there are several important differ-
ences. DM2 presents common proximal muscle weakness at the elbow extensors, the hip flexors and at the 
neck. It is also characterized by large muscle pain, muscle stiffness and muscle fatigue [30]. 
????? ???????????????????? ??????????????????
Facioscapulohumeral Muscular Dystrophy (FSHD) is the third most common muscular dystrophy after DMD 
and DM [14]. It is named after the various muscle groups it affects i.e. the facial muscles, muscles about the 
shoulder (scapula) girdle and upper arm (humerus). It also frequently affects the muscles about the pelvic 
girdle and the foot dorsiflexors leading to foot drop syndrome, although the latter can usually be managed 
with ankle-foot orthosis [31], [32]. Muscle groups commonly involved in FSHD are highlighted on Figure 2-3. 
FSHD is a very slow degenerative disease, with a loss of strength of about 4,4% per decade [32]. Patients in 
the cohort of Kilmer et al. [32] were 36% to 68% weaker than controls in all weak muscle groups, which shows 
Neuromuscular Diseases 
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a relatively moderate weakness. Tawil et al. [33] also reported that about 20% of FSHD patients become 
wheelchair-bound, while the disease has poor incidence on the patient’s longevity. 
 
Figure 2-3 Muscles commonly affected in facioscapulohumeral muscular dystrophy (in red/dark) 
????? ???????????? ??????????????????
Limb Girdle Muscular Dystrophy (LGMD) currently encompasses about 30 forms, identified through the dif-
ferent genes involved in muscle atrophy. There are two types of LGMD; type 1 is autosomal dominant and 
type 2 is autosomal recessive [34]. As highlighted in Figure 2-4, proximal muscles, or muscles around the 
pelvic and shoulder girdles, are commonly affected by LGMD. As LGMD refers to a family of isolated forms of 
NMD, heterogeneity in muscle affection, age of onset, and rate of deterioration can be quite variable. It 
seems that the later the first symptoms appear, the slower the deterioration. As LGMD usually appears in 
adulthood, patients experience serious functional disabilities after a few decades, as the disease is mildly 
progressive [34], [35]. 
2.1 Types and forms of Neuromuscular Diseases 
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Figure 2-4 Muscles commonly affected in limb girdle muscular dystrophy (in red/dark), in lighter red/dark are addi-
tional muscles commonly affected in different forms of limb girdle muscular dystrophy  
????? ??????????????? ????????
Inclusion Body Myositis (IBM) is a form of inflammatory myopathy which falls under the category of auto-
immune diseases. Symptoms are very similar to those of muscular dystrophies and consist largely of muscle 
weakness and deterioration over time. IBM is characterized by late onset; most symptoms occur in patients 
around or over 50 years of age [36]. Another trait of IBM is a high homogeneity of affected muscles with very 
localized weakness. Quadriceps are primarily and most frequently affected, followed by elbow, wrist and 
finger flexors and extensors as illustrated in Figure 2-5 [36]. The disease also commonly affects pharyngeal 
muscles and leads to swallowing problems [36]. People with IBM experience moderate difficulty walking, but 
can suffer from frequent and abrupt falls due to weakness in the quadriceps. While most patients need an 
assistive device (e.g. 73% in the Badrising’s cohort [36]) to ambulate, wheelchair use is much lower in this 
population (e.g. 14% [36]) and does not imply a total loss of ambulation (e.g. 78% of wheelchair users could 
still ambulate on their legs [36]). Badrising et al. [36] reported a mean time of 13 ± 8 years after onset before 




Figure 2-5 Muscles commonly affected in inclusion body myositis (in red/dark) 
????? ?????????????????????????????
Charcot-Marie-Tooth disease (CMT) is a peripheral nerves disease and has the largest prevalence of the NMD 
described in Table 2-1. It affects about 1 in 2’500 persons [18], [19]. CMT, like LGMD, is a family of hereditary 
diseases that includes more than 50 genetic forms that can be dominant or recessive [19]. CMT is a neurop-
athy where the peripheral nerves, whether categorized as motor (efferent nerves) or sensory (afferent 
nerves), are subject to demyelination. Demyelination leads too poor conduction of signals by the nerves and 
thus a loss of sensation and motor control. Demyelination can also be found in major diseases such as multi-
ple sclerosis. Muscle weakness, loss of sensation and general effects upon peripheral nerves are found mostly 
in the feet, calves, hands and forearms first, as seen in Figure 2-6 [37]. The age of onset of CMT varies largely 
due to its different forms [18], [37]. Symptoms are slow to increase in severity, and the disease rarely affects 
life expectancy. 
2.2 Swiss Statistics about Neuromuscular Diseases 
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Figure 2-6 Muscles commonly affected in Charcot-Marie-Tooth disease (in red/dark) 
??? ??????????????????????? ????????????? ????????
As previously discussed, more than a thousand of neuromuscular diseases exist, with very heterogeneous 
symptoms. It is thus difficult to gather statistical data from people suffering from neuromuscular diseases. 
Most complete data sets are kept by medical centers; however, no numerical database has been made that 
would allow a global statistical analysis. The Federal Statistical Office (FSO) in Switzerland collects data from 
the Disability Insurance (DI), which provides the largest available database on people suffering from neuro-
muscular diseases in Switzerland. In this section, data from the year 2012 is presented and discussed.  
The available data sets from the DI have several flaws. First, the statistics reports only documented people 
that benefited from financial support from the DI during the given year, that includes people receiving a 
regular pension due to a reduced working capacity as well as patients with infrequent needs. These needs 
can be related to mobility solutions (car adaptations, home adaptations, wheelchair purchases, etc.). The 
data collected thus represents people with difficulties that impede their ability to work (thus they receive a 
pension). In addition, the report includes a fluctuating number of people without pensions that nevertheless 
benefit from regular financial support. People over 64 are no longer eligible to the DI, but belong to the Old-
Age and Survivor's Insurance (OASI). Another bias comes from the processes of diagnosis, which requires 
extensive investigations and can be inconclusive. Statistics provided corresponds to the group defined by the 
disability code 184: Progressive muscular dystrophies and other congenital myopathies. 
????? ?????????????? ?????????????????????????????????????
In 2012, the Swiss population numbered over 8 million people [38]. 604 persons with muscular dystrophies 
or congenital myopathies are identified in the year 2012. In comparison to the projections made from the 
Neuromuscular Diseases 
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statistical rates of occurrence, this number represents about 56% of the total estimated persons with mus-
cular dystrophies and congenital myopathies. Figure 2-7 shows the distribution across age of people with 
muscular dystrophies as compared to the total population of Switzerland. 
 
Figure 2-7 Demography of persons with a muscular dystrophy or congenital myopathy as reported by the Swiss Dis-
ability Insurance in 2012, on left. Demography in Switzerland, on right. 
Based on the provided statistics, about two third of the persons affected by NMD are younger than 20 years 
old. One can also observe two trends. First, there is a high increase in cases from birth to pre-adolescence. 
Second, there is a constant decrease in cases from adolescence to the thirties. The first trend can be explained 
by the typical appearance of first symptoms during childhood, and therefore an increase in reported cases of 
NMD. The second trend could suggest that radical decrease in support by the DI are due to higher mortality 
rates. The hypothesis of a high mortality during the 20s and 30s is encouraged since the demography change 
is permanent. This idea is also supported by literature on Duchenne muscular dystrophy, as similar trends 
are found in the literature from 0 to 30 years old for Duchenne muscular dystrophy [23]. In conclusion, this 
demographic illustrates the high incidence rate of severe muscle diseases such as Duchenne muscular dys-
trophy with an onset at early childhood and a high mortality rate from adolescence to young adult ages. 
While the absence of reported people with muscular dystrophies over 64 is related to the change insurance 
from DI to OASI as mentioned previously, the low number of instances between 40 and 64 is not totally 
understood. Indeed, a significant portion of NMD cases are detected and diagnosed after the forties and 
represent a considerable amount of people with muscular dystrophies. A possible explanation for the low 
count of people with late disease onset can be related to milder disabilities, where people are less prone to 
benefit from the disability insurance. 
????? ??????????????????????? ????????????? ????????
NMD are characterized by progressive muscle atrophy. Not only does the atrophying of initially affected mus-
cles become exacerbated, but the disease also spreads to other muscle groups with time. As illustrated in 
the figures above, most common NMD affect muscles in both lower and upper limbs. However, the level of 
impairment can vary depending on the level of weakness of the muscle group. The impairments reported to 
the DI are illustrated in Figure 2-8. 
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About 47% of the people with NMD and supported by the DI suffer from a full body impairment, while 24% 
suffer only from lower extremity impairment and 24% have other musculoskeletal impairments. People suf-
fering only from upper extremity impairments represent less than 2%. In conclusion, most impairments are 
reported for the full body. A significant proportion of people with NMD are affected only at the lower ex-
tremities, while impairment of the upper extremities only is rare. 
 
Figure 2-8 Types of impairment and distribution of people with muscular dystrophy or congenital myopathy, based 
on data from the Swiss Disability Insurance in 2012. 
????? ??????? ??? ????????? ????????? ??? ?????????????????????????? ????
??????
The type of services financed by the DI are reported below in Figure 2-9. Wheelchairs, leg orthoses and car 
modifications are the most common services provided, and motorized wheelchair make up the most fre-
quently provided service due to full body impairment from NMD. While non-motorized wheelchair use is less 
common in NMD people, it offers better transportability, e.g. it can be easily carried in a car. Leg orthosis can 
be recommended to be worn at night with severe diseases such as Duchenne muscular dystrophy to prevent 
muscle shortening during childhood, although children often do not tolerate the orthoses well. Other leg 
orthoses are AFO (ankle-foot orthoses) which are effective in correcting foot drop disorders. Car modifica-
tions allow people with NMD to drive a car, as they cannot drive or enter a standard car. Another service is 




Figure 2-9 Proportion of services provided by the Swiss Disability Insurance by type for people with muscular dys-
trophies or congenital myopathies in 2012. 
??? ??????????????????????????? ????????????? ????????
Neuromuscular diseases are the subject of large interest around the world from medical research facilities. 
It is a growing field where new types of diseases are constantly being discovered. A search of the Web of 
Science database (including MEDLINE®) shows that the number of publications per year covering the topic 
“muscular dystrophy” (see Figure 2-10) is constantly growing. The threshold of 300-500 publications per year 
was reached about the 60’s – 70’s. 
 
Figure 2-10 Number of publications per year on the topic “muscular dystrophy” reported by the Web Of Science re-
search engine including Web of Science core collection and MEDLINE® databases 
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????? ????????????? ???????????
The primary and greater research on NMD is genetic, as there currently exists no cure for NMD. Much effort 
has been made towards identifying the mutations in the genome that cause symptoms [39]. Currently, re-
search is oriented towards developing biological mechanisms that could decrease or counter the effects in-
duced by the defective genes [39]. Another promising topic in treatment of neuromuscular diseases is gene 
therapy [40] [41]. Gene therapy consists of injecting subjects with vectors (modified viruses that are meant 
to be innocuous) that carry a selected gene. Those vectors then transmit the gene into the human cells nu-
cleus [42]. Two genetic therapies for NMD have been already granted FDA approval: eteplirsen for Duchenne 
muscular dystrophy and nusinersen for spinal muscular atrophy [41]. However, these therapeutical therapies 
are not completely developed, and trials show that patients respond in very different manners. Gene thera-
pies are also currently very expensive, costing from several hundreds of thousands of dollars to a few million 
for a single therapy [43]. Another issue of gene therapy in rare diseases lies within the very small population 
included in clinical trials; this leads to a lack of evidence for efficacy [43]. 
Other than the recent entry of gene therapy, corticosteroids have typically been used and tested in Duchenne 
muscular dystrophy. Corticosteroids are reported to improve muscle strength over a period of six months to 
two years [44]. Adverse effects of corticosteroids include the apparition of Cushing Syndrome (e.g. weight 
gain, facial puffiness, etc), excessive hair growth and others [44]. Other medications, not specific to NMD 
help to preserve vital organs affected by NMD, such as the heart or the lungs. One example is angiotensin-
converting enzyme inhibitors that reduce the rate of death of people with vascular disease [45].  
????? ????????????????????
Physical treatment refers to physiotherapy-like sessions that consist of stretching exercises, physical exercise, 
respiratory endurance exercises and so on. Muscles and muscle fibers are composed of cells that are con-
stantly subject to atrophy (decrease in cell’s size), hypertrophy (increase in cell’s size) and hyperplasia (in-
crease in cell number). Immobilization or the lack of exercise leads naturally to muscle atrophy, following a 
simple rule of “use it or lose it” [46]. A non-NMD example of this can be seen in astronauts, who live in zero-
gravity conditions in low Earth orbit for significant periods of time. Kawakami et al. [47] highlighted that the 
loss of strength after a bedridden period is not only due to muscle atrophy. They noticed that after being 
bedridden for 20 days, the neural activation levels dropped significantly and better expressed the low forces 
measured than the muscle change in volume (atrophy). It is thus important, in order to loss of strength, for 
NMD-afflicted to maintain a minimal level of exercise for the entire body. While this statement is true for any 
person, people with NMD are more prone to a sedentary lifestyle due to the increased risk of fall, the level 
of fatigue, etc. 
Hypertrophy is caused by mechano-biological stimulus, commonly called resistance exercise, that results in 
an increased muscle volume and strength [48]. The skeletal muscles’ adaptation to some stimulus can take 
three forms: it can expand radially or longitudinally, by the addition of sarcomeres in series or in parallel, or 
it can produce more mitochondrial oxidative enzymes and augment the resistance to fatigue [49]. It seems 
that resistance exercise, typically exercises including muscle overloading, increases muscle atrophy in cases 
of NMD. It has been reported that some exercises induce muscle damage, repair and adaptation [50]. To the 
awareness of the author, no study details the mechanisms of damage and repair, nor the involvement of 
these mechanisms in neuromuscular diseases. However, it is believed that typically, in people with muscular 
dystrophy, the process of repairment is hindered by the disease and leads only to an irreversible damage of 
the muscle fibers. 
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NMD prevents the strengthening of muscle through intensive exercises, meaning that muscular atrophy can 
only be avoided by exercising or maintaining a certain level of physical activity. Recommendations for physi-
cal exercises can be found in the literature. For example, Cup et al. [43] reviewed a total of 58 studies on 
exercise therapy differentiating between motor neuron disorders, motor nerve root disorders and peripheral 
nerve disorders, neuromuscular transmission disorders, muscle disorders and heterogeneous groups. Chil-
dren (<18 yo) were excluded from the review.  Significantly effective studies are reported in Table 2-2. 
Table 2-2 Significantly effective studies considering physical treatments in NMD (N=number of subjects, sn=session, 
wk=week) 
Reference N NMD type Body parts Type of exercise Sessions plan 






? Exercise for strengthening, 
15min walking, stretching 
15min 
5 sn/wk X 12 wk 
Aldehag et al. 
2005 [52] 
5 Myotonic dystrophy Hand ? Exercise with silicone putty 4min 
3 sn/wk X 12 wk 







? Treadmill exercise 70-85% of 
heart rate reserve 
20-30 min 
3-4 sn/wk X 8 wk 







? Treadmill exercise 60-80% of 
heart rate reserve 
20-30 min 
3-4 sn/wk X 8 wk 






? Cycling 70-80% of maximal 
heart rate 
30-40 min 
3-4 sn/wk X 14 
wk 






? Cycling 70-80% of maximal 
heart rate 
30 min 
3 sn/wk X 12 wk 
Haller et al. 
2006 [57] 
8 McArdle’s disease Legs 
? Cycling 70-80% of maximal 
heart rate 
30-40 min 
4 sn/wk X 14 wk 
Olsen et al. 
2005 [58] 
8 Facioscapulohumeral MD Legs ? Cycling 65% of VO2 max 35min 
5 sn/wk X 12 wk 






? Cycling 30min at 70% of peak 
work rate 
? 10-15 repetitions of different 
arm exercises 
60 min 
3 sn/wk X 12 wk 





? Cycling 60% of maximal HR 




2-3 sn/wk X 6 wk 





? Cycling 60% of maximal HR 




1-3 sn/wk X 6 
months 
Aitkens et al. 
1993 [62] 
27 
Various dystrophies (DM, 
LGMD, FSHD), neuropa-
thies and SMA 
Arm, hand, 
legs 
? 3x4 repetitions with load at 
10%-30% for knee, elbow and 
hand grip 
? Increase of resistance and 
repetitions with therapy 
15-20min 
3 sn/wk X 12 wk 
Florence and Hag-
berg 1984 [63] 
12 
Various dystrophies 
(CMD, LGMD, FSHD), my-
opathies, CMT and SMA 
legs 
? Cycling series of 5min with 
2min rest intervals at 70% of 
VO2 max 
3 sn/wk X 12 wk 




(BMD, DM, LGMD, FSHD), 
myositis and myopathies 
legs 
? Walking at light intensity for 
20min then with moderate in-
tensity 
 8 wk 
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In summary of Table 2-2, it is shown that some exercises can improve the quality of life of certain type of 
NMD. Cycling, referred to as an aerobic exercise, shows efficacy in addressing symptoms of: mitochondrial 
myopathies, McArdle’s disease, facioscapulohumeral muscular dystrophy, polymyositis, dermatomyositis 
and to some extent to congenital myopathies, limb girdle muscular dystrophy and spinal muscular atrophy. 
However, persons with Charcot-Marie-Tooth disease were insensitive to the therapy [63]. Treadmill exercise 
has proven effective in cases of mitochondrial myopathies, and to a lesser degree with non-metabolic myo-
pathies [53], [54]. Hand exercises also proved effective in myotonic dystrophy, polymyositis and dermatomy-
ositis [51], [52]. Pure strength training seems to be less beneficial unless done with few repetitions and low 
resistance in poly-/ dermato- myositis and various NMD [51], [64].  
Other studies do not demonstrate significant effectiveness of the physical therapy, however constraints 
make it difficult to address such as large heterogeneity in people with NMD and the low number of partici-
pants recruitable per region. Studies found in the literature primarily address cases of slowly progressive 
diseases and retaining significant muscle capacity (as demonstrated by the more mobile and strenuous types 
of activities proposed during these therapies) [43]. Y. P. Demir [65] investigated the different elements pro-
vided in the literature and reported major points – mainly, that exercise programs need to be tailored re-
garding the disease parameters such as progression, severity, onset, and the patient’s characteristics such as 
age and sex [59]. Exercise programs for strengthening are recommended only at mild to moderate levels and 
at the early stages of the disease while muscle capacity is only mildly affected by the disease [66]. 
??? ?????????????? ????????????? ????????
????? ?????????????
Ambulation in neuromuscular diseases can be very singular and easily recognizable. With the effects of NMD 
often very localized to a particular body part or area, persons with NMD develop unique compensation pat-
terns for frequent movement patterns such as walking and shifting from a sitting to a standing position. In 
order to discuss solutions for improving mobility, exercising and quality of life in persons with NMD, it is 
important to thoroughly investigate the causes and consequences related to muscle atrophy. The next sec-
tion presents a literature review on compensatory motions related to NMD. The following section presents 
the results from a study conducted for this thesis on gait pattern in a heterogeneous group of NMD patients. 
Lastly, these are combined to define the problem space in terms of kinematics and kinetics for improving 
ambulation. 
????? ??????????????????
In order to understand the compensatory motions while walking with NMD, a literature review is summarized 
in this section. Both Web of Science “All databases” (Clarivate Analytics) and SciVerse Scopus® (Elsevier) were 
searched for literature. Details on terms of search and results are described in Table 2-3. The search was first 
performed in Web of Science, then it was sorted based on titles and abstract and finally it was sorted through 
the content. As the first search was very broad, the second search using the Scopus database was refined 
from the search terms to dismiss studies on animals (mostly dogs and mice). Inclusion criteria for the ac-
ceptance of paper were: study on the kinematics of people with NMD, study on the kinetics of people with 
NMD, study on compensatory motions in people with NMD. Exclusion criteria were: case studies on one or 




Table 2-3 Parameters and results of the literature review on gait patterns in neuromuscular diseases 











TS = (( duchenne OR becker OR ((myotonic OR steinert) 
AND dystrophy) OR facioscapulohumeral OR "limb gir-
dle" OR "emery dreifuss" OR oculopharyngeal OR "con-
genital dystrophy" OR "inclusion body myositis" OR poly-
myositis OR dermatomyositis OR "charcot marie tooth" 
OR "spinal muscular atrophy" OR "amyotrophic lateral 
sclerosis" OR "charcot disease" OR dystrophy OR myopa-
thy OR atrophy ) AND (gait OR walk OR walking) AND 






TITLE-ABS-KEY ( ( ( duchenne  OR  becker  OR  ( ( myo-
tonic  OR  steinert )  AND  dystrophy )  OR  facioscapulo-
humeral  OR  "limb girdle"  OR  "emery dreifuss"  OR  oc-
ulopharyngeal  OR  "congenital dystrophy"  OR  "inclu-
sion body myositis"  OR  polymyositis  OR  dermatomyo-
sitis  OR  "charcot marie tooth"  OR  myopathy  OR  myo-
pathies )  AND  ( gait  OR  walk  OR  walking )  AND  ( pat-
tern  OR  motion  OR  kinematics ) )  AND NOT  ( dog  OR  









From the fifty-three studies found in the literature and respecting the inclusion and exclusion criteria, ten 
types of NMD have been studied with a leading interest in Duchenne muscular dystrophy, Charcot-Marie-
Tooth disease and myotonic dystrophy. Table 2-4 summarizes the number of studies per type of NMD, the 
average number of participants per study and whether children or adults or a mix were examined. Most 
studies investigated a single disease, while a few observed a mixed type of disease [67]–[70]. The size of the 
studies is largely limited in NMD, large one with DMD at a national scale can reach up to 60 [71], 70 [72] or 
even 145 [73] participants. While studies are commonly made of 10 participants or less, the average size of 
the studies is about 30 participants. Most studies investigated participants over 18 years old, except for stud-
ies on DMD and SMA type II as these diseases have early onset and shorter lifespan. Studies on CMT cases 
have mixed test sets of both children and adults. The number of studies is correlated with the prevalence (or 
incidence) of the diseases. 
  
2.4 Ambulation in Neuromuscular Diseases 
20 




Studies on  
children/ 
adults/mixed 
Number of NMD partici-
pants (mean ±std) 
Duchenne muscular dystrophy DMD 16 (+1 review) 15 / 1 / 0 26 ±35 
Charcot-Marie-Tooth disease CMT 11 (+1 review) 2 / 2 / 7 21 ±16 
Myotonic dystrophy DM 8 0 / 8 / 0 18 ±14 
Facioscapulohumeral muscular dystrophy 
FSHD 
5 0 / 5 / 0 10 ±4 
Inclusion body myositis IBM 3 0 / 3 / 0 35 ±24 
Limb girdle muscular dystrophy LGMD 2 0 / 2 / 0 17 ±4 
Becker muscular dystrophy BMD 2 0 / 1 / 1 27 ±35 
Spinal muscular atrophy SMA 2 1 / 1 / 0 5 ±4 
Amyotrophic lateral sclerosis ALS 2 ? 26 ±2 
Poly- / dermato- myositis PM/DeM 1 0 / 0 / 1 3 
 
????? ??????????????????????
Studies tackling gait in NMD cases focus on different aspects, and can be categorized into the following broad 
labels: muscle strength vs performance, compensatory kinematics, gait parameters, and decline prediction. 
« Strength vs performance » investigates the correlation between muscle strength and walking perfor-
mances. The muscle strength is usually evaluated by a simple manual muscle test or through magnetic reso-
nance imaging (MRI), which reveals the level of residual muscle fibers. Walking performances are usually 
evaluated using a validated test such as the 2-minute walk test (2MWT) or 6 MWT. The second category 
« kinematics compensation » studies the compensatory motions by comparing the kinematics and kinetics 
between two groups, usually between one group with NMD and one control group. Such an experiment 
requires a motion tracking system and force plates to record the kinematics and kinetics of gait. The third 
category « gait parameters » investigates basic gait parameters, typically compared to a control group. Usual 
gait parameters are parameters such as stride length, stride rate, duration of double stance, walking velocity, 
etc.  A fourth category « decline prediction » investigates correlations between degeneration and effects 
upon lifestyle to predict events; for example, a certain amount of muscle strength is required for ambulation. 
Other isolated studies investigated other factors such as the modifications of the ground reaction forces dur-




Table 2-5 Studies related to gait analysis in NMD people by topics treated 
Category of study 
Number of 
studies 
Diseases Investigated References 
Muscle strength vs performance 9 
DMD, IBM, FSHD, DM, BMD, ALS, 
SMA 
[72], [74]–[81] 
Compensatory kinematics 30 
DMD, CMT, IBM, FSHD, DM, SMA, 
LGMD, PM, DeM  
[67], [68], [70], [71], [82]–
[107] 
Gait parameters 6 DMD, CMT, DM, ALS [108]–[113] 
Decline prediction 2 DMD [73], [114] 
Other 4 DMD, BMD, CMT, DM, IBM, LGMD [69], [115]–[117] 
 
??????? ???????????????????????????????????
Nine studies, covering the correlation between some muscle strength and the functional performances such 
as walking, are presented in Table 2-6. All studies seem to follow a recent interest as they were all published 
over the last six years. All examinations were focused on a single disease each, including inclusion body my-
ositis and dystrophies such as facioscapulohumeral, myotonic, Duchenne and Becker. Three different muscle 
strength tests are reported in the conduction of the studies: maximum voluntary isometric contraction 
(MVIC), manual muscle test (MMT) and magnetic resonance imaging (MRI). Performances in ambulation are 
mostly examined using a 6-minute walk test (6MWT) or 10 meter walk test (10 meter WT). 
The maximum voluntary isometric contraction (MVIC) is a test that allows to quantitatively assess the 
strength of a group of muscles, such as knee flexors or hip extensors. It measures the torque capacity at the 
joint using a dynamometer apparatus. Strength is measured only in a specific position, usually with both hip 
and knee flexed at 90° (sitting position). The manual muscle test (MMT), is a test that does not need a specific 
device. The person being evaluated is asked to perform motions under different constraints such as limb 
gravity, counter-force resistance of varying strength, or no constraint at all. A score is given depending on 
the highest resistance the subject can overcome. While this test is not very precise and is best suited for weak 
muscles, it is very simple and quick to perform. Magnetic resonance imagery (MRI) is commonly used in 
muscular atrophy and dystrophy, as it allows evaluation of how much fat has infiltrated muscles, and gives 
direct access to measuring individual muscle capacity. This approach requires more equipment and re-
sources, but offers more precise results. 
The 6-minute walk test (6MWT) evaluates the distance a person can travel in 6 minutes. This test evaluates 
the walking ability of the person and her/his endurance. It is usually conducted with people without severe 
gait condition as it requires a significant amount of effort. The 10 meter walk test (10 meter WT) assesses 
gait condition without relying as much on endurance, which induces fatigue. This test often records walking 
kinematics and kinetics, and is recommended for people with severely impaired walking abilities who cannot 
cover long distances.  
2.4 Ambulation in Neuromuscular Diseases 
22 




Muscle test Performance test 
Alfano 2017 [74] USA (s)IBM / 55 MVIC 2MWT, 6MWT, timed stairs 
Davenport 2014 [77] USA (s)IBM / 42 MVIC 
10 Meter WT (comfor-
table+fast) 
Aprile 2012 [81] Italy FSHD / 16 MMT 10 meter WT, 2MWT 
Rijken 2015 [80] Netherlands FSHD / 10 MRI (trunk+legs) 
10 meter WT (comfor-
table+fast) 
Bachasson 2016 [75] 
France/ 
Canada 
DM(1) / 22 MVIC (neck+legs flexions) 6MWT 
Park 2017 [78] Korea DM(1) / 19 MRI (trunk to neck) 6MWT 
Park 2018 [79] Korea DM(1) / 19 MRI (legs) 6MWT 
Bozgeyik 2017 [72] Turkey DMD / 70 MMT 6MWT 
Barp 2017 [76] Italy BMD / 51 MRI (legs) 6MWT 
 
Alfano et al. [74] reported that the strength of hip extensors, knee extensors and plantar flexors, and body-
weight, best described performances in 2MWT in sporadic IBM participants. However, only knee extensors 
and plantar flexors expressed performances in 6MWT. The performances for climbing stairs were also eval-
uated and were correlated with the strength of the knee extensors. Davenport et al. [77] studied sporadic 
IBM participants over 10 meters at comfortable and fast walking speed. They reported that the strength of 
the knee flexors and ankle plantar flexors significantly and positively impacted comfortable walking, while 
the strength of the knee extensors alone significantly increases fast walking. 
In people with FSHD, Aprile et al. [81] found that hip flexors, knee extensors and ankle dorsiflexors strength 
better expressed walking speed, but also greater step length and smaller lateral step width. Although step 
width in anterior studies was mostly correlated with hip abductors [118], [119]. Rijken et al. [80] observed 
both MRI of most leg muscles and some of the trunk, but also recorded the gait kinematics and kinetics over 
a 10 meter WT. Results show that performances at comfortable speed is correlated with the ankle push off 
power and muscle tissue proportion in calf (ankle plantar flexors) and gluteus maximus (hip extensor). The 
same correlations are observed for performances at fast walking speed, while an additional correlation is 
found with the hip power generated at push off. 
Studies with people with myotonic dystrophy type 1 show a correlation between walking performances in 
6MWT with ankle plantar flexors and neck muscles strength [75], [78], [79]. Bachasson et al. [75] also found 
some positive correlation between walking speed and knee extensors or ankle dorsi flexors. 
Bozgeyik et al. [72] studied walking performances in children with Duchenne muscular dystrophy. They re-
ported a correlation between neck strength and walking velocity. Barp et al. [76] largely investigated the 
muscle tissue proportion in people with Becker muscular dystrophy. They reported a correlation between 
the 6MWT performance and most lower limb muscles (gluteus maximus, vastus lateralis, adductors, biceps 
femoris, semitendinosus, semimembranosus, tibialis anterior, soleus, and gastrocnemius medialis), where 




From the few studies presented here that investigate the muscle strength correlation with walking perfor-
mances, the results are quite varied. Although each NMD affects different muscle group, gait is frequently 
affected. It seems that the muscles which are needed for walking motion are also those most affected by 
NMD. One possible conclusion is that all muscles contribute largely to the walking performances, however, 
the weakest muscles reflect more significantly the decrease in walking velocity. Another interesting and non-
intuitive observation made in this section is that walking performances are reported to be largely influenced 
by the neck muscles in myotonic dystrophy and Duchenne muscular dystrophy. In conclusion, studies on 
correlations between muscles and performances do not clearly outline the overall scheme, as studies were 
biased by the homogeneity of the muscle weakness in the individual groups. 
????? ????????????????????????
A large group of studies investigated the adaptation of NMD patients to the disease through the motion 
pattern during gait. Studies about compensation kinematics (angle at joints) often also measured the kinetics 
(moments at joints) and EMG (muscle activity). The moments at joint are calculated based on the ground 
reaction forces measured usually over two or three steps by force platforms, plus the kinematics and anthro-
pometrics of the participant. The muscular activity can be measured by EMG sensors placed on the skin and 
are able to provide the timing of the muscle activation and a rate of activation relatively to maximal intensity; 
however, no force or absolute level of contraction can be measured or extracted to directly assess the human 
implication. 
??????? ????????? ???????? ?????????
Duchenne muscular dystrophy is the most frequently seen NMD. The disease evolves largely during childhood 
or adolescent years with severe complications and death usually during early adulthood. The studies with 
DMD participants are resumed in Table 2-7. Trias et al. [106] defines three classes of the evolution of symp-
toms : early, intermediate and final. As the disease evolves rapidly, muscles are globally affected, which dif-
fers from slower diseases where very distinct groups of muscles are affected. The first observations reported 
in children with DMD, compared to controls, are a shorter step length ([85]–[87], [92], [106]), a larger step 
width ([85], [86]) and a similar ([86]) or increased cadence ([87], [92]) and a decreased walking velocity with 
a higher metabolic cost ([106]). 
One of the main characteristics of DMD gait is toe walk, where the person walk mostly on the frontal part of 
the foot while the heel is less loaded [67], [85], [106]. To make it simple, toe walk resembles the gait of 
someone wearing with high heeled shoes. This complication comes at an advanced stage of the disease. 
Linked to that toe walk comes also a foot drop symptom which is due to the poor dorsiflexion capacity at the 
ankle [86], [87]. The foot drop symptom is marked by a larger plantar flexion of the ankle during the swing 
phase compared to controls. In order to allow a good foot clearance and avoid tripping, people adopt a step-
page gait, where compensations are a circumduction motion of the full leg [70] accompanied by an abnor-
mally large hip and knee flexions during swing phase [70], [85], [86], [94]. Hyperlordosis is reported in DMD 
by [86], [87] with a large range of motion of the pelvic frontal tilt [87]. In the frontal plane, large pelvic tilts 
and large hip abduction during swing are measured following waddling gait patterns [86], [87]. Both strate-
gies are adopted to compensate for proximal muscle weakness about the trunk and the thighs. A tendency 
to muscle hyperactivity in all main muscles and proportional to the severity of symptoms has been observed 
in [103], [106]. It seems that hyperactivity helps co-contracting and thus stiffening the joints to diminish the 
effect of unpredicted perturbations and reduces the risk of falling.  
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Table 2-7 Summary of studies examinating compensation patterns in gait in DMD people 
Reference Country Diseases/Participants Participants age Measurement 
Armand 2005 [70] France DMD / 2 – SMA II / 2 Children Kinematics / kinetics 
Armand 2006 [67] France DMD / 1736 Children Kinematics / kinetics 
Boccardi 1997 [84] Italy DMD / 10 Children Kinematics / kinetics / EMG 
Chen 2013 [85] China DMD / 10 Children Kinematics 
D'Angelo 2009 [86] Italy DMD / 21 Children Kinematics 
Doglio 2011 [87] Italy DMD / 15 Children Kinematics / kinetics 
Gaudrealt 2009 [91] Canada DMD / 11 Children Kinematics / kinetics / EMG 
Gaudreault 2010 [92] Canada DMD / 11 Children Kinematics / kinetics 
Goudriaan 2018 [93] Belgium DMD / review paper Children - 
Goudriaan 2018 [94] Belgium DMD / 15 Children Kinematics / kinetics 
Ropars 2016 [103] France DMD / 16 Children Kinematics / kinetics / EMG 
Trias 1994 [106] France DMD / 12 Children 




Ten studies focused on the gait pattern of people with CMT. Main characteristics of the studies can be found 
in Table 2-8. CMT includes several types of diseases; however, all CMT are quite homogeneous and affect 
mainly the flexors of the ankle. The age at onset may still vary, which is why studies include people with a 
large range of age from children to elderly. 
The main gait parameters observed are similar to those seen in DMD: a slower walking velocity, shorter step 




Figure 2-11 Illustration of the posture of a children with Duchenne muscular dystrophy during walking. Credits. 
Werner 19872. 
Characteristic gait patterns will differ depending on the residual strength capacity in ankle dorsiflexors and 
plantarflexors muscles. Three groups have been extracted from studies of several diseases [71], [88], [89], 
[95]: a group presenting good dorsi- and plantar-flexors, a group with poor dorsiflexors but good plantarflex-
ors and a group with both poor dorsi- and plantar-flexors. While the first group with low muscle weakness 
does not present highly noticeable deviations from the kinematics of healthy people, the two other groups 
can present quite different patterns. Since both groups have poor dorsiflexors strength, footdrop is a fre-
quent first symptom [71], [88], [89], [95] that appears during the swing phase and requires the rest of the 
body to compensate for it, in order to mitigate the risk of tripping. Footdrop is marked by an abnormal plantar 
flexion during the swing phase, followed by a first contact with the ground with the toes, compared to a heel 
strike in healthy people, and lands in a stance phase with the foot flat on the ground. Depending on the types 
of ankle weaknesses, different compensating patterns are reported. 
 
                                                                        
2 https://cellbiology.med.unsw.edu.au/cellbiology/index.php?title=File:Congential_Muscular_Dystrophy.jpg 
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Table 2-8 Summary of studies examinating compensation patterns in gait in CMT people 
Reference Country Diseases/Participants Participants age Measurement 
Don 2007 [88] Italy CMT / 21 Adults Kinematics / kinetics / EMG 
Ferrarin 2012 [89] Italy CMT  / 21 Children Kinematics / kinetics 
Guillebastre 2013 [95] France CMT / 26 Adults Kinematics / kinetics 
Kennedy 2016 [97] Australia CMT / review Children - 
Kuruvilla 2000 [98] USA CMT / 5 Adults Kinematics / kinetics 
Lencioni 2018 [99] Italy CMT / 21 Mixed Kinematics / kinetics / EMG 
Marchesi 2011 [100] Italy CMT / 30 Adults Kinematics / kinetics 
Newman 2007 [101] Ireland CMT / 16 Mixed Kinematics / kinetics 
Ounpuu 2013 [120] USA CMT / 33 Children Kinematics / EMG 
Wojciechowski 2017 [71] Australia CMT / 60 Children Kinematics / kinetics 
 
Don et al. [88] observed steppage gait in a group of people with good plantar flexor strength but poor dorsi-
flexors. It compensates the footdrop by augmenting the hip and knee flexion angles to allow a good clearance 
of the foot despite the footdrop. In this case, the metabolic expenditure is increased compared to healthy 
gait [88]. The push-off phase is also impacted, by increasing hip extension and delaying push until higher 
dorsiflexion is reached (the foot stays longer flat on the ground) [88], [120]. The good residual strength in the 
plantar flexor allows a push phase that is a direct factor of the walking velocity. 
In case of both dorsi- and plantar-flexors weakness, the postural stability is largely hindered. Two studies 
observed a compensating pattern in the form of a stiff knee gait. The hip and knee flexions are limited, but 
there is a larger pelvic tilt (hyperlordosis) and a large hip abduction that provides foot clearance [88], [89]. 
The motion is mainly provided by the hip with a greater hip extension moment and power [89]. Woj-
ciechowski et al. [71] reported that both dorsi- and plantar-flexors strength is highly related to the walking 
performances. People being affected at both sides of the group muscles around the ankle, and thus ambulate 
slowly. The walking performances and postural stability in CMT can however be greatly improved by wearing 
ankle-foot orthosis (AFO) than can contribute to correct the footdrop impairment [88]. 
??????? ???????????????
Few studies investigated the compensation kinematics in cases of diseases other than Duchenne muscular 
dystrophy and Charcot-Marie-Tooth disease. Three studies examined myotonic dystrophy (DM), while no 
more than one study were found that tackle facioscapulohumeral dystrophy (FSHD), inclusion body myositis 
(IBM), limb girdle muscular dystrophy (LGMD), dermatomyiositis and polymyositis (DeM and PM) and spinal 
muscular atrophy of type II and III (SMA). These studies are described in Table 2-9. 
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Table 2-9 Summary of studies examinating compensation patterns in gait in non-DMD or non-CMT neuromuscular 
diseases 
Reference Country Diseases/Participants Participants age Measurement 
Galli 2012 [90] Italy DM / 10 
Adults 
Kinematics / kinetics / EMG 
Tiffreau 2012 [105] 
France/Bel-
gium 
DM / 15 
Adults 
Kinematics / kinetics / EMG 
Wright 1995 [107] USA DM / 5 
Adults 
Kinematics / kinetics 
Iosa 2007 [118] Italy FSHD / 12 
Adults 
Kinematics / kinetics 
Moreno Izco 2005 
[68] 
Spain 
DM / 40 – FSHD / 9 – 




USA IBM / 9 
Adults 
Kinematics / kinetics 
Siegel 2007 [104] USA PM / 2 – DeM / 1 
Mixed 
Kinematics / kinetics 
Armand 2005 [70] France SMA II / 2 – DMD / 2 
Children 
Kinematics / kinetics / EMG 
Matjacic 2008 [82] Slovenia SMA III / 7 
Adults 
Kinematics / kinetics / EMG 
 
Myotonic dystrophy primarily affects the distal muscles. DM cases present a low walking velocity due to both 
a low cadence and step length, while the stride width is large [90]. Hyperextension at the knee during stance 
is reported in about 60% of cases and is combined with a high pelvic tilt and a small hip extension at push off 
[90]. Most effort is reported around the hip to minimize the power needed from the knee and ankle [90]. 
Hyper activation of the gastrocnemius (plantar flexor) is reported with a very small range of motion (RoM) 
about the ankle dorsi-/plantar-flexion during swing [105]. Oscillatory motions about the hip during stance in 
flexion/extension were noticed [107] and highlights impairment at nerve level. 
Facioscapulohumeral muscular dystrophy affects first distal muscles and then spreads to proximal limbs. 
Hence, the weakness about the ankle is more severe than about the hip and knee. The main kinematics 
abnormalities reported are a large reduction of the maximal knee flexion (about 50%), combined with knee 
hyperextension during stance [118]. The hip and ankle pattern differs more moderately than the knee in the 
sagittal plane, where lower dorsiflexion can be observed at the ankle and the hip maximal extension before 
push off is also reduced [118]. The gait pattern is close to a stiff knee compensatory behavior. 
Inclusion body myositis affects mostly the quadriceps muscles (knee extensor and hip flexor). The main kin-
ematic compensation to lower the knee loading in extension is the knee hyperextension during the stance 
phase [83]. Foot drop symptoms can also appear later with the progression of the disease [83]. In other 
inflammatory myositis such as polymyositis and dermatomyositis, hip and knee muscles are mostly affected 
and leads to low knee flexion and low hip extension during stance in order to reduce torque [104]. 
Type II spinal muscular atrophy in children generally affects muscles. Hyperlordosis (large pelvic tilt), hyper-
extension of the knee during stance, small flexion of the hip and knee during swing and absence of plantar-
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flexion have been recorded [70]. The combination of all compensations seems particularly effective as tor-
ques were largely decreased at every joints. Step length was increased by pelvic motions [70]. In type III SMA 
in adults, large pelvic tilt, knee hyperextension during stance and larger hip adduction are observed [82]. A 
higher hip adduction torque allows an increase in foot clearance while reducing torque on hip and knee flex-
ion/extension[82]. The plantar flexion at the ankle is only slightly impaired as demonstrated by torque am-
plitudes similar to the one measured in the control group [82]. 
??? ????????????
????? ????????????????? ??????????????????????
Neuromuscular diseases include heterogeneous group of disease marked by progressive muscle wasting on 
variable locations. The research in this field is recent and no cure have been discovered yet. Exercising can 
help maintain a moderate strength of the muscle, but persons with NMD need to be cautious not to overload 
their muscle as it can lead to the destruction of remaining fibers. The full body, including some parts of the 
lower and the upper body, is usually affected. Ambulation disorders are one of the main consequences of 
neuromuscular diseases. However, there is a lack of solutions to support these disorders, canes are rarely 
used and ankle-foot orthosis significantly improve gait, but it is limited to person with mostly ankle weakness. 
The most reimbursed solutions in Switzerland are motorized and non-motorized wheelchairs. There is thus a 
great need for new type of assistive systems for the mobility and promotion of exercising in neuromuscular 
diseases. The biggest challenge of neuromuscular diseases is the large variability in the symptoms that would 
either require a multitude of solutions or only a few solutions that would be modular and adaptable. 
????? ?????????????????????????????????????
Over a literature review of 53 papers that reported observations on ambulation in neuromuscular diseases, 
31 studies focused on the kinematics of compensating pattern. Duchenne and Charcot-Marie-Tooth muscular 
dystrophies account both for about one third of the studies. The rest consist mostly of isolated studies on 
one neuromuscular disease or heterogeneous studies. The following gait patterns have been reported in the 
studies: 
? Toe walk, where the “heel strike” event that occurs at the beginning of the stance phase is replaced 
by a first contact with the ground with the toes. The gait is denoted by large plantarflexion during 
the full gait cycle due to a constant tension on Achilles tendon. 
? Foot drop or steppage, where the dorsiflexors are very weak and the foot tends to plantarflex during 
the swing phase under the effect of the gravity. 
? Hyperlordosis, which is denoted by an abnormal anterior tilt of the pelvis and a large curving of the 
lower back. 
? Hyperextension of the knee, where the knee is slightly bended inwards during stance in order to 
avoid to load the quadriceps group. 
? Waddling gait, where the upper body swings largely laterally during double stance in an inverted 




? Co-contration or stiff gait, which is a common tendency in people with neuromuscular diseases in 
order to increase their stability. 
Each of these compensating patterns are caused by a dysfunction from the musculoskeletal system. Their 
study allows to address the specific need for people with neuromuscular diseases. In a general manner, all 
the studies that observed the gait parameters denoted a lower walking velocity, a shorter stride length and 
a larger stride width in people with neuromuscular diseases compared to the control groups. The large ma-
jority of studies were performed on a small group of people, usually between 5 and 15 people. Moreover, 
apart from Duchenne and Charcot-Marie-Tooth muscular dystrophies, there exist very few studies on the 
other types of neuromuscular diseases.  While the existing studies are non-representative as the number of 
participants are very limited.
  30 
?
  31 




Following the literature review on gait compensations presented in section 2.4, an investigation was per-
formed on a heterogeneous group of people with neuromuscular diseases. This study provided better under-
standing of different symptoms of NMD and its various paths of development, while also illustrating the im-
plication of NMD-related impairments on various aspects of subjects’ daily lives. In order to investigate the 
ambulation in a varied population of people with NMD, a group of NMD-impaired people were collected. 
These subjects all had a residual capacity to walk, whether it be with or without some type of assistive aid. 
Due to the severe symptoms and complex conditions that arise when a child with NMD is growing, only adults 
were included in the study. Subjects were found through advertisements in the neuromuscular disease unit 
of the CHUV (Centre Hospitalier Universitaire Vaudois) and through the ASRIMM (Association Suisse Ro-
mande Intervenant contre les Maladies neuroMusculaires). 
The study consisted of two parts: an interview and a measurement of muscular strength and gait kinematics. 
The interview section addressed subjects’ history of symptoms and collected information on how these 
symptoms impacted activities of daily living (ADL). Then, measurements of muscular strength and recordings 
of the gait kinematics were taken. The primary goal of the study was to observe the different compensation 
patterns in NMD, to understand what kind of needs each joint level had that an assistive device would need 
to provide, and to build up the full specifications for an assistive ambulation device. The work presented here 
is partially based on the publication “From gait measurements to design of assistive orthoses for people with 
neuromuscular diseases” by A. Ortlieb, J. Olivier, M. Bouri, H. Bleuler and T. Kuntzer [69]. The experiment 
was approved by the local Ethics Committee (CER-VD 174/14). 
??? ???????
????? ?????????????
Two groups of participants took part in the study: a group of people with NMD with a residual ability to walk 
at least 100m and a control group composed of healthy people without any walking disorder. Fourteen adult 
subjects with a genetically or histologically confirmed NMD condition volunteered in the study (8 males and 
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6 females, aged 48.7 ± 15.8 years) with the following distribution of conditions: 5 with facioscapulohumeral 
muscular dystrophy (FSHD), 3 with Charcot-Marie-Tooth neuropathies (CMT), 2 with Becker muscular dys-
trophy (BMD), 2 with myotonic dystrophy type 1 (DM1) and 2 with inclusion body myositis (IBM). All partici-
pants satisfied the main criterion of being able to walk at least 100 meters without any support other than 
ankle foot orthoses (AFO), if needed. Seven of the participants required their AFOs to be able to perform the 
gait measurements (see Table 3-1). The control group consisted of five participants (2 males and 3 females, 
aged 32.4 ± 15.5 years) who did not present any walking disorder. 
????? ?????????????
A short questionnaire was provided to participants that collected information on the participants’ daily 
amount of ambulation, the limitations encountered when walking for long distances or durations, over une-
ven ground or while climbing stairs. The questionnaire also gathered history of symptoms and the progres-
sion of the NMD (e.g. age at onset, loss of the capacity to do a certain activity, etc.). 
Following the questionnaire, a manual muscle test was performed on the participant following the medical 
research council (MRC) grading scale. The hip abduction, adduction, flexion, extension and the knee flexion, 
extension and the ankle plantarflexion and dorsiflexion were manually tested and a mark from 0 to 5 based 
on the MRC scale. Both legs of each participant were evaluated; the mean muscle strength over all the joints 
was documented. The MRC scale is as follows: 
?  0 – indicates no contractility felt 
? 1 – small motions are perceived 
? 2 – the participant can largely move while the effect of gravity on the limbs is compensated 
? 3 – the participant can largely move while the limbs are subject to the gravity 
? 4 – the participant can hold against some resistance (manually exerted by the tester) 
? 5 – the participant can hold against full resistance [121]. 
Finally, the main interview consists of recording the kinematics of the participants while walking. All partici-
pants with NMD were asked to walk at a comfortable velocity. The control group was asked to match the 
pace of the NMD participants. The walking path was more than 8 m long, with a handrail to secure partici-
pants; participants were asked to use it only in case of emergency. A custom made mobile tracking system 
recorded the motion of the heels, shanks, thighs and the pelvis of the user [122]. The system is presented in 
Figure 3-1. It is composed of a mobile cart (1) with two independent driving wheels in front (2) that are 
controlled by an embedded computer (7). Two draw-wire displacement sensors (6) mounted on the cart can 
be attached to the participant so that the distance and orientation of the cart can be regulated [123]. The 
tracking system Accutrack 250® (Atracsys LLC, Puidoux, Switzerland) includes a master optical sensor unit 
working in the infrared range and seven (customizable) active markers with 4 LEDs. The tracking sensor (3) is 
mounted on the cart while the markers (4) are placed on the lower limbs of the participant. The aim of the 
cart is to keep the markers within the working range of the tracking sensor (about 1.5m to 3m). The ad-
vantage of using a mobile tracking system is that it is not spatially dependent and permits fewer cameras to 
be used (only one, in this case) [123]. The tracking unit is able to record the 6-D positions (3-D position and 
3-D orientation) of each markers with a sampling rate above 80 Hz [122].  
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Figure 3-1 Representation of the optical tracking setup with: 1. Mobile platform, 2. Motorized front wheels, 3. 
Tracking camera unit, 4. Infrared active markers, 5. Subject, 6. Cable sensor of distance and 7. Embedded computer 
collecting data and controlling the cart motion. Copyright © 2015, IEEE 
The Euler angles about the hip, knee and ankle joints are calculated based on the difference of orientation in 
the three planes of the two adjacent markers of each joint. In order to measure the gait cycle, the heel strike 
events are detected as the heel markers reach their lower vertical position. The collected data are then nor-
malized over the gait cycle and superposed to obtain the mean and standard deviation of each data set.   
??? ????????
????? ?????????????????????????????????
Participants’ ability to walk unaided or with a cane varied greatly, ranging from ten minutes up to two hours. 
None used rollators. Most participants reported that handrails were necessary for most of them to walk uphill 
or to climb stairs. Ankle-foot orthoses were common among the participants; most who used them were 
unable to walk without them. A few participants (2) preferred to use a wheelchair or scooter instead of walk-
ing. Those who used wheelchairs said that balance disorders and the risk of falling were primary reasons that 
they transitioned to regular use of a wheelchair.  
????? ??????????????????????????????????????
The walking condition in the group with NMD is first analyzed based on what we will term “comfortable 
velocity criteria.” Table 3-1 present the subjects and their main characteristics sorted from the low to the 
high comfortable walking velocity. The measured comfortable walking velocity of the group with NMD is, on 
average, 2.1 ±STD 0.6 km/h and ranging from 1.4 km/h to 3.2 km/h. The comfortable walking speed of a 
healthy person, by comparison, are about 4.9 km/h as reported by Bohannon et al. [124]. The average score 
of the group with NMD on the manual muscle test is 2.9 ±STD 0.4, where 3 represents a condition in which 
large motions can be performed if the limbs are only subject to gravity – however, if there is some resistance 
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present, the limbs cannot hold these positions. The estimated mean strength loss is roughly about 40% com-
pared to somebody healthy with a minimum muscle capacity. It was of interest to see if correlations existed 
between some characteristics of the participants and their respective comfortable walking velocities. None 
of the parameters, such as disease, age, sex, affection score and use of orthoses, showed any statistically 
relevant correlation with the walking performances. Figure 3-2 illustrates the poor correlation between the 
comfortable walking velocity and the muscle strength. 
Table 3-1 Subjects characteristics and measured velocities 
Subject 
Characteristics 
Disease Age Sex 
Affection score 
(MRC scale 0 – 5) 
Comfortable walking 
velocity [km/h]  ([cm/s]) 
S1* CMT 70 M 2,88 1,44  (40) 
S2* CMT 58 F 3,13 1,46  (41) 
S3 FSHD 67 F 3,25 1,53  (43) 
S4 BMD 40 M 2,38 1,71  (47) 
S5* CMT 34 F 3,31 1,71  (48) 
S6 FSHD 29 F 2,19 1,77  (49) 
S7 BMD 30 M 3,06 1,89  (53) 
S8* FSHD 54 F 2,88 1,95  (54) 
S9 FSHD 66 M 3,00 2,48  (69) 
S10* DM1 44 M 3,06 2,5  (69) 
S11* FSHD 44 M 2,75 2,58  (72) 
S12 DM1 42 M 3,31 2,63  (73) 
S13* IBM 31 F 2,13 2,9   (81) 
S14 IBM 73 M 3,56 3,17  (88) 
* Were wearing an ankle-foot orthosis during the test  
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Figure 3-2 Regression of comfortable walking velocity versus muscle strength. The blue dots represent the raw data, 
while the black dashed line is a linear fit of the walking velocity by the muscle strength. 
The three Euler angles about the hip, the knee and the ankle during level walking are presented in Figure 3-3. 
The kinematics are normalized over one gait cycle, starting at heel strike. The first 60%-70% of the cycle 
correspond to the stance phase, while the remaining 30%-40% correspond to the swing phase. Among the 
group with NMD, two main gait patterns were identified and results were split into two groups: NMD group 
1 and NMD group 2. No correlations are found between the groups and other parameters such as muscle 
strength, age, sex, use of orthoses or walking velocity. The kinematics of the control group follows the 
schemes of typical gait pattern at low velocity as recorded by Stoquart et al. [125] previously. 
The group 1 with NMD has a quite similar gait pattern than the control group. The hip and knee range of 
motion (RoM) in flexion and extension have the same amplitude in group 1 and in the control group. The 
main dissimilarities appear around the ankle. During the swing phase at the end of the cycle, subjects in group 
1 do not present dorsiflexion of the ankle after push-off during the swing phase. The dorsiflexion happens 
while the foot is in contact with the ground, which modifies both ankle and knee flexion during heel strike. 
Those in group 1 also present a large variation of the foot orientation during swing in the form of large ankle 
rotations and inversion at early swing. Finally, those in group 1 have more pronounced knee extensions dur-
ing mid-stance than subjects in the control group. 
Subjects in group 2 demonstrate a more evident compensation pattern. Hip and knee flexions are more pro-
nounced during the swing phase, and stance is marked by a greater hip extension while the knee is fully, or 
even hyper, extended during the full stance phase. At the ankle level, the stance phase is similar to the control 
group, but subjects in group 2 do not present any plantar flexion at toe-off (early swing) or during the swing 
phase. Compared to those in group 1, subjects in group 2 have a high variation of ankle internal rotation and 
inversion during the swing phase. Eventually, the control group has larger amplitude of internal/external 





Figure 3-3 Hip, knee and ankle angles in function of percentage of gait cycle are presented for healthy subjects at a 
low walking velocity and for the neuromuscular patients at their comfortable walking velocity. Patients are split 
into homogenous group in function of gait pattern. NMD group 1 is composed of patients {5, 6, 8, 10, 11, 12, 14} 
and NMD group 2 of {1, 2, 3, 4, 7, 9, 13} relatively to Table I. Copyright © 2015, IEEE 
In summary, three modified kinematics are observed in the groups with NMD. Knee hyperextension com-
bined with larger hip extension (or pelvic tilt) patterns are observed in subjects in group 2. An absence of 
ankle dorsiflexion during swing is observed in subjects in group 1, while an absence of plantarflexion during 
swing is observed in subjects in group 2. The next section addresses how the previously discussed data, gath-
ered from literature, and findings from this study together illuminate the needs that assistive devices must 
be able to provide for people with NMD.  
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??? ???????????? ?????? ???????? ????????????? ?????? ???? ???
??????????? ????????
Neuromuscular diseases are degenerative diseases that initially affect a small region of musculature and 
spreads, with varying speed, to eventually extend to the full body. Two key characteristics of NMD are thus 
the extent to which each muscle atrophies, and with that atrophying the decrease in functional capacity of 
corresponding joints, and the progression of loss of strength over time.  Assisting persons with NMD requires 
a support than can be tailored to individual user needs, and which can adapt over time to accommodate 
progressing symptoms. Three main activities are prioritized as representative of important daily movements: 
walking on level ground, sit-to-stand transitioning and stair climbing. The three activities are discussed sep-
arately in the following sections. The needs are first examined in terms of the symptoms and gait patterns 
observed in people with NMD, after which the data from the literature on healthy people are taken to eval-
uate the targeted performances and the support needed to achieve them. 
As symptoms in people with NMD can vary in severity, it is important to define the target demographic for 
an assistive mobility device.  There are two primary conditions that must be considered. First, the impairment 
of the subject’s ability to walk should be severe enough; this implies that the burden of being supported will 
not outweigh the benefits provided by the support. Second, the level of impairment cannot be too drastic; 
the user must still be in charge of the motion of the device while receiving a certain level of assistance while 
ambulating and thus the patient’s musculoskeletal system must still be strong enough to ambulate. Quanti-
tatively, the two criteria are expressed as follows: first, at least one joint should be affected with a minimal 
residual strength about 30% (equivalent to a score of 2 on the MRC scale), and second, the mean residual 
strength over all the lower joints (hip, knee and ankle) should be at least 50% (equivalent to a score of 3 on 
the MRC scale). These two criteria express the conditions under which the use of an exoskeleton is recom-
mended to support mobility. These criteria serve also as references as they better define the condition and, 
hence, the need of the end-users. 
????? ???????????? ??????????????????????????????????????????
The first aim of the assistance provided is the compensation of deteriorated or lost functions such as walking, 
climbing stairs or rising from a seated position. The observed nature of the impairments in NMD include the 
following:  
? muscles weakening, which leads to strength limitations and early fatigue 
? altered sensations, which leads to difficulty managing limbs and balance 
? deterioration of reflex and coordination, creating late response time or abnormal movement control  
There are two distinct issues related to the movement of walking while afflicted by NMD. The first issue is 
propulsion; a subject must have the capacity to perform each necessary limb motion to push the upper body 
forward. The second issue is the management of balance, which is highly critical for one’s safety. 
Predicting users’ assistive needs can be initially assessed by exploring the primary questions “what are the 
critical joints that most need support?” and “what is the nature of the support needed?” Observing compen-
sation patterns in people with NMD while walking yields interesting possible answers to these questions. 
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One remarkable compensation pattern is the compensated Trendelenburg gait, also called waddling gait. It 
is a recurring gait pattern in people with proximal muscle weakness around the trunk and hips. The charac-
teristics of this gait pattern is illustrated in Figure 3-4. Due to weak hip abductors, the swinging leg is subject 
to hip drop as the leg weight cannot be supported. In order to compensate and avoid hip drop (pelvic obliq-
uity), people with NMD compensate by moving the upper body laterally on the side of the supporting leg. 
The weight of the upper body counter-balances the weight of the leg and allow adjustment of the pelvis. 
Waddling gait is also often characterized by very small flexions about the hip and the knee, which are com-
pensated by a larger rotation of the pelvis in the transverse plane. Hip flexors and extensors weakness seem 
to originate these compensations. Waddling gait can potentially be rectified by providing additional force to 
support the weakened muscles, i.e. the hip abductors, flexors and extensors. The type and amount of support 
will be investigated in the next section, which analyzes the kinetics about the joints during different activities. 
Another common compensation pattern is “foot drop”. It is caused by weak dorsiflexors (distal weakness) at 
the ankle and impairs mostly the swing phase from push-off to heel strike. As both push-off and heel strike 
cannot be performed with large extension or flexion of the hip, foot drop gait results in a small step length. 
The main issue with foot drop is the poor toe clearance and, as a result, a high risk of tripping. Two patterns 
can be adopted to increase toe clearance. The first one is a higher flexion of both hip and knee during swing 
as illustrated in Figure 3-5. The second uses a circumduction motion that is created by a large abduction of 
the hip on the swinging side. A common solution for people with NMD and others suffering from foot drop 
is an ankle foot orthosis (AFO) brace. An AFO brace is composed of a light structure that is slightly flexible 
and constrains the foot about a small flexion angle of the ankle. It is a passive, non-bulky and very lightweight 
solution to symptoms of foot drop disorder. It does not allow a complete physiological gait as it limits the 
amplitude of plantarflexion (necessary for a strong push-off) and does not adapt to slopes, resulting in bal-
ance issues. However, AFOs have radically improved ambulation in most of the person with weak dorsiflex-
ors. 
AFO braces can also improve discomfort from weak plantar flexors, which often cause poor push-off and 
difficulties in managing balance. A walking study where the ankle flexions of healthy participants were con-
strained using ski boots has been performed and showed that despite some larger flexions of both hip and 
knee, slow walking velocities (3.5 km/h) were achievable [126]. 
Another gait compensation pattern is denoted by knee hyperextension, which is usually combined with hy-
perlordosis of the spine. This is often observed in people who have weak knee extensors. Figure 3-6 illustrates 
the difference in patterns between a physiological gait and a gait affected by knee hyperextension and spine 
hyperlordosis. The compensation pattern exploits the singularity of the knee at 0° of flexion, plus the stability 
of the cruciate ligaments that prevent the knee from bending upwards. In this configuration, with an exten-
sion of a few degrees, the ligaments passively support the high forces directed along the line passing through 
the hip and ankle joints. Without this compensating posture, high extending torques are required and thus 
people with weak quadriceps experience frequent knee buckling and falls. Spine hyperlordosis comes from 
an anterior pelvic tilt which naturally stabilizes the knee hyperextension. Spine hyperlordosis is not caused 
by some muscle weakness about the hip, but rather, it is a result of the orientation of the pelvis which en-
courages the knee to hyperextend. In conclusion, this gait pattern is caused only by weak knee extensors. In 
order to rectify both knee hyperextension during stance and spine hyperlordosis, a support at the knee ex-
tension should be provided. Again, the type and amount of assistance will be addressed in next section based 
on the kinetics observed in physiological gait for different activities. 
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Figure 3-4 Schematic illustration of the difference between the physiological (A) and so-called waddling (B) gait pat-
terns captured at mid-stance. *CoP: Center of pressure 
 
Figure 3-5 Difference of kinematics during swing in a physiological (A) and in foot drop (B) gaits. 
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Figure 3-6 Difference of kinematics during stance in a physiological (A) and in knee hyperextension (B) gaits. Only 
the supporting leg is presented  
????? ???????????????????????????????????????????????
This work uses three activities involving ambulation to qualitatively describe the needs of a “normal” daily 
autonomous lifestyle. These activities are walking, standing up from a seated position and climbing stairs. 
The kinetics related to these different activities have been thoroughfully reported in current literature. This 
section will quantify the amount of support needed to perform a task based on the literature, and then dis-
cuss whether this support should be active, semi-active or passive. The quantification made in this section 
focuses on the propulsion function; the implications of balance and rejection of perturbations will be taken 
into account in a later section. 
??????? ?????? ???????
As demonstrated by Stoquart et al. [125], the torques and powers on joints involved in bipedal locomotion 
are highly dependent on walking velocity. Velocity is determined by the combination of the step length and 
the step rate (walking frequency). Body height and weight are also factors of walking kinetics. Data are usually 
presented normalized over the body weight, as body height is not a significant factor in walking kinetics. 
Walking speed and energy cost are nonlinearly related and plot as a quadratic function with a global mini-
mum [127]. The energetic expenditure at different walking velocities  investigated by Stoquart et al. [125] 
and Ralston [128] are illustrated in Figure 3-7. This figure shows that the most energy-saving walking velocity 
ranges are between 3.5 and 4.5 km/h. Walking slowly (under 3 km/h) has a higher metabolic cost. This is 
twice as disadvantageous for people with muscle weakness, as they are simultaneously subject to early fa-
tigue while using a less energetically efficient gait. 
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Figure 3-7 Evolution of the energy expenditure in function of walking velocity as measured by Ralston [128] and 
Stoquart et al. [125]. 
As demonstrated by previous studies, the exertion and kinetics of walking vary significantly depending on the 
gait velocity. In order to define the amount of support at the various joints, one must also specify the target 
walking velocity. The key knowledge about the walking velocity are the following. First, the mean comfortable 
velocity in healthy people is approximately 4.9 km/h [124]. Second, the most efficient walking velocity is 
between 3.5 km/h and 4.5 km/h. Third, the peak joint torques and power increase significantly with gait 
velocity [125].  With these factors in mind, two target velocities are selected for two levels of muscle weak-
ness.  For people with a global residual muscle capacity about 50%, the targeted velocity is 3,5 km/h, while 
for people with about 30% of residual muscle capacity, the velocity targeted is 2,5 km/h. 
Stoquart et al. [125] investigated the joint kinematics and kinetics for walking speed from 1 km/h to 6 km/h. 
Based on these data, the joint angular velocities were extracted from the angular position curves and data 
for 2.5 km/h and 3.5 km/h were extrapolated by averaging the two available closest data (which were meas-
ured at 2, 3 and 4 km/h). The measurements, presented in Figure 3-8 for the walking speeds of 2.5, 3.5 and 
5 km/h, highlight how subjects modify their gait to increase or decrease their walking speed. Globally, one 
can observe that higher walking speeds are reached by amplifying both peak angles and torques, while keep-
ing timing relatively unchanged. Angular velocities are similarly amplified as both step length and cycle rate 
are increased to perform higher walking speed [125]. As both peak angular velocities and torques are in-
creased, the effect on the peak power generated is tremendous, as it is a product of those two terms. Meas-
urements presented show that there is a rise about 180 % in peak power generated for a 140% increase in 
walking speed. Thus, the peak power observed for each ankle, knee and hip joint is more than doubled when 
comparing a walking speed of 5 km/h to one of 2,5 km/h. 
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Figure 3-8 Illustration of the hip, knee and ankle joint angle, velocity, torque and power during walking at different 
speed on a treadmill. Data are extracted from the measurements reported by Stoquart et al. 2008 [125]. Torque 
and power are normalized over the bodyweight. 
Measurements from Stoquart et al. [125] address the relation between walking speed and gait characteristics 
such as joint angular trajectory, velocity, torque and power. However, the measurements were performed 
over a treadmill, which differs from ground-walking conditions in several significant ways. For example, the 
torque pattern about the knee joint differs largely from measurements of Winter [129] or Ounpuu [130]. 
Table 3-2 documents the main properties in level walking as measured by Ounpuu [130], where the mean 
cycle duration is 0.9 s (cycle rate of 1.11 Hz) for a mean walking speed of 4.2 km/h. This is higher than the 
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Table 3-2 Dynamic Specifications for Level Walking based on Ounpuu [130] and Schache and Baker [131] 
Joints 


















(18 - 36 Nm)b 
0.66 
(33 - 66 Nm)b 
- 
Hip Flexion/Extension 




(15 - 30 Nm)b 
0.72 
(36 - 72 Nm)b 
0.78 
(39 - 78 W)b 
Hip Rotation 




(4.4 – 8.8 Nm)b 
- 
Knee Flexion/Extension 




(9 - 18 Nm)b 
0.53 
(26.5 - 53 Nm)b 
0.59 
(29.5 -59 W)b 
Ankle Inversion/Eversion 




(4.25 – 8.5 Nm)b 
- 
Ankle Dorsi-/Plantarflexion 




(24 - 50 Nm)b 
1.26 
(63 - 126 Nm)b 
3.49 
(175.5 - 349 W)b 
Ankle Rotation 




(6 – 12 Nm)b 
- 
a. Torques are normalized over bodyweight, b. Torque values for a bodyweight range of 50kg - 100kg 
Each human leg has seven degrees of freedom (DoFs), plus several DoFs about the foot and toes. As demon-
strated by Table 3-2, locomotion is mainly achieved in the sagittal plane, where the flexions and extensions 
are generated by large amplitudes of torque and power (several dozen of Newton-meter or Watts). The hip 
abduction also provides an important contribution in terms of torque, although it performs only small dis-
placements (RoM about 10° to 20° [131]). Bohannon et al. [124] reported that abductor strength was the 
factor best correlated to the walking speed, demonstrating the key importance of lateral motion in addition 
to forward motion. The other degrees of freedom about the hip and the ankle, however, seems not to gen-
erate much torque during walking, i.e. less than 10 Nm are reported for each of the hip rotation, ankle rota-
tion and ankle inversion/eversion [131]. During walking cycles, the knee mostly dissipates energy as a 
damper, while the ankle almost only generates energy. The amplitudes of torque generated about the ankle 
while walking are twice as large as the hip and knee flexions, while the power provided is four times larger.  
??????? ????????????????????
Another activity that is required in daily living is the sit-to-stand transition (STS). Mak et al. 2003 [132] meas-
ured the kinematics and kinetics of healthy, elderly subjects rising up from a chair to a vertical standing po-
sition. The obtained data are reported in Table 3-3. The torques that have to be generated depend largely on 
both the bodyweight and height of the person; both tend to increase the strength required, as longer legs 
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induce longer distances between the CoM and the joints. The torques are the product of force and the dis-
tance to the point of application. The height of the sitting position also affects the strength required to rise 
up from a chair. The hip range of motion over the flexion/extension is particularly great during the rising 
phase, because, in order to ensure balance, the CoM needs to be situated over the feet, which are the base 
of support. In order to reach that stability without using the arms for help, one needs to lean forward while 
seated, about 30° [132], before one can start lifting the body to stand up. Once again, the range of flexion of 
hip, knee and ankle depends largely on the initial sitting position, which is determined by the height of the 
seat. The torque required at the knee joint for rising from a chair is much stronger than that required for 
level walking. The amplitudes of torque at the hip joint are similar, and reduced in the ankle joints compared 
to the amplitude found for level walking. The main difference between level walking and rising from a chair 
is that the latter is a single action lasting between one to five seconds; thus, it does not require as much 
continuous torque, as the peak torque is of more interest for the short time in which it is applied.  
Table 3-3 Main kinematic and kinetic characteristics of rising from a chair in healthy elderly people based on [132] 
Joints 
Specifications in Sit-to-Stand (STS) Transition 
STS duration [s] Angle min/max [°] (RoM [°]) 
70% of Peak 
Torque per Leg 
[Nm/kg/m]a 
Total Peak Torque 
per Leg [Nm/kg/m]a 
Hip Flexion/Extension 
1.4 in healthy elderly 
persons 
(2.3 in persons with 
Parkinson) 




















a. Torques are normalized over bodyweight and body height and assumed symmetrical in both legs, b. Torque values for a body-
weight and height of 50kg and 1m55/100kg and 1m90 respectively 
??????? ????????????????
Protopapadaki et al. 2007 [133] measured the torque and duration on joints while ascending and descending 
stairs in a population of young adults. The results for the stair ascent (more strenuous than the descent) are 
reported in Table 3-4. Stair climbing is comparable to level walking; the cycle rate and step length are largely 
reduced compared to level walking, but the exertion required is increased as the joints must lift the body 
weight up each step. All ranges of motion for the hips, knees and ankles in the sagittal plane cover a larger 
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Table 3-4 Main kinematic and kinetic characteristics of climbing stairs based on [133] 
Joints 
Specifications in Ascending Stairs 
Cycle duration [s] 




























a. Torques are normalized over bodyweight and body height, b. Torque values for a bodyweight and height of 50kg and 
1m55/100kg and 1m90 respectively 
??? ???????????
The current chapter presented a study of the gait kinematics in a heterogeneous group of 14 persons with 
neuromuscular diseases. Aside from confirming some observations already made in the literature, this study 
allowed to get information about the preoccupation and daily activities of the participants. One key infor-
mation, for example, is that the transition to a wheelchair is usually made when the risk of fall becomes an 
issue to the person. Thus, most people are still able to ambulate as they start using a wheelchair. Another 
interesting aspect is the burden that can represent STS transitions, that can take up to more than a minute 
to be performed. The compensatory patterns observed in this study are mostly the knee hyperextension, the 
back hyperlordosis, foot drop and the waddling gait. Some participants would adopt four compensating pat-
terns in their gait as they have generalized muscle weaknesses. The experiment also allowed to observe the 
performances of ankle foot orthoses with patients with ankle muscle weaknesses. The AFO proved to be very 
efficient as participants demonstrated to be able to walk at a moderate velocity while wearing them. How-
ever, the stability, in particular in slopes or uneven terrain can be difficult to manage.  
A better understanding of the different compensating pattern following the experiment is presented. The 
implication of poor abductor strength at the hip in the waddling compensating pattern is explained and re-
veals the large need for assistance at that joint. The knee hyperextension that allow to avoid knee buckling 
because of weak knee extensors is also highlighted. It expresses the significant need for the support of the 
knee extension to avoid falls and provide more safety to the user. 
In the second part, the specifications of dynamics required in level-walking, stairs climbing and STS transition 
are studied based on the literature. The study of level walking first shows that a slow gait is energetically 
more demanding than a gait between 3 km/h and 4 km/h which is optimum. Stoquart et al. [125] also demon-
strated that the range of motion and the torques at the joints increase with the walking speed. Hence, the 
level of assistance can be designed in function of the targeted walking speed. The study of stairs climbing and 
sit-to-stand transition revealed that the torque requirements to perform such activities are much greater 
than the peak torques generated during level walking. These data will be further used in the design of the 
actuation units of the assistive design.








An exoskeleton, also referred to as powered orthoses, is an apparatus composed of a structure external to 
the body which is attached to different points of the body and actuated. The role of exoskeletons is to 
transport the user wearing the device or exert force on behalf of the user. Exoskeletons have several appli-
cation domains, including but not limited to: 
? military sectors, where exoskeletons empower the soldiers to augment their capacities or to extend 
their endurance (carry heavy loads, walk faster, etc.) while also offering protection on the battle field. 
? industrial sectors, where exoskeletons allow manipulation of heavier loads or tools by re-distributing 
or alleviating loads on worker’s musculoskeletal system in order to prevent injuries. 
? space missions, where the device can be used as a fitness machine to prevent muscle loss in zero 
gravity. 
? medical sectors, where exoskeletons can be used for rehabilitation by supporting neurological pa-
tients and assisting them in maintaining a vertical position (lower extremity exoskeleton), or in train-
ing motor difficulties. 
? private sectors, where exoskeletons can improve ease in daily tasks by assisting locomotion, dexter-
ity, etc. for those with spinal cord injuries or other afflictions. 
????? ?????????????????????????????
The concept of lower extremity exoskeletons (LEEs) was first found in a patent from the late 19th century 
[134]. Yagn’s invention, presented in Figure 4-1 A, is a passive exoskeleton described as an “exercising appa-
ratus specially adapted for conditioning the cardio-vascular system, for training agility or co-ordination of 
movements” [134]. The first claimed active exoskeleton, which opened the recent era of bipedal robots, was 
developed in 1969 [135], [136] at the Mihailo Pupin Institute in Belgrade, Serbia, under the supervision of 
Miomir Vukobratović, the father of the Zero Moment Point theorem (also published in 1969 [137]). The first 
version of the exoskeleton was pneumatically actuated and electronically programmed, Figure 4-1 B. 
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A  B       
Figure 4-1 A) Illustration taken from the US patent of Nicholas Yagn from 1890, “Apparatus for facilitating walking, 
running, and jumping” [134] B) Picture of one of the first active exoskeletons, developed at Mihailo Pupin Institute 
The group from Mihailo Pupin Institute achieved the first mobilization of a paraplegic patient with an active 
LEE in 1972 [135]. However, the technologies available at the time, particularly in terms of computational 
capacity, were very constraining. The next achievement was realized by the Berkeley lower extremity exo-
skeleton (BLEEX), that is claimed to be the first energetically autonomous exoskeleton (2006) [138] with the 
HAL (Hybrid Assistive Limbs) exoskeleton from Tsukuba university (2002) [139]. Since the beginning of the 
millennium, interest in exoskeletons has exploded. Most advanced developments have reached the market, 
first with stationary LEE such as the rehabilitation product Lokomat® from Hocoma (Volketswil, Switzerland) 
[11] (see Figure 4-2)). The Lokomat® was successful, with 500 devices sold within its first 10 years of com-
mercialization3. It, however, did not succeed in proving a significant improvement in therapy results com-
pared to intensive/standard therapy (non-robotized) [10], [140], [141]. Approximately a decade after the 
emergence of stationary LEE, wearable exoskeletons entered the stage. The first commercial products in-
clude: 
? ReWalk™ (ReWalk Robotics, Marlborough, USA): CE marked in 2010 and FDA cleared in 2014 (home 
and public use) 
? REX (REX bionics LTD, Auckland, New Zealand): CE marked in 2010 and FDA cleared in 2016 
? EksoGT™ (Ekso bionics, Richmond, USA): FDA cleared in 2012 and CE marked in 2012 and 2016 (med-
ical) 
? Hybrid Assistive Limb HAL® (Cyberdyne Inc., Tsukuba, Japan): CE marked in 2013 (medical), FDA 
cleared in 2017 (medical) 
                                                                        
3 Ref. https://www.hocoma.com/news/hocoma-celebrates-the-sale-of-the-500th-neurorehabilitation-robot-lokomat/ 
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? Indego® (Parker Hannifin Corp, Macedonia, USA): CE marked in 2015 and FDA cleared in 2016 (per-
sonal and medical) 
 
Figure 4-2 From left to right: Lokomat® from Hocoma, ReWalk™ from ReWalk bionics, REX from REX bionics, 
EksoGT™ from Eksobionics, HAL® from Cyberdyne and Indego® from Parker Hannifin. 
These devices are shown in Figure 4-2. The first commercialized LEE belongs to the medical sector and is the 
first commercial development targeted towards people suffering from spinal cord injury (SCI) for private 
home use. With a high selling cost between sixty thousand to a few hundred thousand dollars, plus additional 
mobility constraints, i.e. slow walking speed, ease of use, bulky appearance, safety, etc., the number of sales 
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to date is very low. Most devices are now redirected toward rehabilitation applications and larger popula-
tions, such as stroke victims. A review of the past and current clinical trials with wearable LEE has been per-
formed using the “ClinicalTrials.com” database and the trials documented by the exoskeletons’ companies. 
Results are illustrated in Figure 4-3. Out of a total of 110 trials found in the cited database, SCI is the most 
studied disorder (72%), followed by stroke (22%), with a few studies on multiple sclerosis cases and the el-
derly. On the device side, Ekso accounts for half of the studies reported (57), followed by ReWalk and Indego, 
with 17 and 16 studies respectively. Cyberdyne’s HAL accounts for 8 cases, and the remaining account for 
less than 5 studies.  
Miller et al. 2016 [13] performed a systematic review on the effectiveness and safety of LEE assisted gait in 
people with SCI. Fourteen studies (8 ReWalk, 3 EksoGT, 2 Indego, 1 other) with a total of 111 people with SCI 
were included. The success ambulation rate is 76%, with an average walking velocity of 1 km/h and a level of 
effort of 3.3 MET (metabolic equivalent of task, 3 = limit between light ant moderate intensity activity). Im-
provement of the bowel function was seen in 61 % of participants and spasticity diminution in 38% of partic-
ipants. In terms of safety, a fall incidence of 4.4% is reported, while the bone fracture incidence reached 
3.4%. In conclusion, the use of wearable LEE by people with SCI is reasonably safe and brings the user signif-
icant health benefits. There are, however, still limitations in walking speed and mobility. The benefits of 
wearable LEE for people suffering from strokes and other disorders are still unclear, more in-depth studies 
are needed to be able to draw conclusions.  
 
Figure 4-3 Number of studies realized per year and per device (wearable exoskeleoton) 
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Figure 4-4 Number of studies on wearable exoskeleton use per type of disorder 
Although the medical sector launched the first commercializalized exoskeletons for personal use and reha-
bilitation, the military sector, primarily in northern America, played a key role in the development of the 
technology in the early aughts ([142], [143]). Examples include the Berkeley Lower Extremity Exoskeleton, 
BLEEX [138], the Sarcos exoskeleton, and the MIT exoskeleton [144]. 
Currently, the industry sector is investing in exoskeleton research. Minimally actuated exoskeletons are de-
signed to lower the level of exertion and the constraints on the musculoskeletal system in different activities 
such as squatting and lifting up large objects, holding heavy tools in different positions, and repetitively pick-
ing up objects necessitating forward bending of the trunk. 
????? ???????????????????????? ?????????????????????
This section describes several common subsystems that comprise powered wearable exoskeletons. The dif-
ferent components, illustrated in Figure 4-5, are described in Erreur ! Référence non valide pour un signet., 
with a description of their functions and some examples of realization.  








Allow the user(s) to interact with the control unit 
? Turn on/off the device 
? Select a working mode (e.g. select activity) 
? Tune parameters (e.g. walking speed) 
? Provide a visual feedback to the user 
? Remote control with buttons 
? Emergency stop 
? Tactile and visual tablet-like inter-
face 
? Remote computer 
2 Power supply 
Store energy for actuation and powering of joints 
and electronic components  
? Electrical batteries 
? Tank of fuel or other propellant 
? Tank of compressed air 






Manage interaction between actuators, inertia, user 
limbs and body, and ground 
Ball bearing or spherical joint, with 
3D printed, machined aluminium, or 
molded carbon fiber structure  
4 Physical interface 
Integrate forces generated between the limbs of the 
body and the structure of the exoskeleton; distrib-
uting physical stresses prevents user pain and skin 
abrasion and damage 
? Molded thermoplastic thigh inter-
face with straps 
? Textile brace with Velcro fastening 
5 
Central control unit 
and drives 
Run the controller of the actuators and other feed-
back mechanisms using signals received from the hu-
man-robot interfaces and the sensors 
? Embedded computer with linux 
processor (motherboard), con-
nected to multiple microcontroller-
based drivers which control the ac-
tuators 
7 Sensors 
Collect information from the environment to provide 
control inputs for actuators and generate feedback 
for users 
? Potentiometers or encoders as po-
sition sensors 
? Load cells as force sensors 






Generate a force/motion to be provided to the user 
for movement 
? Pneumatic or hydraulic cylinder 
? Electric motor with ballscrew, 
planetary gears or harmonic drive 
? Hybrid electric motor with hydrau-
lic transmission 




Figure 4-5 Illustration of the common subsystems of any powered wearable exoskeletons. Depicted is the HiBSO: a 
powered ball-screw hip orthosis 
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????? ??????? ??????????????? ???? ???????????? ???????? ???????? ??????
????????? ????????
As highlighted in This section describes several common subsystems that comprise powered wearable exo-
skeletons. The different components, illustrated in Figure 4-5, are described in Erreur ! Référence non valide 
pour un signet., with a description of their functions and some examples of realization.  
Table 4-1, a wearable exoskeleton is composed of several sub-systems with large degrees of complexity. 
Designing a full exoskeleton requires advanced techniques encompassing biomechanics, medicine, structure 
mechanics, dynamics, electronics, programmation, control, mechatronics, and orthopedics, at the least. De-
pending on the type of actuators chosen, it could also include electromechanics, fluid mechanics or chemis-
try. The performance of the exoskeleton is inherently linked to the available market options for needed joints, 
sensors, actuators, transmission units, electronic drives and embedded computers. 
The specifications regarding a wearable LEE for walking assistance with people with NMD are sorted in three 
categories: practicality and safety, performance, and collaboration. The specifications and challenges for de-
sign are described by categories in the following sections and discussed in terms of the State of the art.  
????? ????????????????????????
After the validation of main functional performance of an exoskeleton, practicality is usually considered next 
to give a realistic assessment of implementation likelihood. Practicality is defined using the following scenario 
as a test case. The primary use of the exoskeleton would be either in a home or a clinical setting, with an 
auxiliary person available for monitoring and assistance if needed. This also implies that the device will first 
need to be moved out of a storage location by an able-bodied person. The device is then turned on for oper-
ation; the power supply needs to be able to provide steady operation for as long as the person needs. If the 
device is used by multiple people, it will need to be adjusted to size. The user must be able to put the device 
on, meaning they must transfer themselves or be transferred into the device and fasten any and all physical 
interfaces. She/he should be able to turn it on, configure the device for desired activities and start ambulating 
with it. Ambulating includes the three activities of walking, climbing/descending stairs, and standing up 
from/sitting down in a chair. Moving in outdoor environments and public places, including public transpor-
tation should be considered, as well as car transportation while wearing the device. Eventually, the device 
must be turned off and removed from around the user. The critical points are discussed in the following. 
Adjustment of the device to the user size is very important in two aspects: first, the alignment of the joints 
of both the user and the exoskeleton is an important issue, since a poor alignment could have dramatic con-
sequences such as high discomfort or, in the worst case, fracture. Second, a poor fit of the physical interfaces 
to the limbs of the user can lead to skin damage or displacement of the interface during use, which increases 
the risk of falling. Three types of adjustment can be found in the literature/commercialized products: 
1. Mechanical adjustment of each segments based on prismatic joints and a locking system (most fre-
quently found e.g. EksoGT™) 
2. Interchangeable segments of different sizes (e.g. Indego®) 
3. Tailor made exoskeleton (e.g. TWIICE’s startup concept4) 
                                                                        
4 http://twiice.ch/ 
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Options 1 and 2 allow rapid adjustment of the device for patients of varying size; thus, several users can share 
the same device. This is the best scenario in a rehabilitation center. Option 1 involves adjustable segments, 
which usually weaken the structure and thus require use of slightly heavier and bulkier segments. Inter-
changeable segments as in option 2 do not provide as fine an adjustment unless a large set of such segments 
is assumed. It is further complicated by the need for the connection between the control signals and the 
structure to be re-made after each adjustment. Option 3 provides potential, if there is a significant benefit in 
having a perfect adjustment to the user morphology. 
Option 1 is considered first for its ability to accommodate several users with fine adjustment.  Considering a 
target population with body height between 150cm and 188cm (corresponding respectively to the 5th per-
centile of female adults and  95th percentile of male adults in the United States over 2007-2010 [145]), the 
segments sizes are derived from available anthropometric data found in the literature. If no documentation 
covers the span of dimensions needed, sources such as size charts from clothes are applied. The dimensions 
of interest are illustrated in Figure 4-6, and the span of dimensions are reported in Table 4-2.  
 
Figure 4-6 Illustration of the relevant dimensions considered for the adjustment of the lower limb exoskeleton 
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Table 4-2 Range of sizes for different body parts in order to set the span of adjustment of the device’s segments 
# Body part Reference Notes Range of sizes 
A Waist [146] Circumference 60 – 126 cm 
B Hip breadth [147] for fit people, should be increased for higher BMI 30 – 42 cm 
C Thigh Ref5 Circumference size S – XL 41 – 67 cm 
D Calf Ref5 Circumference size S – XL 31 – 45 cm 
E Back to hip distance - No documentation found - 
F Foot length UK chart Size UK 0-13 18 – 30.4 cm 
G Back to hip height - No documentation found - 
H Femur length [148] 0.237-0.245 x Body height (150x0.237 – 188x0.245) 35 – 46 cm 
I Tibia length [148] 0.22-0.237 x Body height (150x0.22 – 188x0.237) 33 – 45 cm 
J Ankle height from heel [148] 0.043-0.048 x Body height (150x0.043 – 188x0.048) 6.5 – 9.0 cm 
 
????? ????????????
The performance of a device relates to its capacity to assist a certain activity with high precision and speed. 
The performances are thus expressed with two metrics: the level of assistance, and speed. The level of assis-
tance is commonly expressed by how much force is provided to the user compared to how much force the 
user would need to exert to perform the task at hand without assistance. Speed is measured through walking 
velocity, the time to climb a few stairs, the time to rise from a chair, or another such action. The ideal perfor-
mances would be to be able to walk, stand up from a chair, and climb stairs with the ability of a healthy 
athlete, for several hours. Unfortunately, there are limiting technological and physical constraints such as the 
density of the power supply, the actuator efficiency and inertia, the torque density of the actuator and trans-
mission unit, etc. As with any other self powered and mobile object, a trade-off in LEE must be made between 
the performance of the system and its weight. 
High performance in LEE is challenging because, as power supplies and actuators are mounted on the device 
to provide more power capacity, device bulk and weight also increase drastically. Actual performance of LEEs 
for assistance in cases of SCI is hard to assess for the following reasons: 
1. The use of crutches, or other supports, largely impacts the distribution of the power exerted by the 
user and by the device during any activities. 
2. Any performance observed is related not only to the device, but also to the management of balance 
and of the crutches by the user. The only device that can be operated without crutch assistance is 
                                                                        
5 Sigvaris compression socks dimensions : https://www.compressionstockings.co.uk/sigvaris-traditional-500-half-thigh-
class-3-ral-beige-compression-stockings-with-open-toe.html 
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the REX exoskeleton, which provides too low of a walking velocity with an average of 0.2 km/h [149], 
mainly due to the static management of balance. 
Hence, it is hard to evaluate the limitations of LEE and, subsequently, to define specifications regarding the 
level of assistance, walking velocity, etc. However, it is still of interest to discuss the challenges in function of 
the different targeted activities and look at achievements previously made in the field. 
??????? ?????? ???????
Out of the three activities used to measure exoskeleton performance, level walking is the least demanding 
in terms of torques; however, it can be very dynamic, with high angular velocities at hip, knee and ankle 
joints. In terms of balance, the mass of the body while walking needs to be transferred from one leg to the 
other at each step. All joints must be well coordinated. As mentioned in section 3.4, the level of assistance is 
a function of the users’s residual muscle capacity. The target walking speed is 3.5 km/h for moderately af-
fected people requiring about 50% of assistance, and 2.5 km/h for people requiring about 70% of assistance. 
Where the percentage of assistance is scaled based on the physiological torques, that vary with the walking 
speed and a person bodyweight. The performance aspects of interest are:  
1. The range of motion of each joint 
Following specifications reported in section 3.4.1, the range of motion can be a challenge if a translational 
type of transmission is selected such as a pneumatic cylinder or a driven screw solution. However, if a rota-
tional transmission such as a gear train is selected, the range of motion would be infinite. The range of motion 
should also be considered in the design of the structure of the exoskeleton. The range of motion is a more of 
a critical factor in STS movement than it is with level walking.  
2. The maximum velocities 
Torques and velocities are critical regarding the design and selection of the actuation unit. Both torque and 
velocity are in opposition since the maximum power of the actuation is usually limited. A compromise has to 
be made between torque and velocity maxima, which is defined by the transmission ratio. Technical solutions 
can also be investigated to increase velocity limits. 
3. The peak and RMS torques 
Torque capacity is certainly the most critical aspect of the design. Augmenting the target torque limit in-
creases the bulkiness of several components quadratically. For example, if a pneumatic solution is used with 
cylinders, doubling the torque capacity can be obtained in two ways. One may augment the cylinder diame-
ter, which leads to a heavier cylinder, and acquire a tank or compressor that has twice the original capacity 
to produce the volume of air that has also doubled. The other option is to double the pressure source, which 
needs a reinforced tank or a high pressure compressor. In both cases, the weight of the solution is usually 
more than doubled. In a more conventional case such as current robotics, electric motors would be used. By 
doubling the length of the rotor, the torque capacity is doubled. This means doubling the inertia, the mass of 
the motor, and the battery capacity.  Gears and other components of transmission mechanics will also in-
crease in size to support the torques required. Eventually, the increase of inertia of the motor will also need 
more torque and power to be compensated, such as the mass of actuators located on moving parts. The 
design of the actuators is thus a very critical aspect and it will be largely discussed in this work. 
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4.  The peak and RMS power 
Power is an important metric, as it includes both torque and velocity specifications. The documentation of 
actuation units is usually reported in terms of power, and the power supply can also be directly designed 
based on the power specifications. Systems usually have two specifications: the peak power, torque or ve-
locity, which can be maintained for a short period of time, and the nominal power, torque, velocity, which 
indicates the limit of the continuous working mode. Typically, an electric motor is mostly limited in torque 
due to the mechanical temperature limit of the rotor. The heat induced is proportional to the square of the 
current as stated by Joule’s first law, and the current is directly proportional to the torque. An electric motor 
has, thus, a continuous working torque (nominal torque) and a peak torque, typically about 2 or 3 times the 
nominal. 
The RMS and peak torques based on Ounpuu [130] and Schache and Backer [131] (gait at 4.2 km/h) are 
illustrated on Figure 4-7 for the seven joints of the leg. Based on Stoquart et al. [125], reducing the walking 
velocity to the targeted velocity (2.5-3.5 km/h) decreases the peak torques of approximately 10-30% (see 
Figure 3-8). At the same time, the exoskeleton assists persons with residual strength. It is assumed that in 
the worst case, the user would still be able to provide about 20% of the peak torques. In the end, the peak 
torque specifications will be based on 70% of what is reported by the literature. The RMS and peak power 
calculated, based on walking cycle frequency of 0.84 Hz (100.8 steps/min) with the trajectory and torque 
curves reported by Ounpuu [130] and Schache and Backer [131], are shown in Figure 4-8. The torques and 
powers involved follow similar patterns for each joint. The ankle plantar-/dorsi- flexion needs large peak 
torque and power. The hip flexion/extension and abduction/adduction, plus the knee flexion/extension re-
quire slightly smaller RMS torques and powers, but largely less peak torques and powers than the ankle flex-
ion/extension. Hip and ankle rotation (internal/external) and the ankle inversion/eversion require less torque 
and power than others.  
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Figure 4-7 RMS torques and peak torques for each joint during walking based on Schache and Baker [131]. The span 
covers the torque needed for a human body weight range of 50 kg to 100 kg. 
 
Figure 4-8 RMS and peak power for each joint during walking based on Schache and Baker [131]. The span covers 
the power needed for human body weight range of 50 kg to 100 kg. 
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The action of rising from a chair, termed the sit-to-stand (STS) transition, is a demanding task in terms of 
power generation. It largely depends on the weight of the body, as the center of mass is risen against the 
gravity, but also on the height of the body because the torques augment proportionally with the length of 
the limbs. The RMS and peak torques are illustrated in Figure 4-9, while the RMS and peak power for the 
joints in the sagittal plane are given in Figure 4-10. Data are extracted from the measurements of Mak et al. 
[132]. The participants in this study were healthy elderly people with weight between 43 and 75 kg and with 
heights from 1.47m to 1.69m. Hence, the data for body weight and height outside of those two ranges have 
been linearly extrapolated from gathered data.  
The hip and knee torques during STS are similar in amplitude with RMS torques ranging from 20 Nm to 50 
Nm and peak torques between 40 and 100 Nm. The ankle torques are slightly greater than the half of those 
of the hip and the knee. The hip peak and RMS powers are high, about 30% higher than those of the knee, 
with maxima about 110 W RMS and 260 W peak. The ankle power is very small, less than 20 W, because the 
torque exerted is for stabilization, and is necessary only once the body is standing still. 
The notion of RMS values does not make a lot of sense here since the motion of standing is not cyclic and 
take only about 2.1 s as reported in [132]. However, it is interesting to know the mean values over the total 
duration. Compared to level walking, and regarding only peak values, there is a slight increase in hip torque, 
a large increase of 200-300% in knee torque and a decrease of 50% in ankle torque. Power compared to level 
walking show an increase of 300% and 500% for the hip and the knee respectively, while there is a 90% 
reduction at the ankle. 
 
Figure 4-9 RMS torques and peak torques for each joint during STSbased on Mak et al. [132]. The span covers 
torque for humans ranging in height from 1m50 to 1m90 and weighing from 50 kg to 100 kg. 
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Figure 4-10 RMS power and peak power for each joint during STS based on Mak et al. [132]. The span covers torque 
for humans ranging in height from 1m50 to 1m90 and weighing from 50 kg to 100 kg. 
It is also interesting to compare the performances of healthy people with those of people who have health 
conditions and yet are able to fully achieve the STS transition without external aid. Mak et al. [132] studied 
the kinematics and kinetics of STS in people with Parkinson’s disease. The results show a longer transition 
time in patients with an increase of about 150%. The hip peak torque is reduced of 20% while the knee peak 
torque is increased of 10%. These measurements demonstrate that for the STS transition, no large torque 
reduction is gained from adapting the trajectories. However, using armrests and arm support has diminishes 
the hip and knee extension peak torques by 40% and 25%, respectively [150], [151]. It could be relevant to 
consider a small contribution from the arms in case of design limitations on the hip and knee peak torques. 
??????? ????????????????
Measurements from healthy people (Protopapadaki et al. [133] ) are reported in the following in  Figure 4-11 
and in Figure 4-12 for the target population weighing between 50 kg and 100 kg, and ranging in height be-
tween 1.50 m and 1.90 m. Stair climbing as an action is normalized to be two steps climbed per cycle (one 
step each with the left and right foot), as healthy people tend to do. However, people with difficulties in 
ambulation such as some elderly people, tend to climb the steps one by one. The torques illustrated in  Figure 
4-11 shows, compared to STS, slightly greater torques at the hip, similar torques at the knee and enormous 
torques at the ankle. The same trends are shown in Figure 4-12 for the power. 
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 Figure 4-11 RMS torques and peak torques for each joint during stairs climbing based on Protopapadaki et al. [133]. 
The span covers torque for human heights from 1m50 to 1m90, and weights from 50 kg to 100 kg. 
 
Figure 4-12 RMS power and peak power for each joint during stairs climbing based on Protopapadaki et al. [133]. 
The span covers torque for human heights from 1m50 to 1m90, and weights from 50 kg to 100 kg. 
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Radtka et al. [152] compared stair locomotion in healthy adults both with and without solid ankle-foot-or-
thosis (AFO) . While subjects were wearing the AFO, a decrease of the climbing velocity of 12 %, a decrease 
in knee extension peak torque of 20%, and an increase of knee flexion peak torque of 5 % was observed. It is 
not clear how much torque was generated at the ankle, since the AFO is supposed to entirely support the 
joint but the participants were all healthy people and thus did not need the support. Hence, it is assumed 
that the contribution from the participants at the ankle was largely decreased by the use of the solid AFO. In 
conclusion, the use of an AFO dramatically reduces the ankle torques, the knee extension peak torque by 
20% while also decreasing stair-climbing velocity by 12 %. 
??????? ???????????
The specifications for each joint are evaluated following the different elements provided above and the ele-
ments already reported in 3.4.1 such as the range of motion and the maximum velocity. These specifications 
are reported in Table 4-3. 
Table 4-3 Specifications of the maximal values considering a pilot of 1.90 m and 100 kg at an assistance level of 70% 
Joints 
Specifications based on the maxima among the three activities (with 70% of assistance) 


















(– 7.5 / + 5) 
12.5 
47 25 46 13 28 
Hip 
Flexion/Extension 
(– 10 / + 110) 
120 
160 40 89 80 180 
Knee 
Flexion/Extension 
(+ 5 / + 90) 
95 
330 34 56 56 133 
Ankle Dorsi-
/Plantarflexion 
(– 23 / + 17) 
40 
197 80 173 98 346 
 
A simulation based on actual technologies will be addressed in the next section that will evaluate, optimize 
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??? ?????????? ?????????????????????????
This section describes the design process of a lower limb exoskeleton named AUTONOMYO. The description 
is primarily oriented towards the design and technological choices for the actuation units, and will also in-
clude a discussion on aspects such as sensors and segment adjustment. 
????? ?????????????????????
Weight, bulkiness and cost are key challenges for the adoption of exoskeleton apparatus as practical solutions 
for people with ambulation impairments. The best way to keep these constraints as low as possible is to keep 
the number of actuators and the power capacity as low as possible. The following guidelines were adhered 
to during the design process:  
? Assist as few joints as necessary 
? Prefer non-actuated compliant and/or lockable systems over actuated systems 
? Optimize (lower) the required energy and peak torques by coupling active systems with compliant 
and/or lockable solutions 
??????? ???????????????????????????????????
The first questions, in order to define the architecture of the exoskeleton, are the following: 
1. Which joints need assistance? 
2. What is the nature of the assistance needed (active, passive and compliant or passive and stiff)? 
3. What technology can best perform the specifications required? 
In order to answer the first question, the contribution of the seven joints per leg are analyzed based on the 
elements provided in sections 3.4 and 4.1.5, which specify the dynamic motions targeted at each joint for 
which the exoskeleton is to provide assistance. 
Hip Flexion/Extension 
Hip flexion/extension is one of the main actor in all three targeted activities (level walking, stair climbing and 
rising from a sitting position). The work generated by the hip flexion/extension is majoritarily positive, as 
shown on Figure 4-13, supporting the need for an actuated assistance. The role of the hip flexion/extension 
is essential in the control of the anterior-posterior balance as it affects the swaying movement of the upper 
body.  In both stairs climbing and STS transition, for example, the phases are initiated by a large forward 
bending of the upper body in order to place the center of mass over the polygon of sustentation. The motion 
of the hip is very important for that change of support from one foot to the other, or from the chair to the 
feet. 
Hip Adduction/Abduction 
The second hip motion is the adduction/abduction. Contrary to the case of flexion, it is not agreed upon if 
this motion needs actuated assistance. This is partially because it is not systematically measured and analyzed 
in the literature of gait dynamics and other stairs climbing, etc. Secondly, most exoskeletons for the mobility 
of people with SCI have a rigid segment in place of the hip adduction/abduction joint; users with the exoskel-
eton are still able to walk at acceptable velocities (2-3km/h) with the aid of devices such as crutches or rolla-
tors. Third, the range of motion at the hip adduction/abduction is small, about 15° in healthy people [131].  
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The author believes that hip adduction/abduction is an important motion for actuated assistance to take into 
account. The lack of abduction strength has been reported as to lead to waddling gait (see section 3.4) with 
large torso lateral displacement, slow gait and hip drop at swing. Other studies have demonstrated that ab-
ductor strength is highly correlated not only with walking speed [124] but also with balance and functionality 
in older adults [153]. In conclusion, hip abduction needs to be supported. What type of assistance would be 
sufficient then? Could it be feasible to use a non-actuated or minimally actuated joint? 
A passive compliant constraint seems impractical, as the abduction energy generated is much greater than 
the energy dissipated during gait (see Figure 4-13). A rigid segment, however, could be a potential candidate 
as demonstrated by the existing exoskeletons using crutches. As experienced by people with complete SCI, a 
locked joint restriction prevents hip drop; however, the weight transferal from one leg to the other can only 
be managed with the assistance of crutches or similar support. The REX exoskeleton has proved that the 
lateral motion of hip abduction/adduction and the ankle inversion/eversion are keys in unlocking static lat-
eral balance control. However, the gait achieved by the REX exoskeleton is very slow and largely exaggerates 
the physiological abduction pattern.  
Abduction at the hip is essential for weight transfers during level walking, which provides lateral balance 
control. An actuated moving mass system could also provide a balance assistance with a much predictable 
behavior. Another benefit of not locking this joint is that it allows the user to perform exercises that can 
strengthen relative abductors. For example, a simple exercise would be to perform a lateral walk while ad-
justing the level of resistance/assistance to the user strength. 
Hip Rotation 
Although the torques (and power) generated during level walking are about ten times smaller than those of 
the hip flexion/extension, the contribution of hip internal/external rotation to walking movement is worth 
investigation and discussion [131]. The hip rotation is often used by people with other hip and/or knee flex-
ion/extension weakness. No specific disorders have been observed in people with neuromuscular diseases 
that could be related to poor hip rotation conditions. The range of motion of this joint is quite small, approx-
imately 10° while walking [131]. In conclusion, it is proposed to keep the hip rotation free for users that do 
not experience any trouble with it, and to have the possibility to lock the motion in the device in the case of 
undesired effects.  
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Figure 4-13 Energies and power transmitted to/from each joint while walking,  taken from Schache and Baker [131]. 
The data shown are the maximum values with a bodyweight of 100 kg. Note that all values can be divided by a fac-
tor two for the minimal bodyweight of 50 kg. 
 
Knee Flexion/Extension 
The knee flexion/extension contributes greatly to the three different movements of discussion. While the 
body walks, the knee is mainly dissipating energy (see Figure 4-13). Exoskeletons (Phoenix, SuitX, USA), or-
thoses [154], and prostheses (Total Knee®, Össur, Iceland or C-Leg, Ottobock, Germany) using only a control-
lable damper or brake to manage knee motion during level walking are examples of implementation of this 
motion. However, the knee needs to generate large amount of torque and power during stair climbing or  
STS transition (see Figure 4-9 to Figure 4-12). Hence, while a passive solution would be able to account for 
level walking, it would not be able to supply the torque and power to support the other activities. Thus, an 
actuated joint is proposed for the knee joint. 
Ankle Dorsi-/Plantar Flexion 
As demonstrated by the very large torques and power shown in Figures 4-7 to 4-12, ankle flexion contributes 
greatly to walking and stair-climbing. The torques and power engaged for these two activities are about two 
times larger than the contributions from hip and knee flexion/extension. As described in the next section, 
placing a weight at the location of the ankle, i.e. at the extremity of the leg, has a dramatic impact on the 
performances due to the addition of inertia created by the weight. While the ankle is frequently used for 
walking and stair-climbing, experiments have also demonstrated that comfortable walking (at least 3km/h) 
can be achieved with a locked ankle [126]. Radtka et al. [152], as cited in section 0, observed that the use of 
ankle-foot-orthosis (AFO) to perform stairs climbing was possible, at the cost of a small climbing reduction in 
velocity. The AFO significantly decreases the power that the user’s ankle must develop without creating more 
loading at the hip or knee as compensation [152]. The ankle torques involved in the STS transition rise only 
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at the end of the phase to stabilize the vertical position [132]. It is thus compatible with the contributions 
provided by an AFO support. Despite the limitations in terms of performances that are inherent to the use of 
an AFO, this solution allows to significantly decrease the weight and inertia that would be generated by the 
use of an actuated design. 
Ankle Inversion/Eversion and Rotation 
The two other DoFs of the ankle, i.e. the inversion/eversion and the internal/external rotation, do not play a 
large role in the three activities based on the small kinematics observed. Inversion/eversion DoF is important 
to stability as it allows compensation for inclination relative to the ground; this is particularly useful in case 
of sloping terrain. 
????? ????????????????????????????
??????? ???????????
There exist three main types of technologies frequently considered for the actuation of exoskeletons. The 
first one is electrical power, using batteries as power supply, electric motors as energy converters, and gears 
or other transmission components as torque amplifier (e.g. belt and pulley system, planetary gears, epicy-
cloidal gears, ballscrew, etc.). The second and third are pneumatic and hydraulic power, with a tank or electric 
pump with batteries as power supply, and cylinder or pneumatic muscle as energy converter and transmitter. 
Because hydraulic energy is not compressible and thus difficult to store, hydraulic technology can best be 
used as a transmission system in combination with electric actuators. It would then be a hybrid system based 
primarily on electrical technology. Pneumatic energy can be stored in a tank under the form of compressed 
air. A lightweight carbon fiber tank of 6.8 liters can hold a pressure of 30 MPa, which is equal to about 1.2 MJ 
of energy in a 3.9-kg bottle. In comparison, 1 liter of lithium-polymer (LiPo) battery weights 2.2 kg and can 
store about 1.4 MJ. Hence, for a similar capacity, a battery is more than 2 times lighter and 6 times less bulky 
than a tank. The alternative to the tank for the pneumatic technology would be a pump that generates a 
stock of compressed air; however, this will include additional mass, batteries, and compressors for operation, 
which at low pressure levels (4-7 bar) often adds vibration. Another drawback of pneumatic actuation is the 
noise from air exhaust when emptying the cylinders. One potential benefit of pneumatic cylinder is that it 
functions as a variable stiffness actuator. Indeed, in adiabatic conditions, the pressure change is proportional 
to the volume change. Since only the piston position varies, the force is proportional to the position of the 
piston (see Figure 4-14). The elastic properties of a pneumatic cylinder have been observed in a previous 
work from the author [155]. It demonstrates the elastic behavior and the possibilities to change the attractive 
position and the stiffness by modulating the pressure in the two chambers of the cylinder. 
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Figure 4-14 Illustration of a pneumatic cylinder acting as a parallel elastic mechanism a) at rest, and, b) under a 
force that creates a displacement of the piston. Copyright © 2016, Springer 
Hydraulic technology enables more compact solutions, as the force density can be very high due to the in-
compressible properties of the fluid. Conversely, it is not compliant as gas would be, and thus, cannot be 
directly used as a variable stiffness actuator. The two main difficulties with hydraulic systems are: the reali-
zation of a fully closed hydraulic system and the design of the supply source. For these reasons, hydraulic 
systems are mostly used as transmission mechanisms with motorized pistons, remotely located from the 
joints, used for the actuation. 
Electric technologies and systems are the most developed elements for compact and embedded systems, 
mostly used in robotics.  Batteries have a high density of energy for a compact and lightweight ratio. Motors 
are quite efficient (about 80-90%), compact, low-cost and lightweight, and benefit from a large diversity of 
manufacturers with a large range of dimensions and power. The main drawbacks of electric motors are their 
low torque and the comparatively high inertia. Due to the high velocity–low torque properties, transmission 
mechanisms including a reduction are necessary for transmission of higher torques at lower velocities. Typi-
cal reductors are spur gears, planetary gears, cable or belt and pulley, leadscrew and ballscrew, worm drive, 
bevel gear, cycloidal gears, etc. These elements have usually an efficiency, size and weight that increase with 
the reduction ratio and the maximal torque supported. 
??????? ?? ???????????????????????????????
In this section, a simple architecture is simulated to evaluate the key aspects for the design of the actuation 
and the additional power required. A simple architecture would be to use the same motorization for the 4 
joints of the hip abduction/adduction and the three flexions/extensions of the hip, knee and ankle. Particular 
attention is paid to the hip and knee flexion/extension as the accelerations are quite large in magnitude at 
these joints, while only small motions are transmitted through the ankle flexions and hip abduction/adduc-
tion. The simulation is a tool for indicating key limitations that can narrow down the potential selection of 
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technology and architecture of the first actuation units. The simulation is simplified to a two dimensional 
study in the sagittal plane of the hip and knee joints during a walking cycle. The goal is to evaluate the im-
portance of the additional efforts the motors must provide in order to reach the performances specified. 
Indeed, the motors do not only need to provide a torque to the user of the exoskeleton, but they do need to 
propel themselves and the rest of the exoskeleton. In order to evaluate this contribution, a single leg model 
of the exoskeleton is used and suspended in the air. This model is simplified since, neither the forward motion 
of the trunk nor the forces generated by maintaining an upright stance are taken into account. However, the 
forces related to the support phase can be approximated by adding the mass of the exoskeleton to the weight 
of the user; this provides a reference for calculating physiological torques during walking. The model is illus-
trated in Figure 4-15 and the dynamic equations for the hip and the knee joints in the sagittal plane are 
presented in Equation 4-1. The model used is similar to a double pendulum, where the two upper joints are 
actuated and the inner inertia of these joints are considered. The mass and inertia of the segments of the 
exoskeleton are not taken into account; however, their effect can be inferred from observation of the mass 
of the knee and ankle actuators. Note that the dynamic model depends neither on the mass of the actuator 
at the hip nor on the inertia of the motor at the ankle, as they are not considered. 
 
Equation 4-1 (a) General expression of dynamic model based on the inertia matrix expressed in (b), the Coriolis and 
centrifugal elements (c) and the gravity elements (d), based on the model and notations from Figure 4-15. 
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Figure 4-15 Model of one leg of the exoskeleton, which isolates the effects of the actuators mass and inertia on the 
amount of the torques required. “J” and “m” denotes the motor inertia and mass respectively, ”l” the distance inter 
joints and “θ” the angular position of the joints. “H”, “K” and “A” indicates the joints to which it belongs, respec-
tively, the hip, knee and ankle. 
Both hip, knee and ankle joints are realized with the same actuating unit that suits the specifications previ-
ously described. A compact solution located directly on the joints is selected. It is composed of a flat brushless 
electric motor EC 90 flat (Maxon motor AG, Sachseln, Switzerland) with 260 W of nominal power and nominal 
torque of 1 Nm. The motor weights 980 g and has an inertia of 5060 gcm2. In order to reach a nominal torque 
at the joint about 40 Nm, the selected reductor is the compact CSD-32-50-2UH from Harmonic Drive® (Tokyo, 
Japan). The reductor has a transmission ratio of 1:50 and can support the torques required (150 Nm in re-
peated peaks). It weighs 2.4 kg and its inertia is neglectable compared to that of the motor. The unit inertia 
is then the motor inertia multiplied by the square of the transmission ratio, which is equal to 1.25 kgm2 at 
the joint. The actuation unit mass is about 3.4 kg. A final mass of 4.5 kg is modeled to take into account the 
structure necessary to hold the actuator. 
The results of the simulation for the hip and the knee are presented in Figure 4-16 and Figure 4-17. The upper 
graphs show the torques required to move the exoskeleton, the physiological torques that correspond to the 
torques required by the person to walk, and the approximate final torque required by the actuators. The 
approximate final torque is the sum of the former two torque quantities. In the lower graphs, the torques 
required only to move the actuators are split into the different constituents, which are the effects from the 
different inertias and masses. Results highlight a considerable effect of the inertia and masses of the actua-
tors. It follows peak torques about three times more important than in physiological gait. For the knee actu-
ation, the additional torques appear only in the swing phase and is related to the mass of the ankle actuator 
located at the ankle joint and to the knee motor inertia. The latter introduces peak extension torque about 
50 Nm and peak flexion torque about 80 Nm, while the additional weight on the ankle is a bit lower with only  
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Figure 4-16 Simulation of the actuator mass and inertia effects on the total torque at the hip for a person walking at 
3.5 km/h based on the kinematics from Schache and Backer [131]. ‘Physiological dynamics’ is defined as the natural 
torque exerted by a person while walking freely. 
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Figure 4-17 Simulation of the actuator mass and inertia effects on the total torque at the knee for a person walking 
at 3.5 km/h based on the kinematics from Schache and Backer [131]. ‘Physiological dynamics’ is defined as the nat-
ural torque exerted by a person while walking freely. 
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about 15 Nm and 35 Nm in peak extension and flexion respectively. These peak torques are large in magni-
tude and highlight the limitations of such actuators due to their inertia and mass. The same peaks are repli-
cated at the hip. The mass at the ankle even has a worse effect as the two joints are further from one another. 
A large peak is denoted at the end of the swing phase due to the motion of the actuation. The negative effects 
(amplification of torque) are felt at the hip from mid-cycle to end of the cycle. However, the actuation has a 
positive effect (reduction of torque) at heel strike and load acceptance as shown in Figure 4-16. Surprisingly, 
the effects of inertia of the actuator at the knee are alleviated by the effects of the mass of the same actuator; 
this is because the hip and knee accelerations are mostly in opposition during gait. 
The knee actuator inertia produces the worst impact on both the knee and the hip torques, followed by the 
effect of the mass of an actuator located at the knee. The effects of the mass of an actuator at the knee and 
of the inertia of the hip actuator require high peak torques of about 25 Nm each, which should be reduced 
in order to reach the targeted performances. Possible ways to reduce these effects are to avoid actuating 
one joint by replacing it with a passive system, to find a more appropriate technology with lower inertia, to 
locate the actuators more proximally to the trunk of the user, or to modify the kinematics so that the accel-
erations are lowered. 
????? ??????????????????????????????????????????????
The design in the sagittal plane is based upon the three flexions/(extensions) of the hip, knee and ankle. As 
highlighted in the previous section, the mass and inertia of the actuators play a key role in determining the 
amount of power required. The challenge of actuator inertia in different motorized hip orthosis, including 
HiBSO (Hip Ball Screw Orthosis), is shown in Figure 4-5 [156]. In [157], J. Olivier ultimately proposes a double 
clutch system in order to use the motor as a power source while also selecting the direction of rotation of 
the joint and modulating the velocity or torque through a variable clutch, based on disk brakes. While neces-
sitating some development, the solution of a double clutch system is bulky and also difficult to control, as 
the modulation of torque is based on the variation of dry friction. 
The challenges are to reduce the effects of the ankle and knee actuators’ collective mass, as well as that of 
the actuator inertia for all the joints. 
Mass and inertia of the ankle actuator 
As discussed in section 4.2.1, and observed in people with large deficits of strength about the ankle, the use 
of a rigid ankle-foot-orthosis offers a large support over the joint. However, it also diminishes performance 
and worsens balance over different terrain in comparison to a fully actuated joint. This configuration allows 
a weight increase of at least 3 kg located at the ankle, which represents an inertia of about 1.92 kgm2 at the 
hip level (estimation assuming a hip-ankle distance of 0.8m). The benefit of using a passive support for the 
ankle is the creation of a large power saving; this significantly reduces the amount of energy required and, 
thus, the volume and weight of the battery system needed. 
Inertia of the actuators 
The inertia of all actuators can be improved by selecting the appropriate technologies. For example, brushless 
electric motors have lower rotor inertia than brushed motors for similar nominal torque and volume specifi-
cations. Some manufacturers can also have some advantages with patented technologies. In order to opti-
mize the inertia at the joint, one should take into account not only the inertia of the motor, but also the 
transmission ratio, which is defined based on the nominal torque of the motor and the required nominal 
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torque at the joint. The derivation of the “reported inertia” criteria for defining the lower motor inertia effect 
at the joint is shown in Equation 4-2. 
 
Equation 4-2 (a) Motor inertia reported to the joint, (b) Definition of the transmission ratio, (c) Replacement of (b) 
in (a), and, (d) Criteria for the minimization of inertia at the joint. With “J ” the inertia, “J’ ” the inertia reported at 
the joint “η ” the transmission ratio and “τ ” the nominal torque from the motor or required at the joint. 
After some research and comparison of different motors based on the « reported inertia » criteria, the se-
lected motor is a brushless EC-i 40, 100 W (Maxon motor AG, Sachseln, Switzerland) with a rotor inertia of 
44 gcm2 and a nominal torque of 207 mNm. If this motor of 40 mm of diameter is compared to the flat motor 
(EC 90 flat) used for the simulation in section 0 with an identical target joint nominal torque of 40 Nm, the 
transmission ratios, based on the motor nominal torques, are respectively of 1:200 and 1:40. Applying Equa-
tion 4-2 (a) to these two solutions gives the projected inertias on the joint that are equal to 0.176 kgm2 for 
the 40mm diameter motor and 0.810 kgm2 for the flat 90 mm diameter motor. Hence the inertia has been 
reduced to 22% of its initial value by optimizing the motor based on the “reported inertia” criteria. 
Mass of the knee actuator 
One possible approach to reduce the effect of the mass of the knee actuator on the hip joint is to remotely 
locate the knee actuator away from the joint. This can be done by using a belt or cable and pulley transmission 
which transmits the torque from a certain distance. Relocating the actuators also allows optimization of the 
volume and the location occupied by these elements. 
By locating the knee actuator ahead of the hip joint, a coupling between the hip and the knee joints can be 
introduced. The impact of such a coupling is explored in the next section. 
??????? ???????????????????????????????????????????????
This section explores the effects of coupling the hip and knee flexion/extension. The design, as presented in 
Figure 4-18, is composed of two actuators located behind the hip joint. Motor B is coupled to the hip joint 
through a cable and pulley transmission, while Motor A is coupled to the knee joint with the same system, 
but passes through the hip joint. Two configurations of coupling can be set with this architecture: a positive 
coupling, where a hip flexion induces a knee flexion, or, a negative coupling, where a hip flexion generates a 
knee extension. Mechanically, the two configurations can be obtained by either crossing or not crossing the 
cables linking the pulley at the hip to the pulley at the knee. 
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Figure 4-18 Hip and knee flexion/extension architecture with remotely located actuators from the hip and knee 
joints, and executed through cable and pulley transmission. A. View in the sagittal plane, B. View in the frontal 
plane. Copyright © 2017, IEEE 
The current section is comparing the three following configurations: 
1. Hip and knee joints are independent 
2. Hip and knee joints are positively coupled, a hip flexion leads to a knee flexion 
3. Hip and knee joints are negatively coupled, a hip flexion leads to a knee extension 
The inverse kinematics for the three configurations can be obtained by inverting the Jacobian which ex-
presses the relationship between the joint velocities and the motor velocities. In order to simplify the calcu-
lations, a transmission ratio of 1:1 is assumed between the motor and the joints. The inverse kinematics of 
the different configurations are calculated by inverting and transposing the Jacobian of the forward kinemat-
ics as presented in Equation 4-3. The value of the Jacobians are reported in Table 4-4. Note that the hip 
flexion is positive and the knee flexion is negative if the two joints share the same referential system. 
  
Equation 4-3 Expression of direct (a) and inverse (b) kinematics. With “J ” the jacobian, “θ” the joint position, “q” 
the motor position and “τ” the torques, while “A” and “B” refers to the different motors. 
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Table 4-4 The Jacobians of the different configurations from the expression of Equation 4-3 
 
In positive coupling, motor B generates both hip and knee flexions or extensions simultaneously. Because 
motor A can also contribute, these combined motions be made faster. However, negative coupling increases 
the hip torque while causing synchronous hip and knee flexions or extensions. The effects of the three con-
figurations are evaluated based on simulated activities such as of level walking, STS transition, and climbing 
stairs. 
Level Walking 
Level walking is denoted by a cyclic motion where high accelerations can occur, typically during the swing 
phase. The amplitude of the torques are, however, moderate in comparison to the two other activities. Figure 
4-19 shows the effect of coupling or uncoupling the hip and the knee flexion/extension and its impact on the 
velocities, the reference torque to be assisted (physiological torque), and the actuator inertia based on the 
optimized technology. The coupling has affects neither on the kinematics of the motor B, which is always 
equal to the hip motion, nor the torque at motor A, which is identical to the torque applied at the knee. 
Figure 4-19 highlights, however, the large effect the coupling has on the velocity motor A must be able to 
achieve. A positive coupling significantly decreases two peaks of velocity on motor A by a factor of 2; how-
ever, the coupling has no effect on the last peak of velocity, which has a magnitude close to that of the 
maximum velocity achieved. Hence, a positive coupling can reduce two of the peak velocities but does not 
affect the specifications on the maximal velocity. The different configurations do not have a significant impact 
on the torque amplitudes. For the torque resulting from the inertia of the actuator, the maximal amplitude 
is about 12 Nm. The positive coupling decreases this effect of about 30%; however, the gain is quite low in 
this application. The main contribution of positively coupling the hip and the knee flexions is primarily found 
in the velocity changes.  
Rising from a Chair 
The STS transition is marked by moderate velocities and high torques at the hip and knee joints as shown in 
Figure 4-20. The positive coupling and the no coupling configurations have lower velocities at motor A, but 
since the STS is not a very dynamic motion, the velocities are acceptable even with the negative coupling 
configuration. For the physiological torques, the negative coupling drastically reduces the peak torques down 
to a value of 40 Nm, while the uncoupled configuration is more moderate, with a peak of about 60 Nm. The 
positive coupling requires about 130 Nm. The third graph in Figure 4-20 shows that the effect of the inertia 
of the actuator is negligible  in all configurations. In conclusion, it is seen that there is a large benefit in using 
a negative coupling configuration to perform STS transitions. 
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Figure 4-19 Effect of the different coupling configurations on the required velocities and torques at the motors dur-
ing level walking. The physiological torque is based on the mechanical properties of a human with median body 
weight of 75kg. 
Assistive Lower Extremity Exoskeletons – Application to Neuromuscular Diseases 
77 
 
Figure 4-20 Effect of the different coupling configurations on the required velocities and torques at the motors dur-
ing a sit-to-stand transition. The physiological torque is based on the mechanical properties of a human with a me-
dian body weight of 75kg and body height of 1.70m. 
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Figure 4-21 Effect of the different coupling configurations on the required velocities and torques at the motors dur-
ing stairs climbing. The physiological torque is based on the mechanical properties of a human with median body 
weight of 75kg and body height of 1.70m. 
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Stairs Climbing 
The effect of the different configurations of coupling upon stair climbing performance are reported in Figure 
4-21. The velocities at motor A reach a high peak during the first half of the swing phase. This peak is moder-
ate in positive coupling (about 250 °/s), large with no coupling (about 420 °/s) and very large in negative 
coupling configuration (600 °/s). The physiological torques produced by the motors are also significantly de-
pendent upon the coupling configuration. In the cases of no coupling and negative coupling, both reach peak 
torques of about 75 Nm at the hip, while in positive coupling, the peak torque reaches up to 140 Nm. The 
effect of the actuator inertia is relatively important for the motor A (about 15 Nm), however the differences 
between the different coupling configurations are small. In conclusion, stair climbing is the most demanding 
activity since it requires simultaneously the greatest velocities and the greatest torques of the three activities. 
There is no clear advantage for any of the coupling configurations. Positive coupling better fulfills the require-
ment for the swing phase, while negative coupling performs better in the stance phase. The configuration 
without coupling would be the most adapted since it avoids both torque and velocity extremes. 
??????? ?????????????????????????
Remote actuation elements 
The systems implemented for both the hip and knee flexion/extension actuation units are identical. It is com-
posed of a motor EC-i 40, 100 W (Maxon motor AG, Sachseln, Switzerland), a planetary gearbox GP 42 HP 
(Maxon motor AG, Sachseln, Switzerland) with a transmission ratio of 1:74, and a custom pulley with helical 
groove for a 2mm-diameter cable. These elements are aligned with the motor axis and are illustrated in 
Figure 4-22 
 
Figure 4-22 The remotely located elements of the hip and knee flexion/extension actuation units, including brush-
less motors, planetary gearbox and pulley 
 
 
4.2 AUTONOMYO Design and Implementation 
80 
Transmission to the joints 
The cable and pulley system chosen for the transmission of power from the remotely located actuation units 
to the joints has a superior compactness compared to belts for comparable torque transmission and is very 
rigid. Mechanical transmission through cables is subject to the main following challenges: 
1. Transmission of efforts between cable and pulley (fastening of the cable)  
2. Limit in the range of motion 
3. Limit of pulley diameter as a function of cable diameter 
4. Limit of cable angle and winding 
5. Tensioning of the cable 
Lowering the transmission ratio of the gearbox implies lowering the torque capacity of the gearbox and 
thereby lowering the size and weight of it. It also diminishes the losses that would otherwise increase with 
the number of gear stages. A ratio about 1:3 between the pulley at the motor and the pulley at the joint is a 
good compromise between the diameter and winding limitations. The pulleys at the joints are realized with 
a groove diameter of 84 mm; the transmission ratio between the pulley is 5:14. The total ratio from the motor 
to the joint is, then, about 1:207. In order to solve the challenge of the transmission of energy between the 
cable and pulley, the cables are built with swaged ends that are anchored on the larger joint pulleys. For the 
small motor pulleys with helical groove, the cables are wound about 3 turns and a half around them. Two 
screws press and lock the cables against the pulley. In order to pre-tension the cables, free-sliding pulleys are 
mounted on the structure and can be tightened with the help of screws. 
The selection of the cable diameter is a compromise between the minimum bending radius, which mostly 
affects the lifespan of the cable and the maximal supported load.  Other cable constructions are made out of 
different strand configurations, thin wires, or materials such as metals or polymers. The selected solution is 
a stainless steel wire rope of diameter 2.0 mm and configuration 6x19-WSC (Carlstahl Technocables, Ger-
many), with terminations swaged with cylinders of 4.0 mm of diameter and 8.0 mm of length. The minimal 
breaking load of such a solution is 2.768 kN and has a minimum bending ratio of 25. A minimum pulley diam-
eter of 50 mm would then be recommended. Because the small pulleys of the current design have a diameter 
of 30mm, they do not fit the recommendations. Tests of durability are required as future work to validate 
the current design. Risks are an early fatigue and the rupture of the most bended little wires which will reduce 
the total load capacity of the wire rope. Hence, it can lead to a higher risk of breakage of the wire ropes that 
would free the joint by cutting the transmission with the actuators. 
Belt and pulleys or gears transmission systems could turn indefinitely (unlimited range of motion). However, 
particular attention is paid to the range of motion. Since the cables are anchored to the pulleys, the range of 
motion is limited by the position of anchorage. The targeted range of motion is about 160° (-20° to +140°) 
for the hip and about 140° for the knee (-10° to +130°). In the case of hip-knee coupling, the range of motion 
of motor B is unchanged, while the range of motion of motor A is a result of both hip and knee flexions and 
has a maximum rotation of 300°. Using a single groove per pulley provides range of motion to about 160°. 
The use of a helical groove is an option; however, it introduces lateral displacement. Ultimately, a design with 
two grooves is chosen; as a result two strands are necessary and are anchored separately and in opposition, 
see Figure 4-23. 
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The concept of the complete actuation of the hip and knee in the sagittal plane is illustrated in Figure 4-18. 
The transmission of motor B is linked to the hip through only one cable-and-pulley stage, from the motor to 
the hip joint. The transmission of motor A, however, needs two stages to reach the knee, as it first needs to 
pass through the hip. A pair of free pulleys transmits the energy from the motors and passes them to the 
knee joint. A key drawback of such a cable transmission is that, in the presented configuration, it is not pos-
sible to adjust the length of the segment along the thigh without changing the length of the cables. A mech-
anism to avoid this drawback is presented in section 4.2.5.2. 
 
Figure 4-23 Illustration of the large pulley at the joint and its range of motion of approximately 270° 
Ankle joint 
The first iteration of the ankle joint design uses a passive approach. The solution should allow the three axes 
of rotation while constraining the motion with a visco-elastic behavior. A rubber system based on skateboard 
bushings are used. The mechanics is presented in Figure 4-24. 
 
Figure 4-24 Illustration of the passive ankle joint, realized with rubber bushings 
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Hip abduction/adduction is less frequently studied than hip, knee and ankle flexions/(extension). The kine-
matics and kinetics can be found in the literature for the walking activity; however, the same data for activi-
ties such as stairs climbing were not found. The RMS and peak torques during walking are reported to be 
slightly smaller than the same torques engaged in the hip flexion/extension. It is assumed that the amplitude 
of peak torques required in a stable gait are significantly less than the torques generated to recover from an 
unstable posture. Also, the efforts generated by a person without muscular weakness can be diminished by 
the use of the muscle about the torso, while people with neuromuscular diseases need to compensate for a 
general weakness through the residual muscle strength.  Based on the curves reported in section 4.1.5, the 
power generated by the abductors during level walking is nominally about 10 W, with peaks about 25W. The 
range of motion about the hip abduction/adduction is quite small. Angles measured in a group of healthy 
persons during level walking range from an adduction of 5.4° to an abduction of 7.5°, hence, a total range of 
motion of 12.9° [131]. 
The constraints on the actuation and transmission unit of the hip abduction/adduction are: first, the mecha-
nism should preferably be located at the back of the user, with the center of rotation aligned as much as 
possible with the natural hip joint. Second, it should be able to reach up to 100 Nm of peak torque and have 
a range of motion of ±20°. It should also be able to reach high dynamics and have a good backdrivability. 
Eventually, the solution should be lightweight and not greater than 60 mm of posterior depth so that the 
user can still sit on conventional chairs. 
The design of the actuation and transmission mechanism is presented in Figure 4-25. A high density power 
motor EC-4pole, 200 W (Maxon motor AG, Sachseln, Switzerland) with a planetary gearbox (1 stage, trans-
mission ratio of 1:14) GP 32 HP (Maxon motor AG, Sachseln, Switzerland). 
 
Figure 4-25 Illustration of the actuation and transmission unit of the hip abduction/adduction. © 2017, IEEE 
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The gearbox is coupled to a belt and pulley in order to transmit the effort on a ballscrew PSS 12 05 (FA com-
pact series, NSK Ltd, Japan) with a pitch of 5 mm. The addition of a gearbox ahead of the screw reduces the 
effect of the inertia of the screw. The gearbox, however, adds some friction and reduces the backdrivability 
of the unit. Eventually, energy is transformed from by the translational motion of the nut back to a rotation 
via a four-bar linkage mechanism (see Figure 4-25). The system has a non-constant transmission ratio due to 
its geometry. However, over the predefined range of motion, the transmission ratio can be approximated by 
a constant with a mean deviation of 0.3°. The total transmission ratio is equal to 1:1’613. 
????? ?????????????????????????????????????
??????? ??????????????????????????????????
The summary of the theoretical capacities of the three different joints of the exoskeleton are summarized in 
Table 4-5. Note that these values are the theoretical values obtained from the ideal case where the maximum 
efficiency possible is 100%. 

















Hip abduction/abduction 92.9 150 - 16'500 / 25’000 49 / 60 
Hip flexion/extension (motor B) 207 43 100 5’000 / 8’000 150 / 231 
Knee flexion/extension (motor A) 207 43 100 5’000 / 8’000 150 / 231 
??????? ????????????????????????
The complete exoskeleton is illustrated in Figure 4-26. It includes six actuated degrees of freedom and three 
passive degrees of freedom. Physical interfaces are located at the feet, the shanks, the thighs (optional) and 
the trunk. Two sets of Lithium-Polymer batteries are in the back of the device with a total capacity of 768Wh 
and a total weight of 4.4 kg. The electronics are fully embedded in the device and can communicate with 
external computers or Android systems, as will be described in the next section. The structure of the exoskel-
eton is mostly made out of aluminium alloys because of of their low density properties, good mechanical 
properties, and ease of machining. The total weight of the device, including batteries, is about 22.5 kg, with 
two-thirds of the weight (about 15 kg) located around the lower back of the user. 
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Figure 4-26 Illustration of the complete AUTONOMYO exoskeleton design. Copyright © 2017, IEEE 
??????? ????????????????????????
The electronics include one main board with an embedded computer and three motor drivers that can con-
trol two motors each.  
Embedded computer 
The embedded computer is based on a Beagle Bone Black computer (BeagleBoardd.org Foundation, Oakland 
USA), with a soft real-time Debian Linux operating system. The board is furtherly equipped with an IMU (in-
ertial measurement unit) sensor that detects the orientation in space, and an Wi-Fi adapter for wireless com-
muniation with external devices. The role of the main board is to manage the high level controller; this in-
cludes activities such as defining the position or torque trajectories and sending them to the motor boards, 
collecting the data from the sensors, and recording logs of the experiment onto an SD card. The main board 
is also programmed with a set of failure detection and can cut power to the motor drivers in case of emer-
gency. 
Motor drivers 
The motor drivers are custom-designed printed circuit boards developed at the Laboratory of Robotic Sys-
tems (EPFL, Lausanne, Switzerland). Each unit can control up to two electric motors, brushed and brushless, 
and collect data from position sensors such as potentiometers or encoders. The motor drivers are also able 
to cut the power transmission to the motor in case failure is detected.  
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Physical interfaces are a challenging aspect of exoskeleton design as their role is to transmit energy and mo-
tion to the body in a comfortable manner. These interfaces can either be tailor-made to best fit the user, or, 
adjustable. An adjustable design significantly augments design complexity, but allows quick interchange be-
tween users. The physical interfaces of each segment are described in the following sections: 
Trunk interface 
The trunk interface is composed of a rigid carbon fiber plate and a polymeric brace with two straps and 
buckles to support supporting high loading. The rigid plate of carbon fiber is molded from the part of the 
exoskeleton to which it is fastened while in use. This allows good mechanical coupling and the use of a single 
screw, which makes it easy to assemble/disassemble to or from the rest of the structure. Interfacing with the 
trunk is challenging since the trunk is a pluri-articulated segment. Thus, controlling the back in a predictive 
manner would result in constraining all motion from the pelvis to the neck. This would be very uncomfortable 
for the user. 
 
Figure 4-27 Pictures of the trunk interface from front and from behind 
Thigh interface and segment adjustment 
The necessity of a thigh interface for people with residual muscular capabilities is still under investigation. 
Tests of assisted walking have not demonstrated an absolute need for a thigh interface, but data need to be 
collected on patients’ feedback and performance observations on other activities such as the sit-to-stand 
transition. The length of the segment going from the hip to the knee joint, however, does need to be adjusted 
in order to align the centers of rotation of the hips and knees of both the user and the exoskeleton. 
As mentioned previously, the use of a remotely located actuator is challenging for the adjustment of the 
length of the segments as cable transmission design is dependent from the segment length. The optimal 
solutio would be a mechanical architecture that adjusts segment length without requiring a change in the 
cable length. A simple design is illustrated in Figure 4-28. In this mechanism, two pulleys, i.e. 702 and 803, 
are introduced, so that the cable makes an “S” shape. Pulleys 701 and 702 are mounted on the same structure 
and pulley 801, 802 and 803 on another one. When these two structures (the hip and the knee joints) are 
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moved closer or away, the length of the three segments of the cable 900, 901 and 902 are modified. However, 
the sum of the length of the three segments is kept unchanged, because segment 900 and 901 move half the 
distance of that of segment 902. Once combined, the sum of the three segments is kept identical. The last 
pulley 802 pretenses the cable. 
 
Figure 4-28 Schematic of an adjustable length mechanism for a cable transmission, where the length of the cable is 
independent from the distance between pulleys 701 and 801 
This solution is, however, only applicable to a single-cable mechanism, while the segment of the exoskeleton 
includes preferably two cables to allow anchoring on both pulleys. A solution would then be to adjust the 
two cables, instead of just one; each cable follows the previously discussed path through the two additional 
pulleys, essentially combining segments 900 and 901. In this case, however, the displacement of the pulleys 
is too large by a factor of two. The chosen solution design keeps pulley 803 at an equal distance from both 
pulleys 701 and 801. Concretely, a double rack and pinion mechanism is used. Each rack is mounted on a 
separate structure and in opposition, so that the pinion can be placed in between them. The pulley 803 is 
freely mounted on the same axis as the pinion, so that when the structures are moved of a certain distance 
close or away from each other, the pulley moves only half the given distance. The final design is adjustable 
for inter hip-knee length from 352 mm to 500 mm as illustrated in Figure 4-29. To modify the dimension of 
the segment, 3 steps have to be performed: first, the tension pulley must be unscrewed until the cable is 
loose. Second, the two screws locking the two frames of the segment together must be unscrewed in order 
until dimensions can be adjusted; the frames should then be locked again. The tension pully must then be 
re-fastened until the cable is tight.  
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Figure 4-29 Design of the thigh segment with a rack and pinion mechanism to keep the same cable length while ad-
justing the segment length 
Shank interface and segment adjustment 
The shank interface is composed of a curved rigid carbon fiber structure padded with foam mounts on the 
front of the lower leg closely under the knee (see Figure 4-30). The part is fastened to other leg with a large 
band and a hook-and-loop locking system. The interface is mounted on the exoskeleton and held by a tube 
structure and locked by two manual fastening clamps (see Figure 4-30). When these clamps are opened, the 
interface can rotate freely and move vertically. This facilitates the donning and doffing of the device, as the 
interface can rotated 90° to let the user in, and rotate back to a close when the user is in position. The inter-
face position can also be adjusted width-wise through an adjustable screw system. The tibia, or shank, seg-
ment of the exoskeleton is composed of two telescopic tubes that are locked by a double clamping fastener. 
This mechanism is very robust and allows rapid and precise adjustment of the segment length. 
Foot interface 
The foot interface is composed of a flexible sole to allow physiological rollover while the back part is rigid to 
allow a good coupling with the exoskeleton. Two straps, one at the back of the foot and one in the middle 
fasten the interface to the user. A ratchet system is used for all the straps; it is very convenient as it allows a 
secure fit without excessive effort.  
Complete exoskeleton 
The complete exoskeleton with all the elements discussed is shown in Figure 4-31. The trunk interface shown 
in the picture is an initial prototype, it has the advantage of being more rigid than the second versionbut is 
poorly adjustable. The segment along the femur in the picture is also the first version prototype that is not 
adjustable in length. The latest version of the exoskeleton can be seen in Chapter 5. 
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Figure 4-30 Shank and foot interface of the exoskeleton with adjustments 
 
Figure 4-31 Picture of the AUTONOMYO exoskeleton being worn by a healthy user
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The exoskeleton is evaluated in two ways. The first evaluation characterizes the actuation units. This identi-
fication builds a model of the torque, which maps the torque applied at the joint with the current in the 
motor. It also investigates the real performances that motorization can achieve. The second evaluation fo-
cuses on assessing and comparing the performances given with different coupling configurations (e.g. posi-
tive and negative).  
????? ???????????????????????????
The characterization of actuation and transmission is performed on two joints that each have a unique type 
of actuation unit: the hip flexion/extension joint is investigated and the hip abduction/adduction. For each 
joint, a data sampling is recorded. It includes the measurement of: 
? the joint position and its derivatives (velocity and acceleration), as measured from the encoders lo-
cated on the shaft of the motors. 
? the current that passes through the motors, as collected from the motor drives. This current is pro-
portional to the torque exerted by the motors. 
? the external torque applied to the joint, as measured by an additional force sensor in the case of the 
isolated hip flexion/extension. 
The force sensor used is a Strain Gauge – Micro Load Cell CZL635 (Phidgets Inc, Canada) with a range of 500N. 
The external force is applied by hand to the sensor. The data are generated possibly through three different 
methods: 
?   open loop current control, with a constant current trajectory and a modulated external force ap-
plied by the investigator 
? current mode, but driven by sinusoidal current trajectories with variable frequencies and amplitudes 
?  closed loop position control, where the target is set as a cyclic trajectory that is modulated in fre-
quency and amplitude.  
After the acquisition of samples, a relationship must be defined between the current command at the motor 
and the kinetics observed at the joint. This is done through construction of a torque model, using a combina-
tion of linear regression andhand tuning. The linear regression approach is based on a linear parametric 
model with least square minimization of the error. The mathematical model of the regression is presented 
in Equation 4-4. An iterative approach is applied, where the number of terms in the model are added one by 
one and are selected based on an analysis of variance (ANOVA) that evaluates if the new model is significantly 
different from the previous iteration. 
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Equation 4-4 Parametric linear regression method (a) definition of the problem, (b)-(d) construction of the different 
matrices and vectors, and (e) resolution of the problem with least square theorem. “Y” is the vector of external tor-
ques applied at the joint “?joint” at different time, “X” is the matrix of variables or function of variables that are rec-
orded (variables of the model(s) as presented above, such as joint angular position, velocity, acceleration, external 
torque or power) at corresponding time, “?” is the vector of coefficients, “?" is the vector of errors, and the symbol 
‘^’ refers to an estimation of the value. 
??????? ????????????????????????????????????????????????????????
The characterization of the hip flexion/extension gives best results with samples acquired based on method 
1, where external torques are exerted on the device by hand while different constant currents are sent to 
the motor. Note that the actuation unit evaluated here is composed of a high torque density motor with a 
nominal torque of 207 mNm, which is coupled to a planetary gearhead of 3 stages with a transmission ratio 
of 1:74. A cable and pulley mechanism with a transmission ratio of 5:14 transmits the torque to the joint. The 
samples are recorded as the exoskeleton is fastened at the trunk level to a rigid structure while the legs can 
freely move in the air.  
It was expected that the torque model would be most affected by gravity and inertia of the leg structure, the 
inertia of the motor, and the frictions of the gearbox and efficiency of the motor and of the cable transmis-
sion.  Friction is usually the hardest effect to identify, as dry friction can present hysteresis, and both dry and 
viscous frictions can be dependent upon the instantaneous power and non-homogeneity in the mechanical 
parts. After the process of model refinement and different trials with friction models, a simple model ex-
presses best the torques measured from the force sensor. This model is shown in Equation 4-5 (a). The good-
ness of fit is presented in a sample in Figure 4-32 where a constant torque from the motor is applied and the 
external torque is modulated as shown in the graphic. 
The friction of the mechanism is identified as being mostly proportional to the torque from the motor and is 
expressed as a coefficient of efficiency. The efficiency largely depends on the direction of the power, because 
it is always opposed to the direction of the motion. The actuation system is generative when it produces 
greater torques than the load (including gravity and inertia), and dissipative when the external loads are 
greater. In dissipation, the actuation acts as a braking system, and the friction efforts working constructively 
with the those of the motor. 
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Equation 4-5 (a) Torque model of the hip flexion/extension actuation and (b), values of the identified parameters. 
“?joint” is the output torque at the joint measured by the force sensor, “?motor” is the input torque at the motor, “i” is 
the transmission ratio, “?” is the angular position at the joint and the dot and double dot symbols on top of a varia-
ble denote the first and second derivatives over time (joint velocity and acceleration respectively). “lmg”, “I” and 
“?” are coefficients of the gravitational term, inertial term and torque ratio (efficiency of the transmission) respec-
tively. 
 
Figure 4-32 Sample of the identified model versus the measured torque at the hip flexion/extension joint. 
The torque model and coefficients identified in Equation 4-5 (b) highlight the main components of the actu-
ation mechanism. First, the gearbox introduces large friction with a high gap between the generative or dis-
sipative power mode. This gap makes the system difficult to control and increases the risk of instability as 
the transmitted power switches from generative to dissipative. The poor efficiency in generative mode of the 
actuation means the motorization must be adjustable for higher power capabilities. Conversely, the large 
dissipative capabilities of the system can be seen as a benefit and a safety feature for activities such as sitting 
down from a standing position. There is, however, a large drawback from that friction on coupled actuation 
such as the one presented for the cable transmission through the hip and the knee. When the motors work 
in opposition, as it would often be the case at the hip joint with a coupled actuation, the leading motor needs 
to overcome three times the friction. For example, if motor A is producing an active torque of 10 Nm at the 
knee, it is producing at the same time a resistive torque of 23.6 Nm at the hip, so that motor B needs to 
generate a torque of 43 Nm for the sole purpose of counteracting motor A. Without friction, motor B would 
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only need to generate 10 Nm. This is a serious drawback that must be considered in the design of coupled 
mechanisms. 
The gravity and inertia follows both the approximate effect of a mass of 1 kg located at a distance of 1 m 
from the joint. The inertia of the actuation (motor + reductor) has a value of about 0.23kgm2. Thus, it repre-
sents about 16% of the inertia perceived by the actuator. This contribution is quite low and means that larger 
motors with greater inertia could be used without significantly affecting performance. 
In conclusion, the sagittal configuration has very good inertial properties with room to increase the motor 
size and capabilities. However, the efficiency of the gearbox is poor and has many drawbacks for the appli-
cation, including that it is highly incompatible with a coupled configuration unless the motors are always 
generating a combined effort. 
??????? ??????????????????????????????????????????????????????????
The actuation unit of the hip abduction/adduction includes a high torque density with low inertia motor, a 
gearbox with a transmission ratio of 1:14, a belt and pulley that transfer the power to another axis, a 
ballscrew with a pitch of 5mm and a four-bar linkage to transmit the translational work of the screw to the 
final hip rotation. The total transmission ratio reaches a value of 1:1’613, while the motor has a nominal 
torque capacity of 92.9 mNm. The characterization is made based on samples of gait trajectories at frequen-
cies ranging from 0.2 Hz to 1 Hz. This method was favored since the actuation system has poor backdrivability  
and is able to reach high torques compare to those generated through hand-operation. For the sampling 
acquisition, the exoskeleton is fastened on a structure at the trunk level, while the legs are free from con-
straints with the ground. The identified model is presented in Equation 4-6. 
 
Equation 4-6 (a) Torque model of the hip abduction/adduction actuation and (b), values of the identified parame-
ters. “?joint” is the output torque at the joint, “?motor” is the input torque at the motor, “i” is the transmission ratio, 
“?” is the angular position at the joint and the dot and double dot symbols on top of a variable denote the first and 
second derivatives over time (joint velocity and acceleration respectively). “lmg”, “I” and “?” are coefficients of the 
gravitational term, inertial term and dry dynamic friction respectively. “sf” represents the static friction that ap-
pears at low velocity and depends if the system is accelerating or decelerating. 
 
The results of the model are shown in Figure 4-33 with the torques reported at the level of the motor, while 
the angle position is at the joint. The trajectory taken as target in the graph is a physiological gait trajectory 
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with a frequency of 0.33 Hz. The dominant terms are the dynamic friction that can be caused by the circula-
tion of the balls between the nut and the screw. At this frequency, peak torques reach up half of the nominal 
torque. The second component is the effect of the gravity, and possibly some friction proportional to the 
torque that has not been identified.  A constant torque of about 1/3 of the nominal torque (55 Nm at the 
joint level) is measured, while the load at the joint due to the gravity is only equal to 10 Nm. At this frequency, 
peak torques related to the inertia are measured at 20 Nm (reported to the joint), where half of the inertia 
is due to the motor and the other is due to the exoskeleton structure and other elements. The static friction 
is projected to be a constant 20 Nm at the joint level.  
 
Figure 4-33 Sample of the identified torque model versus the measured torque (converted from current) at the hip 
abduction/adduction joint 
In conclusion, the actuation unit of the hip abduction/adduction is adapted for position control with gait 
trajectories at frequencies going up to 1 Hz. It can handle high dynamics while also provided substantial 
torque to assist the user. The drawback of this design with a large transmission ratio, however, is that it has 
poor backdrivability, i.e. about 20 Nm of static friction and high resistance to velocity. The transmission ratio 
could possibly be reduced of a factor of two to benefit from better backdrivability and, potentially, without 
significantly diminishing the performances, as the dynamic friction would diminish by the same factor as that 
of the transmission ratio. The need of the user in terms of peak torques required must be clarified through 
more investigation.  
????? ???????????????????? ????????????????????????????????????
In the following of section 4.2.3 where a theoretical analysis of the performances of the different coupling 
configurations is addressed, the present section evaluates the performances of both positive and negative 
coupling directly on the exoskeleton. As previously discussed, one configuration (positive coupling) allows 
simultaneous and rapid motion of hip and knee flexion, but can exert only limited forces in that direction. 
Hence, positive coupling is best suited for swing phases. In opposition, the negative coupling configuration 
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exerts large forces in a flexion-to-extension direction; however, motions of double flexion require motors to 
be able to deliver large velocities. 
In order to perform the tests, each leg of the exoskeleton is assembled with a different configuration. The 
exoskeleton is fastened at the trunk level, while the legs are let free to move. Physiological gait trajectories 
are programmed and run on all the joints at the same time during the tests. The tests are performed with 
different walking frequencies from 0.33 Hz to 1 Hz so that the RMS current required to follow the trajectories 
and the velocity limitations can be recorded. Note that the actuation of the hip and knee flexions is limited 
by the maximal tension of the drivers to their nominal velocity of 5000 RPM or 175 °/s at the joints. The 
measured trajectories from the different joints for three walking frequencies are shown in Figure 4-34. The 
corresponding RMS currents are reported in Table 4-6. 
Table 4-6 RMS current for the different joints during trajectory following at different gait frequencies. 
 RMS current in % of nominal capacity of the motor 
 Negative coupling configuration Positive coupling configuration 
Frequency 0.33 Hz 0.5 Hz 1 Hz 0.33 Hz 0.5 Hz 1 Hz 
Hip abduction/adduction 41,6 51,9 88,3 39,7 51,9 88,0 
Hip flexion/extension 15,1 36,0 72,4 11,7 14,2 25,5 
Knee flexion/extension 11,3 - - 9,6 17,6 - 
 
All the actuation units are able to follow the gait trajectories at a frequency of 0.33 Hz, which represent a 
very slow velocity, see Figure 4-34. The trajectories at 0.5 Hz, which correspond to a moderately slow walking 
velocity, are achieved by all the joints but the knee flexion/extension in negative coupling, as the motor needs 
a higher tension to perform the targeted velocities. At 1 Hz, all the joints are at their limits, and the knee in 
positive coupling cannot follow the desired trajectory. The RMS current increases nonlinearly with the fre-
quency. In positive coupling, only one quarter of the nominal torques are consumed for the trajectory track-
ing at the hip and the knee flexions. In negative coupling, a significant current is consumed for the hip flexion 
at 1 Hz (72.4 %), but the current consumed at lower frequencies and at the knee are acceptable. For the hip 
abduction, the amount of current required to follow the trajectories is significant but the remaining torque 
available is still large enough to provide an important support during gait. 
These results support the observations made above after the characterization of the different actuation 
units. The velocity limitations of the actuation unit can be first improved by using motor drives with higher 
tension capacities or by using motors with a lower nominal voltage. However, even with higher velocity mar-
gins, the 1 Hz frequency will be hard to achieve in the configuration with negative coupling. Conversely, the 
positive coupling configuration seems well adapted to the walking activity as it can almost follow the trajec-
tories at 1 Hz and can still dedicate 75% of its nominal torque to provide assistance to the user. 
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Exoskeletons have been investigated mostly in terms of their use to people suffering from spinal cord injury. 
Such devices could in a similar manner compensate for the muscle weakness in people with neuromuscular 
diseases. Two key aspects need to be adapted in order to fit with such people: first, whereas exoskeletons 
SCI people follow a trajectory without intervention from the user, the human robot interaction must be col-
laborative so that both the user and the exoskeleton contribute to the motion. Second, SCI people use 
crutches or rollator to balance and also to perform some activities, including weight transition during level 
walking. Thus, due to the weak upper limbs of people with NMD, the use of crutches is compromised and 
therefore higher joint velocities and a short swing phase must be achievable. 
A simulation of the leg segment with only the hip, knee and ankle flexion actuation was implemented to 
evaluate the dynamical performances and challenges. For each joint, a flat brushless motor with a harmonic 
drive gear located directly on the joints is simulated. Results show that for a nominal torque capacity of 50 
Nm, peak torques due to the inertia go up to 125 Nm for both the hip and the knee, while both actuators 
follow a typical gait pattern at 0.84 Hz. These peak torques are due to both the inertia of the motor at the 
knee, and the added mass at the ankle of the actuator. This simulation highlights that the inertial effects 
induced by not only the inertia of the rotor of the motor but also the mass of the actuation unit must be 
optimized while designing. 
An analysis of the contribution of each of the seven joint of the legs reveals that the most important joints 
are the hip abduction/adduction and the hip and knee flexion/extension. It is still an open question for future 
resaerch as to whether the ankle contribution can be replaced by a passive joint. It has been reported, even 
in a stair-climbing study, that wearing a rigid ankle foot orthosis reduces ambulation velocity.  
The next step in the design was to optimize and reduce the effect of the inertia due to the actuation units. 
This was done by first selecting brushless motor technology, featuring a small diameter and high torque den-
sity with a planetary gearbox. Then an architecture with the motors remotely located from the joints and run 
with cable-driven transmission is proposed. This reduces the inertia induced by the mass of the actuators 
and keeps the flat segments aligned along the legs. 
As a result of remotely locating the actuators from the joints, the transmission of the knee passes through 
the hip joint. This couples the two joints; two coupling configurations are possible, depending if the cables 
are crossed or not between the pulleys. The study of the coupling shows that one configuration cumulates 
the extension torques, which is beneficial during the stance phases of walking, stairs climbing or STS transi-
tioning. However, this configuration also cumulates the flexion velocities required by the motors, such as 
those present in swing phase. The other configuration has an inverse performance; it allows rapid swing 
motions, but is limited in extension torque. The evaluation of both solutions on a test bench showed that 
one configuration can almost follow the walking trajectories at 1 Hz with a RMS current of one quarter of the 
nominal current while the other configuration could almost follow the trajectories at 2 Hz with the knee while 
consuming about 72 % of the nominal torque at 1 Hz. In conclusion, both configurations are very good in one 
application but underperform in the other. A compromise is to uncouple the two joints, or use a clutch to 
change of configuration as required. 
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The hip abduction/adduction actuation has been designed to deliver high peak torques. A motor with high 
power density and a small diameter was selected in combination with a small gearbox, a ballscrew and a 
four-bar linkage mechanism. The final transmission ratio is 1:1613 with a theoretical nominal torque of 150 
Nm at the joint. The hip and knee flexions/extensions are performed with a three-stage gearbox, followed 
by a cable and pulley transmission. The total transmission ratio is equal to 1:207. A characterization of both 
type of actuation and transmission units was evaluated. The main contributions observed are: a friction pro-
portional to the motor torque for the gearbox about the hip and knee flexion, which can be seen as an effi-
ciency applied to the torque. For the actuation unit of the abduction, the most important factors of perfor-
mance were determined to be the resistance to the velocity from the ballscrew and the dry static friction, 
which measured to approximately 20 Nm. Gait trajectory tests on the hip abduction/adduction show that 
the system could follow frequencies up to 1 Hz; however, about 88% of the nominal current is spent to reach 








This research investigates solutions for assisted ambulation targeting people with chronic muscle weak-
nesses. Previous work has been done to make people with complete spinal cord injury walk again, while other 
works have developed industrial solutions to enable healthy persons to excel in performing extremely phys-
ically intensive tasks. However, though one may not expect it, designing a device to assist a person who has 
a residual ability to walk is no easier than doing so for a person who has almost no ability to walk. In the case 
of a person with complete SCI wearing a LEE, the control of the body is split in two. The upper body and 
crutches (if any) provide the balance and are managed by the user, while the motion of the lower body is 
entirely executed by the exoskeleton upon request of the user. In the case of a healthy operator, the user 
has the capacity to modulate the forces applied to the environment, this is a reliable signal that can be used 
to control the exoskeleton. Another approach is to use a model of the load and compensate it through the 
exoskeleton with a sensor that can identify when the load is carried or not. Eventually, when the exoskeleton 
is used to assist a free motion, a common strategy is to implement negative damping [158], which applies a 
torque proportional to the velocity measured at the joint, and in the direction of the motion. 
Developing a control strategy for a user with muscle weakness has two key aspects that must be addressed. 
First, it is often difficult for these users to move throughout the whole range of motion, not because of joint 
mechanical limitations but rather because of the force needed to lift the leg against the gravity, for example. 
Second, once an assistive procedure is launched, a poorly designed control strategy will make it difficult for 
the user to reverse the motion or provide a perceptible motion that could be detected as a voluntary action. 
In conclusion, strategies that can be used for healthy operators are not suitable for people with neuromus-
cular diseases. 
People with NMD have also two main needs. First, mild exercise is recommended as it prevents muscles from 
wasting too rapidly; it also maintains the respiratory condition [7], [159]. Second, as presented in Chapter 2, 
the upper limbs of people with NMD are usually weakened. This means that the use of crutches is not rec-
ommended. Other auxiliary types of support can be considered, typically those allowing a fully vertical pos-
ture of the back. For these two reasons mainly, the control strategies for people with SCI are not suitable for 
people with NMD. 
There are several specifications regarding an assistive strategy for people with NMD, or more generally, for 
people with debilitating muscle weakness: 
1. The user should be physically involved in the ambulation process. 
5.1 Finite-State Active Impedance Control - Method 
100 
2. The amount of assistance should be tuanble to match the capacity of each user’s muscle so that all 
muscles can be engaged without becoming overloaded. 
3. The controller should be triggered by user intention, as naturally and as smoothly as possible. 
4. The gait parameters should be regulated by user feedback metrics such as step length, step rate and 
walking velocity. 
5. The initiation and termination of ambulation should be robust and intuitive to avoid accidents. 
6. The controller should allow switching between activities (walking, stairs climbing or rising from a 
chair) in a very robust manner to avoid accidents. 
In the following, a preliminary approach is implemented and tested. The control strategy is based on finite-
state active impedance where the sensing is limited to the kinematics of the joints. The method and results 
presented in this chapter have been published in two different documents. First one is part of the IEEE Inter-
national Conference on Biomedical Robotics and Biomechatronics, Enschede (NL), 2018 with the following 
authors: Amalric Ortlieb, Romain Baud, Tommaso Tracchia, Benoît Denkinger, Quentin Herzig, Hannes Bleuler 
and Mohamed Bouri, and under the title “An Active Impedance Controller to Assist Gait in People with Neu-
romuscular Diseases: Implementation to the Hip Joint of the AUTONOMYO Exoskeleton”. Second one is part 
of Springer, “Wearable Robotics: Challenges and Trends, Proceedings of the 4th International Symposium on 
Wearable Robotics”, from the conference WeRob, Pisa (IT), 2018, with the following authors: Amalric Ortlieb, 
Peter Lichard, Florin Dzeladini, Romain Baud, Hannes Bleuler, Auke Ijspeert and Mohamed Bouri, under the 
title “Investigation on Variable Impedance Control for Modulating Assistance in Walking Strategies with the 
AUTONOMYO exoskeleton”.   
??? ???????????????????????????????????????? ??????
Impedance control has been widely used with various actuation-transmission units for both upper and lower 
limbs. Impedance can be used as a soft trajectory corrector where a force is provided by the exoskeleton to 
attract the end-effector along a defined path such as described in [160] and [154]. Such controllers are tra-
jectory and time dependent and thus quite constraining for the user [161]. Another type of impedance based 
controller is called triggered assistance and has been mostly implemented for upper limbs [161]. The archi-
tecture of control proposed in the current section has been largely investigated in the domain of prosthetics 
for the lower limb (transfemoral and transtibial prosthesis) and is referred to as “finite-state controller”. Such 
controllers are defined by a periodic sequence of states with state-constant impedance that typically simu-
lates a spring and damper behavior [162]–[167]. The transition from one state to another is usually based on 
different events such as heel strike or toe off, which are identified using force sensors located in the prosthe-
sis. Other events, such as a muscle activity or joint angle or velocity, are also frequently used [162]–[169]. 
Several activities, such as level walking, stairs or slope ascending / descending and sit-to-stand transition, 
have been studied in these papers. A few studies using foot orthosis [170], [171] or complete lower limb 
exoskeletons (three using the Indego® device [172]–[174]  and two with the Hybrid Assistive Limb (HAL) de-
vice [175], [176]) implemented similar “finite-state” controllers. However, most of these strategies are con-
structed primarily on events related to ground reaction forces (e.g. detection of heel strike, displacement of 
the center of pressure), and also on events related to the motion of the joints. 
In the current thesis, an active variable impedance controller using a finite-state approach designed for peo-
ple with residual ability to ambulate is addressed. In order to involve the user in the ambulation process, the 
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wearer must generate a motion to initiate the stepping. This section addresses the process of designing that 
signal input processing. First, the control scheme is described and its triggering properties are evaluated. 
Then, the controller’s impedance is tuned for two pilots, one healthy and one with neuromuscular disease 
(limb girdle muscular dystrophy). Gait kinematics and dynamics are collected in order to evaluate the collab-
oration of the controller and the pilots. Third, the influence of the impedance parameters on gait is investi-
gated.  
The exoskeleton AUTONOMYO, presented in 1.1, is the investigation platform. The device has been designed 
to assist people with neuromuscular or neurological impairments, where a tradeoff between low impedance 
of the actuation (high backdrivability) and high power is key. AUTONOMYO counts three actuated degrees of 
freedom (DoFs) per leg, i.e. two at the hip and knee flexion/extension plus one at the hip adduction/abduc-
tion. Actuators, electronics and batteries are remotely located in the back of the user in order to optimize 
compactness and inertia along the limbs. More details can be found in 1.1 and in [177], [178]. 
????? ??????????????????????????????????????
Human joints are controlled and stabilized by a set of muscles, tendons and ligaments. Muscles are unilateral 
actuators that are built in antagonist pairs such as the hamstring and quadriceps groups that generate the 
flexion/extension motion of the knee. The muscle-tendon pair can be seen as series elastic actuators due to 
the highly stretchable properties of their tissues [179]. Assembling a set of antagonistic muscles then results 
in a variable stiffness actuator. This is useful for dynamic activities due to its energy management character-
istics, i.e. optimal storage and release of energy. The compensation of muscle weakness through the appli-
cation of supplementary torques about a joint needs to be compatible with the physiological motor architec-
ture in order to assist ambulation. 
The torques applied to the body during walking demonstrates clear elastic behaviors that are quite constant 
during long defined states. As shown on Figure 5-1 for the hip flexion/extension, gait dynamics and kinemat-
ics from D. Winter [129] and S. Ounpuu [130] can be represented graphically to highlight this spring-like 
behavior. The natural gait seems to be generated with constant joint stiffness during two main intervals, 
similar to the stance and swing phases, both lasting about 40% of the cycle. These two phases are then con-
nected by two short states of high impedance, each lasting about 10% of the cycle duration and correspond-
ing to the double support phases.  
Our work begins with an initial postulate that adding a supplementary power based on a spring-like behavior 
would allow to optimally combine both actions. In order to validate this intuition, one can draw the equations 
of two elastic elements in parallel, representing both the impedance of the muscle contraction and the action 
added by the actuator from the exoskeleton.  
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Figure 5-1 Hip flexion/extension torque during walking versus hip angle as reported in the literature by Winter and 
Ounpuu [129], [130]. Curves are split along the different gait phases, i.e. double support, stance and swing phases, 
to highlight the constant spring-like phase-related behavior. Copyright © 2018, IEEE 
Equation 5-1 (a) expresses the natural torque at the joint where km is the muscle-tendon stiffness and ?? is 
the “angle at equilibrium” or “attractive angle”. Equation 5-1 (b) is the torque resulting from the addition of 
an impedance controller through the exoskeleton to the muscle activity, where kexo and ??exo??are the simu-
lated stiffness and angle at equilibrium, respectively, of the exoskeleton. The final impedance of the joint 
assisted by the exoskeleton is reported in Equation 5-1 (c) for the stiffness and Equation 5-1 (d) for the angle 
at equilibrium. 
 
Equation 5-1 (a) Hooke’s law applied to a rotational spring, (b) Expression of two torques in parallel, (c) Equivalent 
stiffness of two spring in parallel and (d) Equivalent point of attraction of two springs in parallel 
Equation 5-1 (a-d) show that the contributions of the muscles and the exoskeleton are linearly and propor-
tionally combined. Simultaneously, the resulting angle at equilibrium is the weighted average between the 
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individual angles at equilibrium over the individual stiffness ratios. Hence, the range of motion and level of 
assistance can easily be modulated following the controller’s angle and stiffness parameters.  
????? ????????????????????????????????????
A finite-state active impedance controller is characterized by the following structure illustrated in Figure 5-2: 
1. A low level controller, which regulates the torque applied by the exoskeleton. 
2. A mid-level impedance controller, which generates a torque command based on the position and the 
orientation measured by the sensors, as well as their temporal derivatives. 
3. A higher level controller, which detects the current state based on either sensors relative to the kin-
ematics or their interactions with the environment. It then communicates the impedance parameters 
corresponding to that state to the impedance controller. 
 
Figure 5-2 Generic structure of the finite-state active impedance controller 
The key elements of a finite-state controller are, first, the definitions of the different states and the transition, 
based on the detection of particular events related to the kinematics or to ground reaction forces. Second, 
the parameters of the impedance for each state or phase must be tuned according to the application. One 
strength of the finite-state active impedance controller is that the impedance models can be very easily tuned 
and thus the level of assistance can be customized to the user. 
????? ???????????????????????? ???????
Based on the observation of the impedance during the gait presented in Figure 5-1, three states with different 
impedances are observed that have similar timing with the swing phase, the single stand phase (as only one 
foot is in contact with the ground) and the double stand phase. It is important to note that any activity should 
be composed of cyclic states which run continuously, while still states should pause and then re-start the 
activity. For example, if walking, the controller should allow the user to voluntarily stop, stand still and walk 
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again as she/he intends to. In the current implementation, three phases are proposed: a “swing” phase, a 
“single stand” phase, and a “transition or double stance” phase. The “transition” phase is the “standing still” 
state. This is quite beneficial, as the controller does not have to differentiate between the walking and the 
standing mode. The schema of the three-phases controller is illustrated  in Figure 5-3; the conditions for the 
transition from one state to the other are described in the next section. The continuous walking pattern is 
illustrated in red with each state duration in percentage of the cycle duration. 
 
Figure 5-3 General schema of the three-phases finite-state controller 
??????? ????????????????
As discussed above, the controller consists of the simulation of impedance behaviors that evolves over the 
different phases of gait. A robust way to detect stance and swing phases is to use contact or force sensors 
under the feet. This approach has been widely explored both with prosthetics [180]–[182] and exoskeletons 
such as the EksoGT™ or HAL [183]. The approach explored here is based only on the kinematics and is able 
to predict motion intentions either while the foot is still in contact with or before it is in contact with the 
ground. Initial investigations indicate that the hip flexion velocity is a good predictor for the detection of the 
different impedance states. Three phases are proposed as candidates and are called “hip flexing”, “hip ex-
tending” and “static” phases. These phases are similar, respectively, to the “swing”, “stance” and “double 
support” standard phases. Equation 5-2 (a)-(c) express the conditions for such phase detection, where Vhip is 
the velocity measured at the hip joint on the reference side (e.g. left hip), Vopp_hip is the velocity measured at 
the opposite side (e.g. right hip), and Vlim+ is an arbitrary threshold determining the detection of the phase 
transition. The latter threshold can be tailored to the user in order to adjust the sensitivity of the detection 
as will be presented in subsequent discussion. 
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Equation 5-2 Conditions defining the different control states : (a) condition for the flexing phase, (b) condition for 
the extending phase and (c) conditions for the static phase 
Similarly, during the swing and (single) stance phases, the hip flexing and hip extending phases are intended 
to be synchronized in both the left and right legs. In order to ensure the symmetry of the controller, the same 
event is tested on both legs Equation 5-2 (a) and (b) to detect flexion. In case of a hip flexing phase on one 
leg, the opposite leg is automatically turned into hip extending mode. When neither leg is flexing, either the 
user is not walking or she/he is walking, but in a transition state. The different phases and impedances of the 
controller in the context of gait initiation, continuous walking, and gait termination are illustrated in Figure 
5-4. 
??????? ????????????????????????????????
Initially, the user stands in an upright, still position which corresponds to the static phase of the controller 
(as none of the hips are flexing). In order to initiate gait, a flexion of one hip up to the velocity threshold Vlim+ 
should be induced by the user such that the controller will turn into the hip flexing phase on that side, while 
the opposite leg turns into hip extending phase. Hence, the user must provide some critical force to move 
the leg and trigger the assistance by the exoskeleton. The amount of force to be exerted depends on both 
the passive (mechanical joints) and active (controller) impedance, which are mainly the dry friction and the 
torque in static phase. The force is also function of other parameters, i.e. the velocity threshold Vlim+ . 
Gait termination is defined as the sequence in which the controller switches to static phase and remains in 
that state. The transition from a flexing/extending phase to a static phase is usually natural. It can occur 
either as the swinging leg reaches a stable (maximum) angle of flexion, or as the wearer makes early contact 
with the ground. The static phase occurs at the end of each flexing phase, as the hip direction needs to revert 
to go forward. Gait can thus be terminated at the end of any step. This offers the full management of each 
step to the user. Time delay and triggering torques required to switch from a static to a hip flexing phase are 
investigated using the same setup as for the characterization of the actuation unit (Section 4.3) where the 
force is operated by hand through a force sensor. The experiment comports six values of Vlim+ ranging from 
10 to 100 [deg/s] and four values of stiffness in static phase from 0.5 to 3.0 [Nm/deg]. Results are presented 
in Figure 5-5 for the detection delay and torque required. Each data is averaged over a set of five measure-
ments. 
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Globally, the parameters of velocity and stiffness have opposite effects on the detection of initiation versus 
termination. The delay and torque necessary for initiating walking while in the static phase increase with the 
velocity threshold and the controller stiffness. Thus, a low velocity threshold is more adapted for people with 
muscle weakness. However, time delay and torque required to stop walking are lowered by increasing the 
velocity threshold and the static phase’s stiffness parameter. In fact, when the velocity threshold is low, the 
controller can misinterpret small motions with intentions of motion, which can possibly induce unwanted 
oscillations. A good compromise between stability and low initiation torque can be found in a range of veloc-
ities between 30 and 60 [deg/s]. 
 
Figure 5-5 Effects of the velocity threshold Vlim+ and stiffness parameter K in the static phase, (top) on the delays 
and (bottom) on the triggering torques 
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??? ????????????????????????????????????????????????????
Two evaluations of the controller are conducted, the first one consists of a feasibility study performed on a 
pilot suffering from limb girdle muscular dystrophy as well as on a healthy user. The second evaluation is 




The three-phase variable impedance gait assistive strategy is used in a haptic context where the human-robot 
interaction is bi-directional. It is important for the evaluation to take place in the context defined originally, 
i.e. in overground walking with the exoskeleton in assistance mode.  
??????? ???????
Two pilots, one healthy and one with a neuromuscular disease (NMD), walk on a pathway approximately 
twelve meters long using the AUTONOMYO exoskeleton. Both pilots are similar in height and weight (about 
185cm and 70-80kg). The affected pilot has a limb girdle muscular dystrophy, with quasi-symmetrical 
strength in the lower limbs which implies the following joint characteristics: good about ankle dorsi- and 
plantar flexion, moderate about hip and knee extensions and poor about hip and knee flexions. The MRC 
manual muscle test on this pilot is reported in Table 5-1. 
Table 5-1 Muscle strength of the pilot with limb girdle muscular dystrophy based on the MRC scale 
Pilot with Limb Girdle Muscular Dystrophy 
Joint / direction Right side Left side 
Hip abduction 1.5 1 
Hip adduction 1.5 1.5 
Hip flexion 1 0.5 
Hip extension 1 1.5 
Knee flexion 0.5 0.5 
Knee extension 2 1.5 
Dorsiflexion 2.5 2.5 
Plantar flexion 2.5 2.5 
* 0 no force felt, 1 can see a contraction but no motion, 2 can move without gravity, 3 can move with gravity, 
4 can exert a moderate force, 5 can exert a strong force 
The exoskeleton is controlled with the three-phase variable impedance strategy, where the impedance mim-
ics a spring mechanism. A damping effect is also provided during the flexing and extending phases in order 
to avoid instability in the controller, particularly during transition between phases. The general form of the 
impedance is related in Equation 5-3, while the parameters depending on the phase and on the pilots are 
reported in Table 5-2. 
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Equation 5-3 Controller impedance based on a visco-elastic behavior, where ?assist is the torque provided to the 
pilot by the exoskeleton,?k is the simulated spring stiffness,??0 the simulated equilibrium angle and ??is the viscosity 
coefficient. 
The impedance parameters have been tuned in accordance with the pilots’ feedback and to match the target 
walking velocity. The evaluation of the controller is made considering its coherence with regards to the 
torque profiles from the literature. At this stage, the impact of the assistance on the energy expenditure or 
muscle activity has not been investigated. 
Table 5-2 Parameters of impedance at the hip for the different phases and pilots 
 Impedance parameters 
 Healthy pilot Pilot with NMD 
Phases k [Nm/deg] ???[deg] k [Nm/deg] ???[deg] 
Static phase “double support” 0,8 
0 0,2 5 
Flexing phase “swing” 1,5 
30 0,6 30 
Extending phase “stance” 1,4 
0 0,4 -5 
 Viscosity coefficient??????0.11 [Nm s/deg] 
??????? ????????
Both pilots were able to initiate and terminate walking at their convenience. The velocity threshold for the 
pilot with NMD is set to 20 deg/s, while for the healthy pilot a best value of 50 deg/s is found. The pilot with 
NMD requires a physical support in order to keep his balance while walking with the exoskeleton (can walk 
without the exoskeleton using a cane).  
Figure 5-6 illustrates the hip angles and torques over one gait cycle (average over N>10 walking steps). The 
angles and torques from the literature are also reported in Figure 5-6. The reference walking kinematics and 
dynamics from the literature correspond to a greater walking velocity than that of the gait of the pilots wear-
ing the exoskeleton. 
1) Hip flexion/extension trajectories 
Ranges of motion (RoM) at the hip are respectively 47° and 31° for the healthy and the NMD pilots, respec-
tively. The NMD pilot reaches the full extension early at 35% of the gait cycle while the healthy pilot reaches 
at approximately 47%. Both perform very well when viewed through the literature; maximal extension has 
reached about 50-55% of the gait cycle. The assisted gait presents an overshoot of flexion about 6 degrees 
preceding heel strike. The healthy pilot has a short flexing phase with a high flexing velocity, compared to a 
long flexing phase with low velocity for the NMD pilot. However, the static phase following the flexion is 
especially long for the healthy pilot. 
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2) Hip flexion/extension torque 
The assistance torques for both healthy and NMD-afflicted pilots are very similar during the extending phase, 
the following static phase and the beginning of the flexing phase. These torque patterns ranging from 10% 
to 85% of the gait cycle are similar, but smaller than torques presented in the literature. The event of heel 
strike, however, is documented in literature to have high extension torques whereas the controller provides 
very small torques during this static phase. This aspect is discussed in the following sections. 
??????? ???????????
Both the healthy pilot and the NMD pilot reported a synchronous and non-constraining motion of the exo-
skeleton while walking. In both cases, the action of the exoskeleton was reported as positive and impactful. 
Differences in kinematics and torque patterns from the use of the exoskeleton, compared to natural gait, 
from the literature have been documented in the previous sections. The most notable event is the long static 
phase experienced by a healthy user wearing the exoskeleton during the heel strike event. During natural 
walking, one tends to have a continuous forward motion of the center of mass (CoM) in order to lower the 
energy cost. In the case of wearing the exoskeleton, the transition phase (static phase during heel strike) is 
managed differently compared to non-assisted gait. First, the exoskeleton does not provide a push-off phase 
that comes originally from a strong flexion propulsion of the ankle. Secondly, it is carefully designed to ensure 
that the motion is quickly stopped during double support so that the pilot has the possibility to terminate 
gait without much effort. 
The assistive torques provided reach about 70% of the peak torques reported by Stoquart et al. on treadmill 
for a bodyweight of 70kg [125] at a walking velocity of 2 km/h. Further comparisons have not been made 
since the dynamics are quite different between walking on a treadmill and walking over even or uneven 
ground.  
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Figure 5-6 Kinematic and dynamic results of a healthy pilot and a pilot with a neuromuscular disease (NMD) assisted 
by the exoskeleton, and data from the literature with healthy adults. 





One of the strengths of the presented three-phase finite-state controller is that the parameters defining the 
simulated impedance can be tailored to the need of the user. The main objective is to be able to tune the 
impedance based on level of assistance provided each joint, the comfortable range of motion for the user, 
and the highest comfortable walking velocity. This section explores the effects of different impedance pa-
rameters upon gait characteristics. The level of user engagement is also varied to evaluate its impact on gait. 
??????? ????????????? ???????
The AUTONOMYO exoskeleton is used for this experiment as shown in Figure 5-7, with the three-phase finite-
state active impedance controller. The impedance model, as described previously in Equation 5-3, is used. 
The stiffness k and the attractive angle α0 can be adjusted to the need of the user. Note that the torque is 
limited, for this experiment, to a maximal value of 25 Nm (limitation to the nominal torque of the motors 
and with the transmission efficiency taken into account). The impedance varies depending on the walking 
phase, which may correspond to the swing-phase, stance-phase or double support-phase. Both gait initiation 
and phase detection are triggered through the hip flexion velocity as previously discussed in Section 5.1.3 
and detailed further in [184]. Each step is triggered by a flexion motion of the hip that indicates the user’s 
intent. The actuations about the hip adduction/abduction were locked to a 0° position to focus on the flex-
ion/extension assistance. Due to this mobility constraint, a light physical support was needed.  
 
Figure 5-7 The latest version of the AUTONOMYO haptic lower limb exoskeleton used to perform the tests 
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Trials have been performed over a ground distance of 18m with a healthy user (203cm, 95kg, 29 year-old) 
wearing the exoskeleton. Parameters explored are attractive angles (α0) and stiffness (k) for the hip and knee 
during swing and stance phases. The level of exertion, which was self-described as low, comfortable or high, 
was modulated by the pilot to demonstrate the influence on the gait characteristics. The level of exertion is 
also referred to as the level of implication of the user, that is the amount of power that is intentionally ex-
erted by the user. To evaluate gait characteristics, the following data were collected: time to travel the 18m, 
number of steps, cadence and range of motion at each joint. The parameters for each trial is shown in Table 
5-3. 
























1 2 40 2 -10 0.5 50 0.5 5 COMFORTABLE 
2 2 60 2 -10 0.5 50 0.5 5 LOW 
3 2 60 2 -10 0.5 50 0.5 5 COMFORTABLE 
4 2 60 2 -10 0.5 50 0.5 5 HIGH 
5 3 60 3 -10 0.5 50 0.5 5 LOW 
6 3 60 3 -10 0.5 50 0.5 5 COMFORTABLE 
7 3 60 3 -10 0.5 50 0.5 5 HIGH 
8 0.5 40 0.5 -10 0.5 20 0.5 5 COMFORTABLE 
9 0.5 40 2 -20 0.5 20 1 5 COMFORTABLE 
10 2 40 0.5 -20 1 20 0.5 5 COMFORTABLE 
11 2 40 2 -20 1 20 1 5 COMFORTABLE 
12 2 40 2 -20 1 20 1 5 HIGH 
??????? ????????
The gait characteristics resulting from the different parameters of the controllers and the exertion of the user 
are summarized in Table 5-4. As depicted in Figure 5-8, the exertion of the user has a large effect on the 
walking speed and step length. The contribution of the stiffness coefficients is unclear, as only small modifi-
cations are observed in trials 8 to 11 while the stiffness is modulated during each phase of the gait. The range 
of motion of both hip and knee are correlated with the flexing phase attractive angles of both hip and knee 
(see Figure 5-8). However, the ranges of motion do not impact the step length. The cadence is inversely 
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Hip range of 
motion [°] 
Knee range 





1 0.37 (1.32) 73 49 51 0.86 
2 0.25 (0.9) 78 65 30 1 
3 0.40 (1.44) 83 68 40 1.2 
4 0.50 (1.8) 89 71 40 1.5 
5 0.29 (1.05) 85 75 31 1.1 
6 0.39 (1.41) 88 70 39 1.2 
7 0.46 (1.66) 86 72 43 1.3 
8 0.55  (1.99) 56 62 52 1.3 
9 0.47 (1.71) 49 60 51 1.1 
10 0.56 (2.01) 51 54 56 1.2 
11 0.51 (1.85) 51 60 55 1.1 




Figure 5-8 Correlation of the hip attractive angle in flexing phase with some gait characteristics 
** indicates statistical significance (with p-value < 0.01)  
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Figure 5-9 Correlation of the user implication with relevant gait characteristics 
??????? ???????????
This section has highlighted the flexibility of the controller. Three factors were preliminary evaluated: two 
impedance parameters (the attractive angle (α0) and the stiffness (k)) and, the physical exertion of the user 
during ambulation. The user is primarily in charge of the walking performance, as demonstrated by the sig-
nificant effect of the user effort on the walking speed and on the step length. This aspect is key, because it 
indicates that the motivation of the user and their subsequent contribution will heavily affect the perfor-
mance of the device. In a rehabilitation setting, it can also provide feedback to therapists on the level of the 
engagement of the user. 
The effect of the attractive angle is also shown to be important in tuning the range of motion of the joints. 
This is seen as a good variable for affecting the gait pattern of the user. However, it does not lead to greater 
walking speed, as it reduces the cadence but does not increase the step length. Neither did the variable 
stiffness correlate to the walking speed, as was expected. This observation can be explained by both a de-
crease of the user activity while receiving more assistance from the device and a difference in the level of 
assistance provided due to the programmed torque limit imposed upon the exoskeleton. These preliminary 
observations need further investigations, including more precise evaluation methods of the user exertion, 




This chapter proposed and evaluated a collaborative strategy for determining the type and level of assistance 
an exoskeleton can provide. Using a rigid transmission over the hip joint of the AUTONOMYO exoskeleton, a 
full gait assistive strategy based on finite-state control is presented. Designed for people with muscle weak-
ness or neurological disorders, particular attention is paid towards triggers to initiate or terminate assisted 
walking. A method actively involving the pilot in the gait through a detection of intention through the hip 
flexion motion is presented. Results show that torques under 8 Nm in flexion of the hip over a duration of 
150 ms are sufficient to control the device. The control strategy, based on three states that can be compared 
to the stance, swing and double support phases of the gait, provides a powerful assistive controller free from 
spatial and temporal constraints. Moreover, impedance variation offers an easy and intuitive way for tuning 
the characteristics of the assistance, by for example, increasing the stiffness or augmenting the attractive 
angles. 
An initial feasability study demonstrated that both a healthy user and a user with severe muscle weakness 
were able to collaborate with the device and walk. Further tests looking at metrics to quantify the impact of 
the exoskeleton on the user need to be performed. This could include the evaluation of the variation of met-
abolic expenditure with support from the exoskeleton as well as without. A study could evaluate muscular 
activity by observing the difference of timing and of amplitude in electromyography sensors. The impact of 
wearing the exoskeleton upon gait kinematics could also be observed to see if the user range of motion could 
be increased by using the exoskeleton. 
This chapter also presents the evaluation of the impact of different parameters on the gait characteristics. 
The variables investigated are the user exertion and the different impedance parameters, such as the virtual 
stiffness or the attractive angle. Results show that user implication can affect step length and walking veloc-
ity. The attractive angle of the hip does not significantly impact the step length. However, it does have an 
important impact on the hip range of motion, the knee range of motion, and the cadence.  
Further examinations need to be performed to investigate the potential impact of the AUTONOMYO exoskel-
eton, combined with a simple assistive controller, on a larger group of people with neuromuscular disorder. 
The preliminary results are promising. A further axis of research will be to combine a balance augmentation 
strategy with the current controller, so that the pilot can potentially walk independently.
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 ???????????
Neuromuscular diseases are a large and heterogeneous set of diseases characterized by localized or general 
degenerative muscle wasting. Walking impairments are recurrent among these persons and are noted by 
characteristic gait with uncommon compensating patterns. At the time of this publication, most existing am-
bulation supporting devices are not adapted to the unique needs of people with neuromuscular diseases. 
Only ankle-foot orthoses have demonstrated a significant improvement in the gait in people with ankle weak-
ness. This work investigates solutions for assisting people with muscle weakness in walking and performing 
other activities requiring ambulation. The concept is largely inspired by the work of pioneers in the develop-
ment of exoskeleton devices for the mobilization of people with spinal cord injuries. 
The challenges of designing assistive devices for people with neuromuscular diseases are numerous. One of 
the first challenges is also one of the most crucial: to build an exoskeleton that can walk on its own without 
the need of external support. This implies that the exoskeleton can either offer a stability zone that is so large 
that the risk of losing balance is very small, or, can dynamically recover from a dangerous situation as a 
healthy human body is able to. The difficulty in creating such an ability lies in the shared control between 
user and exoskeleton. In order to manage balance, there will be cases in which the exoskeleton will likely 
need to fully guide the user. Aside from these future perspectives, an infinite list of challenges can be cited, 
from the difficulty of fitting a device with different morphologies encountered in a large population to provid-
ing safety in a defined environment. 
Despite the numerous challenges that exoskeleton designers are facing right now, academic and industrial 
communities have a significant interest in the development of new technologies for exoskeleton design. This 
is a driving force that will generate extremely useful resources in the near future. Although exoskeletons are 
still seen as a life changing device for many, the number of sales of such devices over the past few years in 
the limited market demonstrates the gap between the dream and the reality. Despite this projection, exo-
skeletons have nonetheless demonstrated their many health and lifestyle benefits for people who would 
otherwise be wheelchair-bound.  
People with neuromuscular diseases are excellent candidates for exoskeleton design as they stand to benefit 
immensely from the technology. Exoskeletons can reduce the early fatigue that affects people with neuro-
muscular diseases and thereby promote a more active lifestyle. It is likely that, for safety reasons, the first 





????? ?????????????????????????????? ???? ????????????? ????????
The first contribution consists of the first thorough literature survey on gait in neuromuscular diseases. The 
conclusions of this survey demonstrates the lack of comprehensive studies with a representative number of 
participants enrolled in the study. Only two types of NMD have been significantly studied, but rarely with a 
representive sample size. The other types of NMD can be found in, at most, 2 or 3 studies; however, a large 
number of them have not been investigated and, if so, the sample sizes are rarely representative. Despite 
the small number and limited quality of the studies, a description of most of the compensating patterns can 
be found in the literature. 
In addition to the literature survey, an experimental study on a heterogeneous group of 14 persons with 
NMD was performed. The results consolidate the previous findings of gait patterns; such as knee hyperex-
tension or foot drop. The study qualifies the need of participants, based on the observation of their compen-
sating patterns. Thus, the contribution of this work is related not only to the observation of compensating 
patterns in people with neuromuscular diseases, but also to a greater understanding of the terms of assis-
tance for people with neuromuscular diseases. 
????? ????????????????????????????????????????????????
The main tangible contributions of this thesis is the realization of a full lower limb exoskeleton that is adjust-
able to the size of the user and includes six actuated degrees of freedom. A particular focus was placed on 
the optimization of the inertial effects of the actuators. This resulted in the use of small diameter and long 
electrical actuation remotely located from the joints. A first proof of concept was constructed in the form of 
a leg with three actuated degrees of freedom. The different contributions stemming from the mechanical 
design of the exoskeleton are described in the following sections. 
??????? ???????????????????? ??????????????????????????????
A pulley system connects the motor to the hip joint, as well as the hip with the knee. The second stage is 
particularly critical, as the segment (elaborate – “the segment” is very vague) must be adjusted to fit user 
dimensions. A novel solution of a rack and pinion system is designed which allows the length of the cable to 
be kept constant while the segment length is changed. The stainless steel cables are anchored on each pulley 
and have a range of motion of 270° in a very limited space.  
??????? ??????????????????????????????????????
Another contribution is the kinematic analysis of different coupling configurations that are introduced by 
remotely locating the knee actuation unit in the upper back of the exoskeleton. The analysis is put in the 
perspective of the different activities such as level-walking, STS and stairs climbing. Both configurations have 
certain activities where they excel, but others where they perform badly in the others. Eventually, it is ob-
served that the configuration without coupling is the most versatile one and has the highest potential for 
fitting the requirements. 
??????? ????????????????????????????????? ??????????
Two backdrivable mechanisms were designed and then characterized. A ballscrew transmission with a four 
bar linkage was proposed for the actuation of the hip abduction/adduction. The transmission of the hip and 
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knee flexion/extension was realized with a three-stage planetary gearbox before transmitting the efforts to 
a cable-pulley system described previously. Both systems present different types of friction that affects the 
backdrivability. An unconventional model with a variable efficiency in function of the sign of the power in the 
motor is proposed and validated for the actuation with the gearbox. A totally different model was identified 
for the ballscrew actuation unit, where the most important contribution comes from the friction that is pro-
portional to the velocity. 
????? ??????????????????????????????????????
A novel architecture of finite-state controller based on active impedance was proposed and implemented on 
the exoskeleton. It is based on the study the relationship of gait between kinematics and kinetics, which 
reveals constant impedance behavior for different phases. The controller is implemented with a combined 
detection of state and detection of intention, which allows it to switch between adjustable preprogrammed 
constant-impedance behaviors. 
??????? ???????????????????????
A novel method of phase detection was implemented that also includes detection of intention, i.e. the gait 
initiation and termination. The characteristics of the detection of intention were evaluated on a test bench 
and measured in terms of required torque and detection delay. The relationship between these characteris-
tics and the velocity detection threshold were also measured.  
??????? ?????????????????? ??????????? ???????????????????????????
The controller was tested over five sessions with a pilot with limb girdle muscular dystrophy. After the first 
preliminary session, a set of parameters was determined to adapt to the pilot needs. In all four sessions, the 
pilot was able to initiate gait, and walk as he wanted while he was assisted in balancing with two people. The 
limitations of the pilot’s capabilities in step length (hip range of motion) and sensitivity of detection of inten-
tion were addressed. 
??????? ???????????????????????????????????????????? ??????????????????????
One of the key aims of the assistive strategy is to for any assistive device to be adaptable to different joints 
and level of assistance. The goal is to assist as needed so that the pilot can be independent whenever possible 
while functioning within his/her capabilities. A preliminary test investigating the influence of the user impli-
cation and different parameters from the simulated impedance (attractive angle or simulated stiffness during 
different phases) on gait characteristics (range of motion, step length, stride rate, walking velocity). Results 
show that step length and walking velocity are correlated with the user independence, while the attractive 
angle of the controller modulates the range of motion and the step length. The simulated stiffness was as-
sumed to increase the level of assistance, as it increases the torque provided by the device; however, no 






The aim of the mechanical development was to design and validate powerful, lightweight and compact actu-
ation units that can precisely allow force control and be as transparent (or backdrivable) as possible. Different 
architectures are used for the different joints. The characterization of the transmission units shows that 
ballscrew mechanisms have a significant resistance that is proportional to the velocity, while planetary gears 
provide important friction that is proportional to the torque. Some modifications can thus improve the back-
drivability, for example, reducing the rotation velocity of the ballscrew by using a greater pitch (and reduce 
the transmission ratio) can decrease the resistance by a factor of two. For the friction induced by the plane-
tary gears, it is important to reduce it as much as possible to reach 70-80% of efficiency. This could be attained 
by selecting more carefully the materials used, design technologies, and manufacturing precision. 
One of the first limitations encountered was the velocity constraint due to the motor selection and the max-
imum voltage capacity of the electronics of the drive. For safety reasons, it is preferable to keep the initial 
electronics (with max. 50V), but to select equivalent motors with a different voltage over velocity ratio. The 
unique consequence is that it will consume more current, but will be able to reach twice the actual speed 
limit. The required velocity then depends on the coupling configuration for the hip and knee flexion/exten-
sion. Two configurations with a positive or negative coupling were tested, and the non-coupled configuration 
was simulated. The positive coupling shows velocity benefits, mostly in the swing phase, but also increases 
torques required by the actuation in stairs climbing or STS transition. The negative coupling helps the device 
benefit from more torque available during stance phase, but implies higher velocities at the motor. One of 
the main concerns with coupling is that, in the case of accumulated friction, a joint can be overly constrained 
and can become uncontrollable. A configuration without coupling will be more versatile but requires a de-
coupling mechanism that can be difficult to integrate. Another possibility, among others, would be to use 
both coupling and a clutching mechanism to allow switching from one configuration to the other. A thorough 
study of the different solutions in the future can address the feasibility of implementation and pros/cons of 
each solution. 
????? ???????????????????????
A control strategy based on a limited state of impedance has been presented. The detection of intention and 
the state transitions are part of the controller, and are commanded by the hip velocity using only the encoder 
of the actuator. It performs well in terms of reactivity and controllability during level-walking, even with a 
pilot with large muscle weakness at the hip. However, in the case of uphill motion, steps were difficult to 
initiate due to the supplementary force required to flex the hip. Another negative aspect of this simple form 
of detection is that it cannot determine if the foot is in contact with the ground. This can particularly be an 
issue during stairs climbing, as an error of timing can lead to strong strike of the steps and bad foot positioning 
on the stair. Additional sensors such as instrumented soles to measure ground reaction forces are being de-
veloped in order to get more information on the load redistribution and contact with the ground. Inertial 
measurement units placed in each foot and mounted on the back of the exoskeleton help to provide infor-
mation on the orientation of the adjacent limbs. The improvement of detection of intention and of some 
safety controllers will be investigated with a modified strategy based on these sensors. For example, ground 
reaction forces will help better trigger phase detection by better identifying the swing and the stance phase. 
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Impedance control in finite state is shown to be a good solution for adaptable and collaborative strategy in 
people with residual walking abilities. Stairs climbing and STS strategies have been implemented but not yet 
tested due to the mechanical limitations in the current configuration. Key variables to address are the num-
ber of finite states and the original impedance parameters that will be tuned afterwards. The pre-tuning 
should be done with a healthy pilot for each activity, until satisfactory supportive behavior of the exoskeleton 
is found. Once this step is complete, tests and tuning can be done with a pilot with muscle weakness. 
Eventually, strategies for the augmentation of balance should be addressed. These strategies will be largely 
based on the ground reaction forces, which give an indication on the center of pressure and are one of the 
main indicators of balance stability. Static balance management strategies will be investigated and evaluated 
before exploring stepping methods for dynamic balance control. This step requires a tremendous work and 
is an active area of research.  
????? ??????????? ?????????????
In the framework of the current thesis, the level walking strategy has been tested on a few healthy subjects 
and one pilot with muscular dystrophy. The results are promising and a feasibility study is being set up with 
three groups of people: a small group of people with inclusion body myositis, a neuromuscular disease af-
fecting mostly the knee muscles, a small group of people with multiple sclerosis, and a control group of 
healthy subjects. The feasibility study will consist of 3 to 5 sessions in which the participants will perform gait 
assessment exercises through 2- or 6-minutes walk test and undergo gait analysis with and without wearing 
the exoskeleton. This first clinical evaluation is planned for early 2019 and will lead to further assessment of 
rehabilitation perspective and/or safety in personal use. Due to its modular assistance capabilities, assistive 
full lower limb exoskeleton can offer support to a large range of neurological and neuromuscular disorders. 
Some of the candidates are people with incomplete spinal cord injury, multiple sclerosis, hip surgery, hemi-
plegia, etc. in addition to people with neuromuscular diseases and including elderly people. Further prelimi-
nary studies should investigate the compatibility and impact of wearing such an assistive device on the quality 
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